U.S. patent application number 14/812158 was filed with the patent office on 2016-01-14 for azaindoles useful as inhibitors of janus kinases.
The applicant listed for this patent is Vertex Pharmaceuticals Incorporated. Invention is credited to Luc Farmer, Gabriel Martinez-Botella, Albert Pierce, Francesco Salituro, Jian Wang, Tiansheng Wang, Marion W. Wannamaker.
Application Number | 20160008359 14/812158 |
Document ID | / |
Family ID | 38197739 |
Filed Date | 2016-01-14 |
United States Patent
Application |
20160008359 |
Kind Code |
A1 |
Farmer; Luc ; et
al. |
January 14, 2016 |
AZAINDOLES USEFUL AS INHIBITORS OF JANUS KINASES
Abstract
The present invention relates to compounds useful as inhibitors
of protein kinases, particularly of JAK family kinases. The
invention also provides pharmaceutically acceptable compositions
comprising said compounds and methods of using the compositions in
the treatment of various disease, conditions, or disorders.
Inventors: |
Farmer; Luc; (Montreal,
CA) ; Martinez-Botella; Gabriel; (West Roxbury,
MA) ; Pierce; Albert; (Cambridge, MA) ;
Salituro; Francesco; (Marlborough, MA) ; Wang;
Jian; (Newton, MA) ; Wannamaker; Marion W.;
(Stow, MA) ; Wang; Tiansheng; (Concord,
MA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Vertex Pharmaceuticals Incorporated |
Boston |
MA |
US |
|
|
Family ID: |
38197739 |
Appl. No.: |
14/812158 |
Filed: |
July 29, 2015 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
14339514 |
Jul 24, 2014 |
9120790 |
|
|
14812158 |
|
|
|
|
13870173 |
Apr 25, 2013 |
8822681 |
|
|
14339514 |
|
|
|
|
13409702 |
Mar 1, 2012 |
8450489 |
|
|
13870173 |
|
|
|
|
12775885 |
May 7, 2010 |
8163917 |
|
|
13409702 |
|
|
|
|
11654375 |
Jan 17, 2007 |
7767816 |
|
|
12775885 |
|
|
|
|
60842471 |
Sep 6, 2006 |
|
|
|
60759367 |
Jan 17, 2006 |
|
|
|
Current U.S.
Class: |
514/8.3 ;
514/210.18; 514/234.5; 514/245; 514/252.18; 514/256;
514/266.21 |
Current CPC
Class: |
A61P 9/00 20180101; A61P
25/18 20180101; A61K 31/517 20130101; A61P 25/16 20180101; C12Y
207/10002 20130101; A61P 25/28 20180101; A61P 7/00 20180101; A61P
35/02 20180101; A61P 3/10 20180101; A61P 37/02 20180101; A61P 43/00
20180101; A61P 9/10 20180101; A61P 9/02 20180101; A61P 19/02
20180101; A61P 31/18 20180101; A61P 21/00 20180101; A61P 21/02
20180101; A61P 37/00 20180101; A61P 37/06 20180101; A61P 9/04
20180101; C07D 471/04 20130101; A61P 11/06 20180101; A61P 25/14
20180101; C07D 519/00 20130101; A61P 35/00 20180101; A61P 37/04
20180101; A61K 45/06 20130101; A61P 17/14 20180101; A61K 31/5377
20130101; C07D 495/10 20130101; A61K 31/506 20130101; A61K 31/53
20130101; A61P 19/00 20180101; A61P 37/08 20180101; C12N 9/12
20130101; A61P 29/00 20180101; A61P 25/00 20180101 |
International
Class: |
A61K 31/506 20060101
A61K031/506; A61K 31/517 20060101 A61K031/517; A61K 31/53 20060101
A61K031/53; A61K 45/06 20060101 A61K045/06; A61K 31/5377 20060101
A61K031/5377 |
Claims
1-44. (canceled)
45. A method of treating or lessening the severity of a disease of
condition selected from a proliferative disorder, a cardiac
disorder, a neurodegenerative disorder, an autoimmune disorder, a
condition associated with organ transplantation, an inflammatory
disorder, or an immunologically mediated disorder in a patient,
comprising the step of administering to said patient a compound of
formula (I): ##STR00432## or a pharmaceutically acceptable salt
thereof, wherein: R.sup.3 is H, Cl or F; X.sup.1 is N or CR.sup.4;
R.sup.2 is H, F, R', OH, OR', COR', COOH, COOR', CONH.sub.2,
CONHR', CON(R').sub.2, or CN; R.sup.4 is H, F, R', OH, OR', COR',
COOH, COOR', CONH.sub.2, CONHR', CON(R').sub.2, or CN; or R.sup.2
and R.sup.4, taken together, form a 5-7 membered aryl or heteroaryl
ring optionally substituted with 1-4 occurrences of R.sup.10; R' is
a C.sub.1-3 aliphatic optionally substituted with 1-4 occurrences
of R.sup.5; each R.sup.5 is independently selected from halogen,
CF.sub.3, OCH.sub.3, OH, SH, NO.sub.2, NH.sub.2, SCH.sub.3,
NCH.sub.3, CN or unsubstituted C.sub.1-2 aliphatic, or two R.sup.5
groups, together with the carbon to which they are attached, form a
cyclopropyl ring or C.dbd.O; each R.sup.10 is independently
selected from halogen, OCH.sub.3, OH, NO.sub.2, NH.sub.2, SH,
SCH.sub.3, NCH.sub.3, CN or unsubstituted C.sub.1-2aliphatic;
R.sup.1 is ##STR00433## R'' is H or is a --C.sub.1-2 aliphatic
optionally substituted with 1-3 occurrences of R.sup.11; each
R.sup.11 is independently selected from halogen, OCH.sub.3, OH, SH,
NO.sub.2, NH.sub.2, SCH.sub.3, NCH.sub.3, CN, CON(R.sup.15).sub.2
or unsubstituted C.sub.1-2 aliphatic, or two R.sup.11 groups,
together with the carbon to which they are attached, form a
cyclopropyl ring or C.dbd.O; R.sup.6 is a C.sub.1-4 aliphatic
optionally substituted with 1-5 occurrences of R.sup.12; each
R.sup.12 is independently selected from halogen, OCH.sub.3, OH,
NO.sub.2, NH.sub.2, SH, SCH.sub.3, NCH.sub.3, CN or unsubstituted
C.sub.1-2aliphatic, or two R.sup.12 groups, together with the
carbon to which they are attached, form a cyclopropyl ring; Ring A
is a 4-8 membered saturated nitrogen-containing ring comprising up
to two additional heteroatoms selected from N, O or S and
optionally substituted with 1-4 occurrences of R.sup.13; each
R.sup.13 is independently selected from halogen, R', NH.sub.2,
NHR', N(R').sub.2, SH, SR', OH, OR', NO.sub.2, CN, CF.sub.3, COOR',
COOH, COR', OC(O)R' or NHC(O)R'; or any two R.sup.13 groups, on the
same substituent or different substituents, together with the
atom(s) to which each R.sup.13 group is bound, form a 3-7 membered
saturated, unsaturated, or partially saturated carbocyclic or
heterocyclic ring optionally substituted with 1-3 occurrences of
R.sup.5; R.sup.8 is C.sub.1-4 aliphatic substituted with 1-5
occurrences of R.sup.12; R.sup.9 is C.sub.1-2 alkyl; or R.sup.8 and
R.sup.9 are taken together to form a 3-7 membered carbocyclic or
heterocyclic saturated ring optionally substituted with 1-5
occurrences of R.sup.12; R.sup.14 is H or unsubstituted C.sub.1-2
alkyl; R.sup.15 is H or unsubstituted C.sub.1-2 alkyl; and R.sup.7
is a C.sub.2-3 aliphatic or cycloaliphatic optionally substituted
with up to 6 occurrences of F.
46. The method of claim 45, comprising the additional step of
administering to said patient an additional therapeutic agent
selected from a chemotherapeutic or anti-proliferative agent, an
anti-inflammatory agent, an immunomodulatory or immunosuppressive
agent, a neurotrophic factor, an agent for treating cardiovascular
disease, an agent for treating diabetes, or an agent for treating
immunodeficiency disorders, wherein said additional therapeutic
agent is appropriate for the disease being treated.
47. The method according to claim 45, wherein the disease or
disorder is allergic or type I hypersensitivity reactions, asthma,
diabetes, Alzheimer's disease, Huntington's disease, Parkinson's
disease, AIDS-associated dementia, amyotrophic lateral sclerosis
(AML, Lou Gehrig's disease), multiple sclerosis (MS),
schizophrenia, cardiomyocyte hypertrophy, reperfusion/ischemia,
stroke, baldness, transplant rejection, graft versus host disease,
rheumatoid arthritis, a solid malignancy, a hematologic malignancy,
a leukemia, a lymphoma and a myeloproliferative disorder.
48. The method according to claim 47, wherein said disease or
disorder is asthma.
49. The method according claim 47, wherein said disease or disorder
is transplant rejection.
50. The method according claim 47, wherein said disease or disorder
is rheumatoid arthritis.
51. The method according to claim 47, wherein said disease is a
myeloproliferative disorder selected from polycythemia vera,
essential thrombocythemia, chronic idiopathic myelofibrosis,
myeloid metaplasia with myelofibrosis, chronic myeloid leukemia,
chronic myelomonocytic leukemia, chronic eosinophilic leukemia,
hypereosinophilic syndrome or systematic mast cell disease.
52. The method according to claim 45, wherein the compound of
Formula (I) has formula I-A: ##STR00434##
53. The method according to claim 52, wherein R.sup.3 is H or
Cl.
54. The method according to claim 52, wherein R.sup.2 is H, F, R',
OH or OR'.
55. The method according to claim 52, wherein the compound is of
formula I-A and R.sup.4 is H, F, R', OH or OR', or R.sup.2 and
R.sup.4 are taken together to form a 6-membered aryl ring.
56. The method according to claim 52, wherein R.sup.7 is
CH.sub.2CH.sub.3, CH.sub.2CF.sub.3, CH.sub.2CHF.sub.2,
CH.sub.2CH.sub.2F, CH.sub.2CH.sub.2CH.sub.3,
CH.sub.2CH.sub.2CF.sub.3, CH.sub.2CH.sub.2CH.sub.2F or
CH.sub.2CH.sub.2CHF.sub.2.
57. The method according to claim 52, wherein R'' is H or
CH.sub.3.
58. The method according to claim 52, wherein R.sup.8, R.sup.9 and
the carbon atom to which they are attached form ##STR00435##
59. The method according to claim 52, wherein R.sup.8 and R.sup.9
are taken together to form a ring selected from ##STR00436##
wherein one or more carbon atoms in of said ring are optionally and
independently replaced by N, O or S.
60. The method according to claim 52, wherein Ring A is
##STR00437## and R.sup.13, is H or R.sup.13.
Description
CROSS REFERENCE TO RELATED APPLICATION
[0001] This divisional application claims the benefit of U.S.
application Ser. No. 14/339,514, filed on Jul. 24, 2014, which is a
divisional of U.S. application Ser. No. 13/870,173, filed on Apr.
25, 2013, which is a divisional of U.S. application Ser. No.
13/409,702, filed on Mar. 1, 2012, which is a division of U.S.
application Ser. No. 12/775,885, filed on May 7, 2010, which is a
continuation of U.S. application Ser. No. 11/654,375, filed Jan.
17, 2007, which claims the benefit of U.S. Provisional Application
No. 60/759,367, filed Jan. 17, 2006 and U.S. Provisional
Application No. 60/842,471, filed Sep. 6, 2006. Each of these
applications is incorporated herein by reference.
TECHNICAL FIELD OF THE INVENTION
[0002] The present invention relates to compounds useful as
inhibitors of Janus kinases (JAK). The invention also provides
pharmaceutically acceptable compositions comprising the compounds
of the invention and methods of using the compositions in the
treatment of various disorders.
BACKGROUND OF THE INVENTION
[0003] The Janus kinases (JAK) are a family of tyrosine kinases
consisting of JAK1, JAK2, JAK3 and TYK2. The JAKs play a critical
role in cytokine signaling. The down-stream substrates of the JAK
family of kinases include the signal transducer and activator of
transcription (STAT) proteins. JAK/STAT signaling has been
implicated in the mediation of many abnormal immune responses such
as allergies, asthma, autoimmune diseases such as transplant
rejection, rheumatoid arthritis, amyotrophic lateral sclerosis and
multiple sclerosis as well as in solid and hematologic malignancies
such as leukemias and lymphomas. JAK2 has also been implicated in
myeloproliferative disorders, which include polycythemia vera,
essential thrombocythemia, chronic idiopathic myelofibrosis,
myeloid metaplasia with myelofibrosis, chronic myeloid leukemia,
chronic myelomonocytic leukemia, chronic eosinophilic leukemia,
hypereosinophilic syndrome and systematic mast cell disease.
[0004] Accordingly, there is a great need to develop compounds
useful as inhibitors of protein kinases. In particular, it would be
desirable to develop compounds that are useful as inhibitors of JAK
family kinases.
SUMMARY OF THE INVENTION
[0005] It has now been found that compounds of this invention, and
pharmaceutically acceptable compositions thereof, are effective as
inhibitors of protein kinases, particularly the JAK family kinases.
These compounds have the general formula I:
##STR00001##
or a pharmaceutically acceptable salt thereof, wherein X.sup.1,
R.sup.1, R.sup.2 and R.sup.3 are as defined herein.
[0006] These compounds, and pharmaceutically acceptable
compositions thereof, are useful for treating or lessening the
severity of a variety of disorders, including proliferative
disorders, cardiac disorders, neurodegenerative disorders,
autoimmune disorders, conditions associated with organ
transplantation, inflammatory disorders, or immunologically
mediated disorders in a patient.
[0007] The compounds and compositions provided by this invention
are also useful for the study of JAK kinases in biological and
pathological phenomena; the study of intracellular signal
transduction pathways mediated by such kinases; and the comparative
evaluation of new kinase inhibitors.
DETAILED DESCRIPTION OF THE INVENTION
Definitions and General Terminology
[0008] As used herein, the following definitions shall apply unless
otherwise indicated. For purposes of this invention, the chemical
elements are identified in accordance with the Periodic Table of
the Elements, CAS version, and the Handbook of Chemistry and
Physics, 75.sup.th Ed. 1994. Additionally, general principles of
organic chemistry are described in "Organic Chemistry", Thomas
Sorrell, University Science Books, Sausalito: 1999, and "March's
Advanced Organic Chemistry", 5.sup.th Ed., Smith, M. B. and March,
J., eds. John Wiley & Sons, New York: 2001, the entire contents
of which are hereby incorporated by reference.
[0009] As described herein, compounds of the invention may
optionally be substituted with one or more substituents, such as
are illustrated generally above, or as exemplified by particular
classes, subclasses, and species of the invention. It will be
appreciated that the phrase "optionally substituted" is used
interchangeably with the phrase "substituted or unsubstituted." In
general, the term "substituted", whether preceded by the term
"optionally" or not, refers to the replacement of one or more
hydrogen radicals in a given structure with the radical of a
specified substituent. Unless otherwise indicated, an optionally
substituted group may have a substituent at each substitutable
position of the group. When more than one position in a given
structure can be substituted with more than one substituent
selected from a specified group, the substituent may be either the
same or different at each position.
[0010] As described herein, when the term "optionally substituted"
precedes a list, said term refers to all of the subsequent
substitutable groups in that list. If a substituent radical or
structure is not identified or defined as "optionally substituted",
the substituent radical or structure is unsubstituted. For example,
if X is halogen; optionally substituted C.sub.1-3alkyl or phenyl; X
may be either optionally substituted alkyl or optionally
substituted phenyl. Likewise, if the term "optionally substituted"
follows a list, said term also refers to all of the substitutable
groups in the prior list unless otherwise indicated. For example:
if X is halogen, C.sub.1-3alkyl or phenyl wherein X is optionally
substituted by J.sup.X, then both C.sub.1-3alkyl and phenyl may be
optionally substituted by J.sup.X. As is apparent to one having
ordinary skill in the art, groups such as H, halogen, NO.sub.2, CN,
NH.sub.2, OH, or OCF.sub.3 would not be included because they are
not substitutable groups.
[0011] Combinations of substituents envisioned by this invention
are preferably those that result in the formation of stable or
chemically feasible compounds. The term "stable", as used herein,
refers to compounds that are not substantially altered when
subjected to conditions to allow for their production, detection,
and, preferably, their recovery, purification, and use for one or
more of the purposes disclosed herein. In some embodiments, a
stable compound or chemically feasible compound is one that is not
substantially altered when kept at a temperature of 40.degree. C.
or less, in the absence of moisture or other chemically reactive
conditions, for at least a week.
[0012] The term "aliphatic" or "aliphatic group", as used herein,
means a straight-chain (i.e., unbranched) or branched, substituted
or unsubstituted hydrocarbon chain that is completely saturated or
that contains one or more units of unsaturation. Unless otherwise
specified, aliphatic groups contain 1-20 aliphatic carbon atoms. In
some embodiments, aliphatic groups contain 1-10 aliphatic carbon
atoms. In other embodiments, aliphatic groups contain 1-8 aliphatic
carbon atoms. In still other embodiments, aliphatic groups contain
1-6 aliphatic carbon atoms, and In yet other embodiments, aliphatic
groups contain 1-4 aliphatic carbon atoms. Suitable aliphatic
groups include, but are not limited to, linear or branched,
substituted or unsubstituted alkyl, alkenyl, or alkynyl groups.
Further examples of aliphatic groups include methyl, ethyl, propyl,
butyl, isopropyl, isobutyl, vinyl, and sec-butyl.
[0013] The term "cycloaliphatic" (or "carbocycle" or "cycloalkyl")
refers to a hydrocarbon that is completely saturated or that
contains one or more units of unsaturation, but which is not
aromatic, that has a single point of attachment to the rest of the
molecule, and wherein any individual ring in said bicyclic ring
system has 3-7 members. Unless otherwise specified, the term
"cycloaliphatic" refers to a monocyclic C.sub.3-C.sub.8 hydrocarbon
or bicyclic C.sub.8-C.sub.12 hydrocarbon. Suitable cycloaliphatic
groups include, but are not limited to, cycloalkyl, cycloalkenyl,
and cycloalkynyl. Further examples of aliphatic groups include
cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl,
cyclohexenyl, cycloheptyl, and cycloheptenyl.
[0014] The term "heterocycle", "heterocyclyl" or "heterocyclic" as
used herein refers to a monocyclic, bicyclic, or tricyclic ring
system in which one or more ring members are an independently
selected heteroatom and that is completely saturated or that
contains one or more units of unsaturation, but which is not
aromatic, that has a single point of attachment to the rest of the
molecule. In some embodiments, the "heterocycle", "heterocyclyl" or
"heterocyclic" group has three to fourteen ring members in which
one or more ring members is a heteroatom independently selected
from oxygen, sulfur, nitrogen, or phosphorus, and each ring in the
system contains 3 to 7 ring members.
[0015] Examples of heterocyclic rings include, but are not limited
to, the following monocycles: 2-tetrahydrofuranyl,
3-tetrahydrofuranyl, 2-tetrahydrothiophenyl,
3-tetrahydrothiophenyl, 2-morpholino, 3-morpholino, 4-morpholino,
2-thiomorpholino, 3-thiomorpholino, 4-thiomorpholino,
1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl,
1-tetrahydropiperazinyl, 2-tetrahydropiperazinyl,
3-tetrahydropiperazinyl, 1-piperidinyl, 2-piperidinyl,
3-piperidinyl, 1-pyrazolinyl, 3-pyrazolinyl, 4-pyrazolinyl,
5-pyrazolinyl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl,
4-piperidinyl, 2-thiazolidinyl, 3-thiazolidinyl, 4-thiazolidinyl,
1-imidazolidinyl, 2-imidazolidinyl, 4-imidazolidinyl,
5-imidazolidinyl; and the following bicycles:
3-1H-benzimidazol-2-one, 3-(1-alkyl)-benzimidazol-2-one, indolinyl,
tetrahydroquinolinyl, tetrahydroisoquinolinyl, benzothiolane,
benzodithiane, and 1,3-dihydro-imidazol-2-one.
[0016] The term "heteroatom" means one or more of oxygen, sulfur,
nitrogen, phosphorus, or silicon, including any oxidized form of
nitrogen, sulfur, phosphorus, or silicon, the quaternized form of
any basic nitrogen, or a substitutable nitrogen of a heterocyclic
ring, for example N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in
pyrrolidinyl) or NR.sup.+ (as in N-substituted pyrrolidinyl).
[0017] The term "unsaturated", as used herein, means that a moiety
has one or more units of unsaturation.
[0018] The term "aryl" used alone or as part of a larger moiety as
in "aralkyl", "aralkoxy", or "aryloxyalkyl", refers to monocyclic,
bicyclic, and tricyclic carbocyclic ring systems having a total of
six to fourteen ring members, wherein at least one ring in the
system is aromatic, wherein each ring in the system contains 3 to 7
ring members and that has a single point of attachment to the rest
of the molecule. The term "aryl" may be used interchangeably with
the term "aryl ring". Examples of aryl rings would include phenyl,
naphthyl, and anthracene.
[0019] The term "heteroaryl", used alone or as part of a larger
moiety as in "heteroaralkyl" or "heteroarylalkoxy", refers to
monocyclic, bicyclic, and tricyclic ring systems having a total of
five to fourteen ring members, wherein at least one ring in the
system is aromatic, at least one ring in the system contains one or
more heteroatoms, wherein each ring in the system contains 3 to 7
ring members and that has a single point of attachment to the rest
of the molecule. The term "heteroaryl" may be used interchangeably
with the term "heteroaryl ring" or the term "heteroaromatic".
[0020] Further examples of heteroaryl rings include the following
monocycles: 2-furanyl, 3-furanyl, N-imidazolyl, 2-imidazolyl,
4-imidazolyl, 5-imidazolyl, 3-isoxazolyl, 4-isoxazolyl,
5-isoxazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, N-pyrrolyl,
2-pyrrolyl, 3-pyrrolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl,
2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, pyridazinyl (e.g.,
3-pyridazinyl), 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, tetrazolyl
(e.g., 5-tetrazolyl), triazolyl (e.g., 2-triazolyl and
5-triazolyl), 2-thienyl, 3-thienyl, pyrazolyl (e.g., 2-pyrazolyl),
isothiazolyl, 1,2,3-oxadiazolyl, 1,2,5-oxadiazolyl,
1,2,4-oxadiazolyl, 1,2,3-triazolyl, 1,2,3-thiadiazolyl,
1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, pyrazinyl, 1,3,5-triazinyl,
and the following bicycles: benzimidazolyl, benzofuryl,
benzothiophenyl, indolyl (e.g., 2-indolyl), purinyl, quinolinyl
(e.g., 2-quinolinyl, 3-quinolinyl, 4-quinolinyl), and isoquinolinyl
(e.g., 1-isoquinolinyl, 3-isoquinolinyl, or 4-isoquinolinyl).
[0021] In some embodiments, an aryl (including aralkyl, aralkoxy,
aryloxyalkyl and the like) or heteroaryl (including heteroaralkyl
and heteroarylalkoxy and the like) group may contain one or more
substituents. Suitable substituents on the unsaturated carbon atom
of an aryl or heteroaryl group are selected from those listed in
the definitions of R.sup.2 and R.sup.4 below. Other suitable
substituents include: halogen; --R.sup..smallcircle.;
--OR.sup..smallcircle.; --SR.sup..smallcircle.; 1,2-methylenedioxy;
1,2-ethylenedioxy; phenyl (Ph) optionally substituted with
R.sup..smallcircle.; --O(Ph) optionally substituted with
R.sup..smallcircle.; --(CH.sub.2).sub.1-2(Ph), optionally
substituted with R.sup..smallcircle.; --CH.dbd.CH(Ph), optionally
substituted with R.sup..smallcircle.; --NO.sub.2; --CN;
--N(R.sup..smallcircle.).sub.2;
--NR.sup..smallcircle.C(O)R.sup..smallcircle.;
--NR.sup..smallcircle.C(S)R.sup..smallcircle.;
--NR.sup..smallcircle.C(O)N(R.sup..smallcircle.).sub.2;
--NR.sup..smallcircle.C(S)N(R.sup..smallcircle.).sub.2;
--NR.sup..smallcircle.CO.sub.2R.sup..smallcircle.;
--NR.sup..smallcircle.NR.sup..smallcircle.C(O)R.sup..smallcircle.;
--NR.sup..smallcircle.NR.sup..smallcircle.C(O)N(R.sup..smallcircle.).sub.-
2;
--NR.sup..smallcircle.NR.sup..smallcircle.CO.sub.2R.sup..smallcircle.;
--C(O)C(O)R.sup..smallcircle.;
--C(O)CH.sub.2C(O)R.sup..smallcircle.;
--C(O)CH.sub.2C(O)R.sup..smallcircle.;
--CO.sub.2R.sup..smallcircle.; --C(O)R.sup..smallcircle.;
--C(S)R.sup..smallcircle.; --C(O)N(R.sup..smallcircle.).sub.2;
--C(S)N(R.sup..smallcircle.).sub.2;
--OC(O)N(R.sup..smallcircle.).sub.2; --OC(O)R.sup..smallcircle.;
--C(O)N(OR.sup..smallcircle.)R.sup..smallcircle.;
--C(NOR.sup..smallcircle.)R.sup..smallcircle.;
--S(O).sub.2R.sup..smallcircle.; --S(O).sub.3R.sup..smallcircle.;
--SO.sub.2N(R.sup..smallcircle.).sub.2; --S(O)R.sup..smallcircle.;
--NR.sup..smallcircle.SO.sub.2N(R.sup..smallcircle.).sub.2;
--NR.sup..smallcircle.SO.sub.2R.sup..smallcircle.;
--N(OR.sup..smallcircle.)R.sup..smallcircle.;
--C(.dbd.NH)--N(R.sup..smallcircle.).sub.2; or
--(CH.sub.2).sub.0-2NHC(O)R.sup..smallcircle.; wherein each
independent occurrence of R.sup..smallcircle.is selected from
hydrogen, optionally substituted C.sub.1-6 aliphatic, an
unsubstituted 5-6 membered heteroaryl or heterocyclic ring, phenyl,
--O(Ph), or --CH.sub.2(Ph), or, two independent occurrences of
R.sup..smallcircle., on the same substituent or different
substituents, taken together with the atom(s) to which each
R.sup..smallcircle.group is bound, form a 5-8-membered
heterocyclyl, aryl, or heteroaryl ring or a 3-8-membered cycloalkyl
ring, wherein said heteroaryl or heterocyclyl ring has 1-3
heteroatoms independently selected from nitrogen, oxygen, or
sulfur. Optional substituents on the aliphatic group of
R.sup..smallcircle.are selected from NH.sub.2,
NH(C.sub.1-4aliphatic), N(C.sub.1-4aliphatic).sub.2, halogen,
C.sub.1-4aliphatic, OH, O(C.sub.1-4aliphatic), NO.sub.2, CN,
CO.sub.2H, CO.sub.2(C.sub.1-4aliphatic), O(haloC.sub.1-4
aliphatic), or haloC.sub.1-4aliphatic, wherein each of the
foregoing C.sub.1-4aliphatic groups of R.sup..smallcircle.is
unsubstituted.
[0022] In some embodiments, an aliphatic or heteroaliphatic group,
or a non-aromatic heterocyclic ring may contain one or more
substituents. Suitable substituents on the saturated carbon of an
aliphatic or heteroaliphatic group, or of a non-aromatic
heterocyclic ring are selected from those listed above for the
unsaturated carbon of an aryl or heteroaryl group and additionally
include the following: .dbd.O, .dbd.S, .dbd.NNHR*,
.dbd.NN(R*).sub.2, .dbd.NNHC(O)R*, .dbd.NNHCO.sub.2(alkyl),
.dbd.NNHSO.sub.2(alkyl), or .dbd.NR*, where each R* is
independently selected from hydrogen or an optionally substituted
C.sub.1-6 aliphatic. Optional substituents on the aliphatic group
of R* are selected from NH.sub.2, NH(C.sub.1-4 aliphatic),
N(C.sub.1-4 aliphatic).sub.2, halogen, C.sub.1-4 aliphatic, OH,
O(C.sub.1-4 aliphatic), NO.sub.2, CN, CO.sub.2H, CO.sub.2(C.sub.1-4
aliphatic), O(halo C.sub.1-4 aliphatic), or halo(C.sub.1-4
aliphatic), wherein each of the foregoing C.sub.1-4aliphatic groups
of R* is unsubstituted.
[0023] In some embodiments, optional substituents on the nitrogen
of a non-aromatic heterocyclic ring include --R.sup.+,
--N(R.sup.+).sub.2, --C(O)R.sup.+, --CO.sub.2R.sup.+,
--C(O)C(O)R.sup.+, --C(O)CH.sub.2C(O)R.sup.+, --SO.sub.2R.sup.+,
--SO.sub.2N(R.sup.+).sub.2, --C(.dbd.S)N(R.sup.+).sub.2,
--C(.dbd.NH)--N(R.sup.+).sub.2, or --NR.sup.+SO.sub.2R.sup.+;
wherein R.sup.+is hydrogen, an optionally substituted C.sub.1-6
aliphatic, optionally substituted phenyl, optionally substituted
--O(Ph), optionally substituted --CH.sub.2(Ph), optionally
substituted --(CH.sub.2).sub.1-2(Ph); optionally substituted
--CH.dbd.CH(Ph); or an unsubstituted 5-6 membered heteroaryl or
heterocyclic ring having one to four heteroatoms independently
selected from oxygen, nitrogen, or sulfur, or, two independent
occurrences of R.sup.+, on the same substituent or different
substituents, taken together with the atom(s) to which each
R.sup.+group is bound, form a 5-8-membered heterocyclyl, aryl, or
heteroaryl ring or a 3-8-membered cycloalkyl ring, wherein said
heteroaryl or heterocyclyl ring has 1-3 heteroatoms independently
selected from nitrogen, oxygen, or sulfur. Optional substituents on
the aliphatic group or the phenyl ring of R.sup.+are selected from
NH.sub.2, NH(C.sub.1-4 aliphatic), N(C.sub.1-4 aliphatic).sub.2,
halogen, C.sub.1-4 aliphatic, OH, O(C.sub.1-4 aliphatic), NO.sub.2,
CN, CO.sub.2H, CO.sub.2(C.sub.1-4 aliphatic), O(halo C.sub.1-4
aliphatic), or halo(C.sub.1-4 aliphatic), wherein each of the
foregoing C.sub.1-4aliphatic groups of R.sup.+is unsubstituted.
[0024] As detailed above, in some embodiments, two independent
occurrences of R.sup..smallcircle.(or R.sup.+, or any other
variable similarly defined herein), may be taken together with the
atom(s) to which each variable is bound to form a 5-8-membered
heterocyclyl, aryl, or heteroaryl ring or a 3-8-membered cycloalkyl
ring. Exemplary rings that are formed when two independent
occurrences of R.sup..smallcircle.(or R.sup.+, or any other
variable similarly defined herein) are taken together with the
atom(s) to which each variable is bound include, but are not
limited to the following: a) two independent occurrences of
R.sup..smallcircle.(or R.sup.+, or any other variable similarly
defined herein) that are bound to the same atom and are taken
together with that atom to form a ring, for example,
N(R.sup..smallcircle.).sub.2, where both occurrences of
R.sup..smallcircle.are taken together with the nitrogen atom to
form a piperidin-1-yl, piperazin-1-yl, or morpholin-4-yl group; and
b) two independent occurrences of R.sup..smallcircle.(or R.sup.+,
or any other variable similarly defined herein) that are bound to
different atoms and are taken together with both of those atoms to
form a ring, for example where a phenyl group is substituted with
two occurrences of
##STR00002##
these two occurrences of R.sup..smallcircle.are taken together with
the oxygen atoms to which they are bound to form a fused 6-membered
oxygen containing ring:
##STR00003##
It will be appreciated that a variety of other rings can be formed
when two independent occurrences of R.sup..smallcircle.(or R.sup.+,
or any other variable similarly defined herein) are taken together
with the atom(s) to which each variable is bound and that the
examples detailed above are not intended to be limiting.
[0025] In some embodiments, an alkyl or aliphatic chain can be
optionally interrupted with another atom or group. This means that
a methylene unit of the alkyl or aliphatic chain is optionally
replaced with said other atom or group. Examples of such atoms or
groups would include, but are not limited to, --NR--, --O--, --S--,
--CO.sub.2--, --OC(O)--, --C(O)CO--, --C(O)--, --C(O)NR--,
--C(.dbd.N--CN), --NRCO--, --NRC(O)O--, --SO.sub.2NR--,
--NRSO.sub.2--, --NRC(O)NR--, --OC(O)NR--, --NRSO.sub.2NR--,
--SO--, or --SO.sub.2--, wherein R is defined herein. Unless
otherwise specified, the optional replacements form a chemically
stable compound. Optional interruptions can occur both within the
chain and at either end of the chain; i.e. both at the point of
attachment and/or also at the terminal end. Two optional
replacements can also be adjacent to each other within a chain so
long as it results in a chemically stable compound. Unless
otherwise specified, if the replacement or interruption occurs at
the terminal end, the replacement atom is bound to an H on the
terminal end. For example, if --CH.sub.2CH.sub.2CH.sub.3 were
optionally interrupted with --O--, the resulting compound could be
--OCH.sub.2CH.sub.3, --CH.sub.2OCH.sub.3, or
--CH.sub.2CH.sub.2OH.
[0026] As described herein, a bond drawn from a substituent to the
center of one ring within a multiple-ring system (as shown below),
represents substitution of the substituent at any substitutable
position in any of the rings within the multiple ring system. For
example, Compound a represents possible substitution in any of the
positions shown in Compound b.
##STR00004##
[0027] This also applies to multiple ring systems fused to optional
ring systems (which would be represented by dotted lines). For
example, in Compound c, X is an optional substituent both for ring
A and ring B.
##STR00005##
[0028] If, however, two rings in a multiple ring system each have
different substituents drawn from the center of each ring, then,
unless otherwise specified, each substituent only represents
substitution on the ring to which it is attached. For example, in
Compound d, Y is an optionally substituent for ring A only, and X
is an optional substituent for ring B only.
##STR00006##
[0029] Unless otherwise stated, structures depicted herein are also
meant to include all isomeric (e.g., enantiomeric, diastereomeric,
and geometric (or conformational)) forms of the structure; for
example, the R and S configurations for each asymmetric center, (Z)
and (E) double bond isomers, and (Z) and (E) conformational
isomers. Therefore, single stereochemical isomers as well as
enantiomeric, diastereomeric, and geometric (or conformational)
mixtures of the present compounds are within the scope of the
invention.
[0030] Unless otherwise stated, all tautomeric forms of the
compounds of the invention are within the scope of the invention.
Additionally, unless otherwise stated, structures depicted herein
are also meant to include compounds that differ only in the
presence of one or more isotopically enriched atoms. For example,
compounds having the present structures except for the replacement
of hydrogen by deuterium or tritium, or the replacement of a carbon
by a .sup.13C- or .sup.14C-enriched carbon are within the scope of
this invention. Such compounds are useful, for example, as
analytical tools or probes in biological assays.
Description of Compounds of the Invention
[0031] The present invention relates to a compound of formula
I:
##STR00007## [0032] or a pharmaceutically acceptable salt thereof,
wherein [0033] R.sup.3 is H, Cl or F; [0034] X.sup.1 is N or
CR.sup.4; [0035] R.sup.2 is H, F, R', OH, OR', COR', COOH, COOR',
CONH.sub.2, CONHR', CON(R').sub.2, or CN; [0036] R.sup.4 is H, F,
R', OH, OR', COR', COOH, COOR', CONH.sub.2, CONHR', CON(R').sub.2,
or CN; [0037] or R.sup.2 and R.sup.4, taken together, form a 5-7
membered aryl or heteroaryl ring optionally substituted with 1-4
occurrences of R.sup.10; [0038] R' is a C.sub.1-3 aliphatic
optionally substituted with 1-4 occurrences of R.sup.5; [0039] each
R.sup.5 is independently selected from halogen, CF.sub.3,
OCH.sub.3, OH, SH, NO.sub.2, NH.sub.2, SCH.sub.3, NCH.sub.3, CN or
unsubstituted C.sub.1-2 aliphatic, or two R.sup.5 groups, together
with the carbon to which they are attached, form a cyclopropyl ring
or C.dbd.O; [0040] each R.sup.10 is independently selected from
halogen, OCH.sub.3, OH, NO.sub.2, NH.sub.2, SH, SCH.sub.3,
NCH.sub.3, CN or unsubstituted C.sub.1-2aliphatic; [0041] R.sup.1
is
[0041] ##STR00008## [0042] R'' is H or is a --C.sub.1-2 aliphatic
optionally substituted with 1-3 occurrences of R''; [0043] each
R.sup.11 is independently selected from halogen, OCH.sub.3, OH, SH,
NO.sub.2, NH.sub.2, SCH.sub.3, NCH.sub.3, CN, CON(R.sup.15).sub.2
or unsubstituted C.sub.1-2 aliphatic, or two R.sup.11 groups,
together with the carbon to which they are attached, form a
cyclopropyl ring or C.dbd.O; [0044] R.sup.6 is a C.sub.1-4
aliphatic optionally substituted with 1-5 occurrences of R.sup.12;
[0045] each R.sup.12 is independently selected from halogen,
OCH.sub.3, OH, NO.sub.2, NH.sub.2, SH, SCH.sub.3, NCH.sub.3, CN or
unsubstituted C.sub.1-2aliphatic, or two R.sup.12 groups, together
with the carbon to which they are attached, form a cyclopropyl
ring; [0046] Ring A is a 4-8 membered saturated nitrogen-containing
ring comprising up to two additional heteroatoms selected from N, O
or S and optionally substituted with 1-4 occurrences of R.sup.13;
[0047] each R.sup.13 is independently selected from halogen, R',
NH.sub.2, NHR', N(R').sub.2, SH, SR', OH, OR', NO.sub.2, CN,
CF.sub.3, COOR', COOH, COR', OC(O)H, OC(O)R', CONH.sub.2, CONHR',
CON(R').sub.2, NHC(O)R' or NR'C(O)R'; or any two R.sup.13 groups,
on the same substituent or different substituents, together with
the atom(s) to which each R.sup.13 group is bound, form a 3-7
membered saturated, unsaturated, or partially saturated carbocyclic
or heterocyclic ring optionally substituted with 1-3 occurrences of
R.sup.5; [0048] R.sup.8 is C.sub.1-4 aliphatic optionally
substituted with 1-5 occurrences of R.sup.12; [0049] R.sup.9 is
C.sub.1-2 alkyl; or [0050] R.sup.8 and R.sup.9 are taken together
to form a 3-7 membered carbocyclic or heterocyclic saturated ring
optionally substituted with 1-5 occurrences of R.sup.12; [0051]
R.sup.14 is H or unsubstituted C.sub.1-2 alkyl; [0052] R.sup.15 is
H or unsubstituted C.sub.1-2 alkyl; and [0053] R.sup.7 is a
C.sub.2-3 aliphatic or cycloaliphatic optionally substituted with
up to 6 occurrences of F.
[0054] In one embodiment, a compound of the invention has one of
formulae I-A or I-B:
##STR00009##
[0055] In one embodiment, R.sup.3 is H or Cl. In a further
embodiment, R.sup.3 is Cl. In a further embodiment, R.sup.3 is
H.
[0056] In one embodiment, R.sup.2 is H, F, R', OH or OR'. In a
further embodiment, R.sup.2 is H or F.
[0057] In one embodiment, the compound is of formula I-A and
R.sup.4 is H, F, R', OH or OR'. In another embodiment, R.sup.4 is H
or F. In a further embodiment, R.sup.4 is F and R.sup.2 is H. In
another embodiment, R.sup.2 is F and R.sup.4 is H. In another
embodiment, R.sup.2 and R.sup.4 are both H. In a further
embodiment, R.sup.3 is Cl. In an alternative embodiment, R.sup.3 is
H.
[0058] In another embodiment, the compound is of formula I-A and
R.sup.2 and R.sup.4 are taken together to form a 6-membered aryl
ring. In a further embodiment, R.sup.3 is Cl. In an alternative
embodiment, R.sup.3 is H.
[0059] In another embodiment, R.sup.7 is CH.sub.2CH.sub.3,
CH.sub.2CF.sub.3, CH.sub.2CHF.sub.2, CH.sub.2CH.sub.2F,
CH.sub.2CH.sub.2CH.sub.3, CH.sub.2CH.sub.2CF.sub.3,
CH.sub.2CH.sub.2CH.sub.2F or CH.sub.2CH.sub.2CHF.sub.2. In a
further embodiment, R.sup.7 is CH.sub.2CH.sub.3, CH.sub.2CF.sub.3,
CH.sub.2CH.sub.2CH.sub.3 or CH.sub.2CH.sub.2CF.sub.3. In yet a
further embodiment, R.sup.7 is CH.sub.2CF.sub.3.
[0060] In another embodiment, R'' is H or CH.sub.3. In a further
embodiment, R'' is H.
[0061] In another embodiment, R.sup.14 is H. In yet another
embodiment, R.sup.15, if present, is H. In another embodiment,
R.sup.15 is absent.
[0062] In another embodiment, the invention provides a compound of
formula II:
##STR00010##
wherein X.sup.1A is N, CH or CF and R.sup.1A is
##STR00011##
In a further embodiment, R.sup.7 is CH.sub.2CH.sub.3,
CH.sub.2CF.sub.3, CH.sub.2CH.sub.2CH.sub.3 or
CH.sub.2CH.sub.2CF.sub.3. In yet a further embodiment, R.sup.7 is
CH.sub.2CF.sub.3.
[0063] In another embodiment, the invention provides a compound of
formula III:
##STR00012##
wherein X.sup.1A is N, CH or CF and R.sup.1A is
##STR00013##
In a further embodiment, R.sup.7 is CH.sub.2CH.sub.3,
CH.sub.2CF.sub.3, CH.sub.2CH.sub.2CH.sub.3 or
CH.sub.2CH.sub.2CF.sub.3. In yet a further embodiment, R.sup.7 is
CH.sub.2CF.sub.3.
[0064] In another embodiment of any of formulae I, II or III,
R.sup.6 is selected from
##STR00014##
[0065] In a further embodiment, R.sup.6 is selected from
##STR00015##
[0066] In yet a further embodiment, R.sup.6 is selected from
##STR00016##
[0067] In another embodiment of any of formulae I, II or III, Ring
A is
##STR00017##
and R.sup.13, is H or R.sup.13.
[0068] In a further embodiment, Ring A is
##STR00018##
[0069] In a further embodiment, Ring A is
##STR00019##
[0070] In one embodiment, each R.sup.13 is independently selected
from halogen, R', NH.sub.2, NHR', N(R').sub.2, SH, SR', OH, OR',
NO.sub.2, CN, CF.sub.3, COOR', COOH, COR', OC(O)R' or NHC(O)R'; or
any two R.sup.13 groups, on the same substituent or different
substituents, together with the atom(s) to which each R.sup.13
group is bound, form a 3-7 membered saturated, unsaturated, or
partially saturated carbocyclic or heterocyclic ring optionally
substituted with 1-3 occurrences of R.sup.5.
[0071] In one embodiment of this invention, R.sup.13 is absent. In
another embodiment, Ring A is substituted with one occurrence of
R.sup.13. In a further embodiment, the one occurrence of R.sup.13
is OH, CH.sub.3, F, OR' or NHR'. In yet a further embodiment, R' is
C.sub.1-2 alkyl or C.sub.2-3 alkenyl. In another embodiment,
R.sup.13 is OH.
[0072] In another embodiment of any of formulae I, II or III,
R.sup.8 and R.sup.9 are taken together to form a ring selected
from
##STR00020##
wherein one or more carbon atoms in of said ring are optionally and
independently replaced by N, O or S.
[0073] In another embodiment of any of formulae I, II or III,
R.sup.8 and R.sup.9 are
##STR00021##
[0074] In a further embodiment, R.sup.8 and R.sup.9 are
##STR00022##
[0075] In yet a further embodiment, R.sup.8 and R.sup.9 are
##STR00023##
[0076] In still a further embodiment, R.sup.8 and R.sup.9 are
##STR00024##
[0077] In another embodiment, the invention provides a compound of
formulae I, IA, IB, II or III, wherein said compound inhibits a JAK
kinase with a lower K.sub.i (i.e., is more potent) than said
compounds inhibits one or more kinases selected from Aurora-1
(AUR-B), Aurora-2 (AUR-A), Src, CDK2, Flt-3 or c-Kit. In another
embodiment, the invention provides a compound of formulae I, IA,
IB, II or III, wherein said compound inhibits JAK3 with a lower
K.sub.i than said compound inhibits one or more kinases selected
from JAK2, Aurora-1, Aurora-2, Src, CDK2, Flt-3 or c-Kit.
[0078] In another embodiment, the invention provides a compound of
any of formulae I, IA, IB, II or III, wherein said compound
inhibits JAK3 with a K.sub.i of less than 0.1 .mu.M. In a further
embodiment, the invention provides a compound of any of formulae I,
IA, IB, II or III, wherein said compound inhibits JAK3 with a
K.sub.i of less than 0.01 .mu.M. In another embodiment, the
invention provides a compound of any of formulae I, IA, IB, II or
III, wherein said compound inhibits JAK3 with a K.sub.i of less
than 0.01 .mu.M and inhibits Aurora-2 with a K.sub.i that is at
least 5-fold higher than the K.sub.i of JAK3. In a further
embodiment, the invention provides a compound of any of formulae I,
IA, IB, II or III, wherein said compound inhibits JAK3 with a
K.sub.i of less than 0.01 .mu.M and inhibits Aurora-2 with a
K.sub.i that is at least 10-fold higher than the K.sub.i of
JAK3.
[0079] In another embodiment, the invention provides a compound of
formulae I, IA, IB, II or III, wherein said compound inhibits JAK3
in a cellular assay with an IC.sub.50 of less than 5 .mu.M. In a
further embodiment, said compound inhibits JAK3 in a cellular assay
with an IC.sub.50 of less than 1 .mu.M.
[0080] In another embodiment, said compound inhibits JAK3 in a
cellular assay with an IC.sub.50 that is at least 5-fold less than
said compound inhibits one or more kinases selected from JAK2,
Aurora-1, Aurora-2, Src, CDK2, Flt-3 or c-Kit in a cellular assay.
In another embodiment, the invention provides a compound of
formulae I, IA, IB, II or III, wherein said compound inhibits JAK3
in a cellular assay with an IC.sub.50 of less than 5 .mu.M, wherein
the IC.sub.50 of JAK2 is at least 5-fold higher than the IC.sub.50
of JAK3. In a further embodiment, said compound inhibits JAK3 in a
cellular assay with an IC.sub.50 of less than 1 .mu.M, wherein the
IC.sub.50 of JAK2 is at least 5-fold higher than the IC.sub.50 of
JAK3. In a further embodiment, said compound inhibits JAK3 in a
cellular assay with an IC.sub.50 of less than 5 .mu.M, wherein the
IC.sub.50 of JAK2 is at least 10-fold higher than the IC.sub.50 of
JAK3. In a further embodiment, said compound inhibits JAK3 in a
cellular assay with an IC.sub.50 of less than 1 .mu.M, wherein the
IC.sub.50 of JAK2 is at least 10-fold higher than the IC.sub.50 of
JAK3. In yet a further embodiment, the invention provides a
compound of formulae I, IA, IB, II or III, wherein said compound
inhibits JAK3 in a cellular assay with an IC.sub.50 of less than 1
.mu.M, wherein the IC.sub.50 of JAK2 is at least 5-fold higher than
the IC.sub.50 of JAK3, and wherein said compound inhibits JAK3 with
a K.sub.i of less than 0.01 .mu.M and inhibits Aurora-2 with a
K.sub.i that is at least 5-fold higher than the K.sub.i of JAK3. In
yet a further embodiment, said compound inhibits JAK3 in a cellular
assay with an IC.sub.50 of less than 1 .mu.M, wherein the IC.sub.50
of JAK2 is at least 10-fold higher than the IC.sub.50 of JAK3, and
wherein said compound inhibits JAK3 with a K.sub.i of less than
0.01 .mu.M and inhibits Aurora-2 with a K.sub.i that is at least
10-fold higher than the K.sub.i of JAK3.
[0081] In another embodiment, the invention provides a compound of
Table 1, Table 2 or Table 3:
TABLE-US-00001 TABLE 1 ##STR00025## 1 ##STR00026## 2 ##STR00027## 3
##STR00028## 4 ##STR00029## 5 ##STR00030## 6 ##STR00031## 7
##STR00032## 8 ##STR00033## 9 ##STR00034## 10 ##STR00035## 11
##STR00036## 12 ##STR00037## 13 ##STR00038## 14 ##STR00039## 15
##STR00040## 16 ##STR00041## 17 ##STR00042## 18 ##STR00043## 19
##STR00044## 20 ##STR00045## 21 ##STR00046## 22 ##STR00047## 23
##STR00048## 24 ##STR00049## 25 ##STR00050## 26 ##STR00051## 27
##STR00052## 28 ##STR00053## 29 ##STR00054## 30 ##STR00055## 31
##STR00056## 32 ##STR00057## 33 ##STR00058## 34 ##STR00059## 35
##STR00060## 36 ##STR00061## 37 ##STR00062## 38 ##STR00063## 39
##STR00064## 40 ##STR00065## 41 ##STR00066## 42 ##STR00067## 43
##STR00068## 44 ##STR00069## 45 ##STR00070## 46 ##STR00071## 47
##STR00072## 48 ##STR00073## 49 ##STR00074## 50 ##STR00075## 51
##STR00076## 52 ##STR00077## 53 ##STR00078## 54 ##STR00079## 55
##STR00080## 56 ##STR00081## 57 ##STR00082## 58 ##STR00083## 59
##STR00084## 60 ##STR00085## 61 ##STR00086## 62 ##STR00087## 63
##STR00088## 64 ##STR00089## 65 ##STR00090## 66 ##STR00091## 67
##STR00092## 68 ##STR00093## 69 ##STR00094## 70 ##STR00095## 71
##STR00096## 72 ##STR00097## 73 ##STR00098## 74 ##STR00099## 75
##STR00100## 76 ##STR00101## 77 ##STR00102## 78 ##STR00103## 79
##STR00104## 80 ##STR00105## 81 ##STR00106## 82 ##STR00107## 83
##STR00108## 84 ##STR00109## 85 ##STR00110## 86 ##STR00111## 87
##STR00112## 88 ##STR00113## 89 ##STR00114## 90 ##STR00115## 91
##STR00116## 92 ##STR00117## 93 ##STR00118## 94 ##STR00119## 95
##STR00120## 96 ##STR00121## 97 ##STR00122## 98 ##STR00123## 99
##STR00124## 100 ##STR00125## 101 ##STR00126## 102 ##STR00127## 103
##STR00128## 104 ##STR00129## 105 ##STR00130## 106 ##STR00131## 107
##STR00132## 108 ##STR00133## 109 ##STR00134## 110 ##STR00135## 111
##STR00136## 112 ##STR00137## 113 ##STR00138## 114 ##STR00139## 115
##STR00140## 116 ##STR00141## 117 ##STR00142## 118 ##STR00143## 119
##STR00144## 120 ##STR00145## 121 ##STR00146## 122 ##STR00147## 123
##STR00148## 124
##STR00149## 125 ##STR00150## 126 ##STR00151## 127 ##STR00152## 128
##STR00153## 129 ##STR00154## 130 ##STR00155## 131 ##STR00156## 132
##STR00157## 133 ##STR00158## 134 ##STR00159## 135 ##STR00160## 136
##STR00161## 137 ##STR00162## 138 ##STR00163## 139 ##STR00164## 140
##STR00165## 141 ##STR00166## 142 ##STR00167## 143 ##STR00168## 144
##STR00169## 145 ##STR00170## 146 ##STR00171## 147 ##STR00172## 148
##STR00173## 149 ##STR00174## 150 ##STR00175## 151 ##STR00176## 152
##STR00177## 153 ##STR00178## 154 ##STR00179## 155 ##STR00180## 156
##STR00181## 157 ##STR00182## 158 ##STR00183## 159 ##STR00184## 160
##STR00185## 161 ##STR00186## 162 ##STR00187## 163 ##STR00188## 164
##STR00189## 165 ##STR00190## 166 ##STR00191## 167 ##STR00192## 168
##STR00193## 169 ##STR00194## 170 ##STR00195## 171 ##STR00196## 172
##STR00197## 173 ##STR00198## 174 ##STR00199## 175 ##STR00200## 176
##STR00201## 177 ##STR00202## 178 ##STR00203## 179 ##STR00204##
180
TABLE-US-00002 TABLE 2 ##STR00205## 181 ##STR00206## 182
##STR00207## 183 ##STR00208## 184 ##STR00209## 185 ##STR00210## 186
##STR00211## 187 ##STR00212## 188 ##STR00213## 189 ##STR00214## 190
##STR00215## 191 ##STR00216## 192 ##STR00217## 193 ##STR00218## 194
##STR00219## 195 ##STR00220## 196 ##STR00221## 197 ##STR00222## 198
##STR00223## 199 ##STR00224## 200 ##STR00225## 201 ##STR00226## 202
##STR00227## 203 ##STR00228## 204 ##STR00229## 205 ##STR00230## 206
##STR00231## 207 ##STR00232## 208 ##STR00233## 209 ##STR00234## 210
##STR00235## 211 ##STR00236## 212 ##STR00237## 213 ##STR00238## 214
##STR00239## 215 ##STR00240## 216 ##STR00241## 217 ##STR00242## 218
##STR00243## 219 ##STR00244## 220 ##STR00245## 221 ##STR00246## 222
##STR00247## 223 ##STR00248## 224 ##STR00249## 225 ##STR00250## 226
##STR00251## 227 ##STR00252## 228 ##STR00253## 229 ##STR00254## 230
##STR00255## 231 ##STR00256## 232 ##STR00257## 233 ##STR00258## 234
##STR00259## 235 ##STR00260## 236 ##STR00261## 237 ##STR00262## 238
##STR00263## 239 ##STR00264## 240 ##STR00265## 241 ##STR00266## 242
##STR00267## 243 ##STR00268## 244 ##STR00269## 245 ##STR00270## 246
##STR00271## 247 ##STR00272## 248 ##STR00273## 249 ##STR00274## 250
##STR00275## 251 ##STR00276## 252 ##STR00277## 253 ##STR00278## 254
##STR00279## 255 ##STR00280## 256 ##STR00281## 257 ##STR00282## 258
##STR00283## 259 ##STR00284## 260 ##STR00285## 261 ##STR00286## 262
##STR00287## 263 ##STR00288## 264 ##STR00289## 265 ##STR00290## 266
##STR00291## 267 ##STR00292## 268 ##STR00293## 269 ##STR00294## 270
##STR00295## 271 ##STR00296## 272 ##STR00297## 273 ##STR00298## 274
##STR00299## 275 ##STR00300## 276 ##STR00301## 277 ##STR00302## 278
##STR00303## 279 ##STR00304## 280 ##STR00305## 281 ##STR00306## 282
##STR00307## 283 ##STR00308## 284 ##STR00309## 285 ##STR00310## 286
##STR00311## 287 ##STR00312## 288 ##STR00313## 289 ##STR00314## 290
##STR00315## 291 ##STR00316## 292 ##STR00317## 293 ##STR00318## 294
##STR00319## 295 ##STR00320## 296 ##STR00321## 297 ##STR00322## 298
##STR00323## 299 ##STR00324## 300 ##STR00325## 301 ##STR00326## 302
##STR00327## 303 ##STR00328## 304
##STR00329## 305 ##STR00330## 306 ##STR00331## 307 ##STR00332## 308
##STR00333## 309
TABLE-US-00003 TABLE 3 ##STR00334## 310 ##STR00335## 311
##STR00336## 312 ##STR00337## 313 ##STR00338## 314 ##STR00339## 315
##STR00340## 316 ##STR00341## 317 ##STR00342## 318 ##STR00343## 319
##STR00344## 320 ##STR00345## 321 ##STR00346## 322 ##STR00347## 323
##STR00348## 324 ##STR00349## 325 ##STR00350## 326 ##STR00351## 327
##STR00352## 328 ##STR00353## 329 ##STR00354## 330 ##STR00355## 331
##STR00356## 332 ##STR00357## 333 ##STR00358## 334 ##STR00359## 335
##STR00360## 336 ##STR00361## 337 ##STR00362## 338 ##STR00363## 339
##STR00364## 340 ##STR00365## 341 ##STR00366## 342 ##STR00367## 343
##STR00368## 344 ##STR00369## 345 ##STR00370## 346 ##STR00371## 347
##STR00372## 348 ##STR00373## 349 ##STR00374## 350 ##STR00375## 351
##STR00376## 352 ##STR00377## 353 ##STR00378## 354 ##STR00379## 355
##STR00380## 356 ##STR00381## 357 ##STR00382## 358 ##STR00383## 359
##STR00384## 360 ##STR00385## 361 ##STR00386## 362 ##STR00387## 363
##STR00388## 364 ##STR00389## 365 ##STR00390## 366 ##STR00391## 367
##STR00392## 368 ##STR00393## 369 ##STR00394## 370 ##STR00395## 371
##STR00396## 372 ##STR00397## 373 ##STR00398## 374 ##STR00399## 375
##STR00400## 376 ##STR00401## 377 ##STR00402## 378 ##STR00403## 379
##STR00404## 380 ##STR00405## 381 ##STR00406## 382 ##STR00407## 383
##STR00408## 384 ##STR00409## 385 ##STR00410## 386 ##STR00411## 387
##STR00412## 388 ##STR00413## 389 ##STR00414## 390 ##STR00415## 391
##STR00416## 392 ##STR00417## 393 ##STR00418## 394 ##STR00419## 395
##STR00420## 396 ##STR00421## 397 ##STR00422## 398 ##STR00423## 399
##STR00424## 400 ##STR00425## 401 ##STR00426## 402 ##STR00427## 403
##STR00428## 404 ##STR00429## 405
Uses, Formulation and Administration
Pharmaceutically Acceptable Compositions
[0082] In another embodiment, the invention provides a
pharmaceutical composition comprising a compound of formulae I, IA,
IB, II or III.
[0083] In a further embodiment, the composition additionally
comprising a therapeutic agent selected from a chemotherapeutic or
anti-proliferative agent, an anti-inflammatory agent, an
immunomodulatory or immunosuppressive agent, a neurotrophic factor,
an agent for treating cardiovascular disease, an agent for treating
destructive bone disorders, an agent for treating liver disease, an
anti-viral agent, an agent for treating blood disorders, an agent
for treating diabetes, or an agent for treating immunodeficiency
disorders.
[0084] According to another embodiment, the invention provides a
composition comprising a compound of this invention or a
pharmaceutically acceptable derivative thereof and a
pharmaceutically acceptable carrier, adjuvant, or vehicle. The
amount of compound in the compositions of this invention is such
that is effective to measurably inhibit a protein kinase,
particularly a JAK family kinase, in a biological sample or in a
patient. Preferably the composition of this invention is formulated
for administration to a patient in need of such composition. Most
preferably, the composition of this invention is formulated for
oral administration to a patient.
[0085] The term "patient", as used herein, means an animal,
preferably a mammal, and most preferably a human.
[0086] Accordingly, in another aspect of the present invention,
pharmaceutically acceptable compositions are provided, wherein
these compositions comprise any of the compounds as described
herein, and optionally comprise a pharmaceutically acceptable
carrier, adjuvant or vehicle. In certain embodiments, these
compositions optionally further comprise one or more additional
therapeutic agents.
[0087] It will also be appreciated that certain of the compounds of
present invention can exist in free form for treatment, or where
appropriate, as a pharmaceutically acceptable derivative thereof.
According to the present invention, a pharmaceutically acceptable
derivative includes, but is not limited to, pharmaceutically
acceptable prodrugs, salts, esters, salts of such esters, or any
other adduct or derivative which upon administration to a patient
in need is capable of providing, directly or indirectly, a compound
as otherwise described herein, or a metabolite or residue thereof.
As used herein, the term "inhibitorily active metabolite or residue
thereof" means that a metabolite or residue thereof is also an
inhibitor of a JAK family kinase.
[0088] As used herein, the term "pharmaceutically acceptable salt"
refers to those salts which are, within the scope of sound medical
judgement, suitable for use in contact with the tissues of humans
and lower animals without undue toxicity, irritation, allergic
response and the like.
[0089] Pharmaceutically acceptable salts are well known in the art.
For example, S. M. Berge et al., describe pharmaceutically
acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66,
1-19, incorporated herein by reference. Pharmaceutically acceptable
salts of the compounds of this invention include those derived from
suitable inorganic and organic acids and bases. Examples of
pharmaceutically acceptable, nontoxic acid addition salts are salts
of an amino group formed with inorganic acids such as hydrochloric
acid, hydrobromic acid, phosphoric acid, sulfuric acid and
perchloric acid or with organic acids such as acetic acid, oxalic
acid, maleic acid, tartaric acid, citric acid, succinic acid or
malonic acid or by using other methods used in the art such as ion
exchange. Other pharmaceutically acceptable salts include adipate,
alginate, ascorbate, aspartate, benzenesulfonate, benzoate,
bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate,
cyclopentanepropionate, digluconate, dodecylsulfate,
ethanesulfonate, formate, fumarate, glucoheptonate,
glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate,
hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate,
laurate, lauryl sulfate, malate, maleate, malonate,
methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate,
oleate, oxalate, palmitate, pamoate, pectinate, persulfate,
3-phenylpropionate, phosphate, picrate, pivalate, propionate,
stearate, succinate, sulfate, tartrate, thiocyanate,
p-toluenesulfonate, undecanoate, valerate salts, and the like.
Salts derived from appropriate bases include alkali metal, alkaline
earth metal, ammonium and N.sup.+(C.sub.1-4alkyl).sub.4 salts. This
invention also envisions the quaternization of any basic
nitrogen-containing groups of the compounds disclosed herein. Water
or oil-soluble or dispersable products may be obtained by such
quaternization. Representative alkali or alkaline earth metal salts
include sodium, lithium, potassium, calcium, magnesium, and the
like. Further pharmaceutically acceptable salts include, when
appropriate, nontoxic ammonium, quaternary ammonium, and amine
cations formed using counterions such as halide, hydroxide,
carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate and
aryl sulfonate.
[0090] As described above, the pharmaceutically acceptable
compositions of the present invention additionally comprise a
pharmaceutically acceptable carrier, adjuvant, or vehicle, which,
as used herein, includes any and all solvents, diluents, or other
liquid vehicle, dispersion or suspension aids, surface active
agents, isotonic agents, thickening or emulsifying agents,
preservatives, solid binders, lubricants and the like, as suited to
the particular dosage form desired. Remington's Pharmaceutical
Sciences, Sixteenth Edition, E. W. Martin (Mack Publishing Co.,
Easton, Pa., 1980) discloses various carriers used in formulating
pharmaceutically acceptable compositions and known techniques for
the preparation thereof. Except insofar as any conventional carrier
medium is incompatible with the compounds of the invention, such as
by producing any undesirable biological effect or otherwise
interacting in a deleterious manner with any other component(s) of
the pharmaceutically acceptable composition, its use is
contemplated to be within the scope of this invention.
[0091] Some examples of materials which can serve as
pharmaceutically acceptable carriers include, but are not limited
to, ion exchangers, alumina, aluminum stearate, lecithin, serum
proteins, such as human serum albumin, buffer substances such as
phosphates, glycine, sorbic acid, or potassium sorbate, partial
glyceride mixtures of saturated vegetable fatty acids, water, salts
or electrolytes, such as protamine sulfate, disodium hydrogen
phosphate, potassium hydrogen phosphate, sodium chloride, zinc
salts, colloidal silica, magnesium trisilicate, polyvinyl
pyrrolidone, polyacrylates, waxes,
polyethylene-polyoxypropylene-block polymers, wool fat, sugars such
as lactose, glucose and sucrose; starches such as corn starch and
potato starch; cellulose and its derivatives such as sodium
carboxymethyl cellulose, ethyl cellulose and cellulose acetate;
powdered tragacanth; malt; gelatin; talc; excipients such as cocoa
butter and suppository waxes; oils such as peanut oil, cottonseed
oil; safflower oil; sesame oil; olive oil; corn oil and soybean
oil; glycols; such a propylene glycol or polyethylene glycol;
esters such as ethyl oleate and ethyl laurate; agar; buffering
agents such as magnesium hydroxide and aluminum hydroxide; alginic
acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl
alcohol, and phosphate buffer solutions, as well as other non-toxic
compatible lubricants such as sodium lauryl sulfate and magnesium
stearate, as well as coloring agents, releasing agents, coating
agents, sweetening, flavoring and perfuming agents, preservatives
and antioxidants can also be present in the composition, according
to the judgment of the formulator.
[0092] The term "measurably inhibit", as used herein means a
measurable change in kinase activity, particularly JAK kinase
activity, between a sample comprising a compound of this invention
and a JAK kinase and an equivalent sample comprising JAK kinase in
the absence of said compound.
[0093] The compositions of the present invention may be
administered orally, parenterally, by inhalation spray, topically,
rectally, nasally, buccally, vaginally or via an implanted
reservoir. The term "parenteral" as used herein includes
subcutaneous, intravenous, intramuscular, intra-articular,
intra-synovial, intrasternal, intrathecal, intraocular,
intrahepatic, intralesional and intracranial injection or infusion
techniques. Preferably, the compositions are administered orally,
intraperitoneally or intravenously. Sterile injectable forms of the
compositions of this invention may be aqueous or oleaginous
suspension. These suspensions may be formulated according to
techniques known in the art using suitable dispersing or wetting
agents and suspending agents. The sterile injectable preparation
may also be a sterile injectable solution or suspension in a
non-toxic parenterally-acceptable diluent or solvent, for example
as a solution in 1,3-butanediol. Among the acceptable vehicles and
solvents that may be employed are water, Ringer's solution and
isotonic sodium chloride solution. In addition, sterile, fixed oils
are conventionally employed as a solvent or suspending medium.
[0094] For this purpose, any bland fixed oil may be employed
including synthetic mono- or di-glycerides. Fatty acids, such as
oleic acid and its glyceride derivatives are useful in the
preparation of injectables, as are natural
pharmaceutically-acceptable oils, such as olive oil or castor oil,
especially in their polyoxyethylated versions. These oil solutions
or suspensions may also contain a long-chain alcohol diluent or
dispersant, such as carboxymethyl cellulose or similar dispersing
agents that are commonly used in the formulation of
pharmaceutically acceptable dosage forms including emulsions and
suspensions. Other commonly used surfactants, such as Tweens, Spans
and other emulsifying agents or bioavailability enhancers which are
commonly used in the manufacture of pharmaceutically acceptable
solid, liquid, or other dosage forms may also be used for the
purposes of formulation.
[0095] The pharmaceutically acceptable compositions of this
invention may be orally administered in any orally acceptable
dosage form including, but not limited to, capsules, tablets,
aqueous suspensions or solutions. In the case of tablets for oral
use, carriers commonly used include lactose and corn starch.
Lubricating agents, such as magnesium stearate, are also typically
added. For oral administration in a capsule form, useful diluents
include lactose and dried cornstarch. When aqueous suspensions are
required for oral use, the active ingredient is combined with
emulsifying and suspending agents. If desired, certain sweetening,
flavoring or coloring agents may also be added.
[0096] Alternatively, the pharmaceutically acceptable compositions
of this invention may be administered in the form of suppositories
for rectal administration. These can be prepared by mixing the
agent with a suitable non-irritating excipient that is solid at
room temperature but liquid at rectal temperature and therefore
will melt in the rectum to release the drug. Such materials include
cocoa butter, beeswax and polyethylene glycols.
[0097] The pharmaceutically acceptable compositions of this
invention may also be administered topically, especially when the
target of treatment includes areas or organs readily accessible by
topical application, including diseases of the eye, the skin, or
the lower intestinal tract. Suitable topical formulations are
readily prepared for each of these areas or organs.
[0098] Topical application for the lower intestinal tract can be
effected in a rectal suppository formulation (see above) or in a
suitable enema formulation. Topically-transdermal patches may also
be used.
[0099] For topical applications, the pharmaceutically acceptable
compositions may be formulated in a suitable ointment containing
the active component suspended or dissolved in one or more
carriers. Carriers for topical administration of the compounds of
this invention include, but are not limited to, mineral oil, liquid
petrolatum, white petrolatum, propylene glycol, polyoxyethylene,
polyoxypropylene compound, emulsifying wax and water.
Alternatively, the pharmaceutically acceptable compositions can be
formulated in a suitable lotion or cream containing the active
components suspended or dissolved in one or more pharmaceutically
acceptable carriers. Suitable carriers include, but are not limited
to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl
esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and
water.
[0100] For ophthalmic use, the pharmaceutically acceptable
compositions may be formulated, e.g., as micronized suspensions in
isotonic, pH adjusted sterile saline or other aqueous solution, or,
preferably, as solutions in isotonic, pH adjusted sterile saline or
other aqueous solution, either with or without a preservative such
as benzylalkonium chloride. Alternatively, for ophthalmic uses, the
pharmaceutically acceptable compositions may be formulated in an
ointment such as petrolatum. The pharmaceutically acceptable
compositions of this invention may also be administered by nasal
aerosol or inhalation. Such compositions are prepared according to
techniques well-known in the art of pharmaceutical formulation and
may be prepared as solutions in saline, employing benzyl alcohol or
other suitable preservatives, absorption promoters to enhance
bioavailability, fluorocarbons, and/or other conventional
solubilizing or dispersing agents.
[0101] Most preferably, the pharmaceutically acceptable
compositions of this invention are formulated for oral
administration.
[0102] Liquid dosage forms for oral administration include, but are
not limited to, pharmaceutically acceptable emulsions,
microemulsions, solutions, suspensions, syrups and elixirs. In
addition to the active compounds, the liquid dosage forms may
contain inert diluents commonly used in the art such as, for
example, water or other solvents, solubilizing agents and
emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl
carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate,
propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in
particular, cottonseed, groundnut, corn, germ, olive, castor, and
sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene
glycols and fatty acid esters of sorbitan, and mixtures thereof.
Besides inert diluents, the oral compositions can also include
adjuvants such as wetting agents, emulsifying and suspending
agents, sweetening, flavoring, and perfuming agents.
[0103] Injectable preparations, for example, sterile injectable
aqueous or oleaginous suspensions may be formulated according to
the known art using suitable dispersing or wetting agents and
suspending agents. The sterile injectable preparation may also be a
sterile injectable solution, suspension or emulsion in a nontoxic
parenterally acceptable diluent or solvent, for example, as a
solution in 1,3-butanediol. Among the acceptable vehicles and
solvents that may be employed are water, Ringer's solution, U.S.P.
and isotonic sodium chloride solution. In addition, sterile, fixed
oils are conventionally employed as a solvent or suspending medium.
For this purpose any bland fixed oil can be employed including
synthetic mono- or diglycerides. In addition, fatty acids such as
oleic acid are used in the preparation of injectables.
[0104] The injectable formulations can be sterilized, for example,
by filtration through a bacterial-retaining filter, or by
incorporating sterilizing agents in the form of sterile solid
compositions which can be dissolved or dispersed in sterile water
or other sterile injectable medium prior to use.
[0105] In order to prolong the effect of a compound of the present
invention, it is often desirable to slow the absorption of the
compound from subcutaneous or intramuscular injection. This may be
accomplished by the use of a liquid suspension of crystalline or
amorphous material with poor water solubility. The rate of
absorption of the compound then depends upon its rate of
dissolution that, in turn, may depend upon crystal size and
crystalline form. Alternatively, delayed absorption of a
parenterally administered compound form is accomplished by
dissolving or suspending the compound in an oil vehicle. Injectable
depot forms are made by forming microencapsule matrices of the
compound in biodegradable polymers such as
polylactide-polyglycolide. Depending upon the ratio of compound to
polymer and the nature of the particular polymer employed, the rate
of compound release can be controlled. Examples of other
biodegradable polymers include poly(orthoesters) and
poly(anhydrides). Depot injectable formulations are also prepared
by entrapping the compound in liposomes or microemulsions that are
compatible with body tissues.
[0106] Compositions for rectal or vaginal administration are
preferably suppositories which can be prepared by mixing the
compounds of this invention with suitable non-irritating excipients
or carriers such as cocoa butter, polyethylene glycol or a
suppository wax which are solid at ambient temperature but liquid
at body temperature and therefore melt in the rectum or vaginal
cavity and release the active compound.
[0107] Solid dosage forms for oral administration include capsules,
tablets, pills, powders, and granules. In such solid dosage forms,
the active compound is mixed with at least one inert,
pharmaceutically acceptable excipient or carrier such as sodium
citrate or dicalcium phosphate and/or a) fillers or extenders such
as starches, lactose, sucrose, glucose, mannitol, and silicic acid,
b) binders such as, for example, carboxymethylcellulose, alginates,
gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants
such as glycerol, d) disintegrating agents such as agar-agar,
calcium carbonate, potato or tapioca starch, alginic acid, certain
silicates, and sodium carbonate, e) solution retarding agents such
as paraffin, f) absorption accelerators such as quaternary ammonium
compounds, g) wetting agents such as, for example, cetyl alcohol
and glycerol monostearate, h) absorbents such as kaolin and
bentonite clay, and i) lubricants such as talc, calcium stearate,
magnesium stearate, solid polyethylene glycols, sodium lauryl
sulfate, and mixtures thereof. In the case of capsules, tablets and
pills, the dosage form may also comprise buffering agents.
[0108] Solid compositions of a similar type may also be employed as
fillers in soft and hard-filled gelatin capsules using such
excipients as lactose or milk sugar as well as high molecular
weight polyethylene glycols and the like. The solid dosage forms of
tablets, dragees, capsules, pills, and granules can be prepared
with coatings and shells such as enteric coatings and other
coatings well known in the pharmaceutical formulating art. They may
optionally contain opacifying agents and can also be of a
composition that they release the active ingredient(s) only, or
preferentially, in a certain part of the intestinal tract,
optionally, in a delayed manner. Examples of embedding compositions
that can be used include polymeric substances and waxes. Solid
compositions of a similar type may also be employed as fillers in
soft and hard-filled gelatin capsules using such excipients as
lactose or milk sugar as well as high molecular weight polethylene
glycols and the like.
[0109] The active compounds can also be in micro-encapsulated form
with one or more excipients as noted above. The solid dosage forms
of tablets, dragees, capsules, pills, and granules can be prepared
with coatings and shells such as enteric coatings, release
controlling coatings and other coatings well known in the
pharmaceutical formulating art. In such solid dosage forms the
active compound may be admixed with at least one inert diluent such
as sucrose, lactose or starch. Such dosage forms may also comprise,
as is normal practice, additional substances other than inert
diluents, e.g., tableting lubricants and other tableting aids such
a magnesium stearate and microcrystalline cellulose. In the case of
capsules, tablets and pills, the dosage forms may also comprise
buffering agents. They may optionally contain opacifying agents and
can also be of a composition that they release the active
ingredient(s) only, or preferentially, in a certain part of the
intestinal tract, optionally, in a delayed manner. Examples of
embedding compositions that can be used include polymeric
substances and waxes.
[0110] Dosage forms for topical or transdermal administration of a
compound of this invention include ointments, pastes, creams,
lotions, gels, powders, solutions, sprays, inhalants or patches.
The active component is admixed under sterile conditions with a
pharmaceutically acceptable carrier and any needed preservatives or
buffers as may be required. Ophthalmic formulation, ear drops, and
eye drops are also contemplated as being within the scope of this
invention. Additionally, the present invention contemplates the use
of transdermal patches, which have the added advantage of providing
controlled delivery of a compound to the body. Such dosage forms
can be made by dissolving or dispensing the compound in the proper
medium. Absorption enhancers can also be used to increase the flux
of the compound across the skin. The rate can be controlled by
either providing a rate controlling membrane or by dispersing the
compound in a polymer matrix or gel.
[0111] The compounds of the invention are preferably formulated in
dosage unit form for ease of administration and uniformity of
dosage. The expression "dosage unit form" as used herein refers to
a physically discrete unit of agent appropriate for the patient to
be treated. It will be understood, however, that the total daily
usage of the compounds and compositions of the present invention
will be decided by the attending physician within the scope of
sound medical judgment. The specific effective dose level for any
particular patient or organism will depend upon a variety of
factors including the disorder being treated and the severity of
the disorder; the activity of the specific compound employed; the
specific composition employed; the age, body weight, general
health, sex and diet of the patient; the time of administration,
route of administration, and rate of excretion of the specific
compound employed; the duration of the treatment; drugs used in
combination or coincidental with the specific compound employed,
and like factors well known in the medical arts.
[0112] The amount of the compounds of the present invention that
may be combined with the carrier materials to produce a composition
in a single dosage form will vary depending upon the host treated,
the particular mode of administration. Preferably, the compositions
should be formulated so that a dosage of between 0.01-100 mg/kg
body weight/day of the inhibitor can be administered to a patient
receiving these compositions.
[0113] Depending upon the particular condition, or disease, to be
treated or prevented, additional therapeutic agents, which are
normally administered to treat or prevent that condition, may also
be present in the compositions of this invention. As used herein,
additional therapeutic agents that are normally administered to
treat or prevent a particular disease, or condition, are known as
"appropriate for the disease, or condition, being treated".
[0114] For example, chemotherapeutic agents or other
anti-proliferative agents may be combined with the compounds of
this invention to treat proliferative diseases and cancer. Examples
of known chemotherapeutic agents include, but are not limited to,
Gleevec.TM., adriamycin, dexamethasone, vincristine,
cyclophosphamide, fluorouracil, topotecan, taxol, interferons, and
platinum derivatives.
[0115] Other examples of agents the inhibitors of this invention
may also be combined with include, without limitation: treatments
for Alzheimer's Disease such as Aricept.RTM. and Excelon.RTM.;
treatments for Parkinson's Disease such as L-DOPA/carbidopa,
entacapone, ropinrole, pramipexole, bromocriptine, pergolide,
trihexephendyl, and amantadine; agents for treating Multiple
Sclerosis (MS) such as beta interferon (e.g., Avonex.RTM. and
Rebif.RTM.), Copaxone.RTM., and mitoxantrone; treatments for asthma
such as albuterol and Singulair.RTM.; agents for treating
schizophrenia such as zyprexa, risperdal, seroquel, and
haloperidol; anti-inflammatory agents such as corticosteroids, TNF
blockers, IL-1 RA, azathioprine, cyclophosphamide, and
sulfasalazine; immunomodulatory and immunosuppressive agents such
as cyclosporin, tacrolimus, rapamycin, mycophenolate mofetil,
interferons, corticosteroids, cyclophophamide, azathioprine, and
sulfasalazine; neurotrophic factors such as acetylcholinesterase
inhibitors, MAO inhibitors, interferons, anti-convulsants, ion
channel blockers, riluzole, and anti-Parkinsonian agents; agents
for treating cardiovascular disease such as beta-blockers, ACE
inhibitors, diuretics, nitrates, calcium channel blockers, and
statins; agents for treating liver disease such as corticosteroids,
cholestyramine, interferons, and anti-viral agents; agents for
treating blood disorders such as corticosteroids, anti-leukemic
agents, and growth factors; and agents for treating
immunodeficiency disorders such as gamma globulin.
[0116] The amount of additional therapeutic agent present in the
compositions of this invention will be no more than the amount that
would normally be administered in a composition comprising that
therapeutic agent as the only active agent. Preferably the amount
of additional therapeutic agent in the presently disclosed
compositions will range from about 50% to 100% of the amount
normally present in a composition comprising that agent as the only
therapeutically active agent.
[0117] Uses of the Compounds and Compositions
[0118] In one embodiment, the invention provides a method of
inhibiting JAK kinase activity in a patient, comprising
administering to said patient a compound or composition of the
invention.
[0119] In another embodiment, the invention comprises a method of
treating or lessening the severity of a JAK-mediated condition or
disease in a patient. The term "JAK-mediated disease", as used
herein means any disease or other deleterious condition in which a
JAK family kinase, in particular JAK2 or JAK3, is known to play a
role. In a further embodiment, the invention comprises a method of
treating a JAK3-mediated disease. Such conditions include, without
limitation, immune responses such as allergic or type I
hypersensitivity reactions, asthma, autoimmune diseases such as
transplant rejection, graft versus host disease, rheumatoid
arthritis, amyotrophic lateral sclerosis, and multiple sclerosis,
neurodegenerative disorders such as familial amyotrophic lateral
sclerosis (FALS), as well as in solid and hematologic malignancies
such as leukemias and lymphomas.
[0120] In another embodiment, the invention provides a method of
treating or lessening the severity of a disease of condition
selected from a proliferative disorder, a cardiac disorder, a
neurodegenerative disorder, an autoimmune disorder, a condition
associated with organ transplant, an inflammatory disorder, an
immune disorder or an immunologically mediated disorder, comprising
administering to said patient a compound or composition of the
invention.
[0121] In a further embodiment, the method comprises the additional
step of administering to said patient an additional therapeutic
agent selected from a chemotherapeutic or anti-proliferative agent,
an anti-inflammatory agent, an immunomodulatory or
immunosuppressive agent, a neurotrophic factor, an agent for
treating cardiovascular disease, an agent for treating diabetes, or
an agent for treating immunodeficiency disorders, wherein said
additional therapeutic agent is appropriate for the disease being
treated and said additional therapeutic agent is administered
together with said composition as a single dosage form or
separately from said composition as part of a multiple dosage
form.
[0122] In one embodiment, the disease or disorder is allergic or
type I hypersensitivity reactions, asthma, diabetes, Alzheimer's
disease, Huntington's disease, Parkinson's disease, AIDS-associated
dementia, amyotrophic lateral sclerosis (ALS, Lou Gehrig's
disease), multiple sclerosis (MS), schizophrenia, cardiomyocyte
hypertrophy, reperfusion/ischemia, stroke, baldness, transplant
rejection, graft versus host disease, rheumatoid arthritis,
amyotrophic lateral sclerosis, and multiple sclerosis, and solid
and hematologic malignancies such as leukemias and lymphomas. In a
further embodiment, said disease or disorder is asthma. In another
embodiment, said disease or disorder is transplant rejection. In
another embodiment, said disease or disorder is rheumatoid
arthritis.
[0123] In another embodiment, a compound or composition of this
invention may be used to treat a myeloproliferative disorder. In
one embodiment, the myeloproliferative disorder is polycythemia
vera, essential thrombocythemia, or chronic idiopathic
myelofibrosis. In another embodiment, the myeloproliferative
disorder is myeloid metaplasia with myelofibrosis, chronic myeloid
leukemia (CML), chronic myelomonocytic leukemia, chronic
eosinophilic leukemia, hypereosinophilic syndrome, systematic mast
cell disease, atypical CML or juvenile myelomonocytic leukemia.
[0124] In another embodiment, the invention provides for the use of
a compound of formulae I, IA, IB, II or III to treat a JAK-mediated
disease. In a further embodiment, the invention provides for the
use of said compound to treat any of the diseases discussed above.
In another embodiment, the invention provides for the use of a
compound of formulae I, IA, IB, II or III for the manufacture of a
medicament for treating a JAK-mediated disease. In a further
embodiment, the invention provides for the use of said compound for
the manufacture of a medicament for treating any of the diseases
discussed above.
[0125] In another embodiment, the invention provides a method of
inhibiting JAK kinase activity in a biological sample, comprising
contacting said biological sample with a compound or composition of
the invention.
[0126] The term "biological sample", as used herein, means an ex
vivo sample, and includes, without limitation, cell cultures or
extracts thereof; tissue or organ samples or extracts thereof;
biopsied material obtained from a mammal or extracts thereof; and
blood, saliva, urine, feces, semen, tears, or other body fluids or
extracts thereof.
[0127] Inhibition of kinase activity, particularly JAK kinase
activity, in a biological sample is useful for a variety of
purposes that are known to one of skill in the art. Examples of
such purposes include, but are not limited to, blood transfusion,
organ-transplantation, biological specimen storage, and biological
assays.
[0128] In certain embodiments of the present invention an
"effective amount" of the compound or pharmaceutically acceptable
composition is that amount effective for treating or lessening the
severity of one or more of the aforementioned disorders. The
compounds and compositions, according to the method of the present
invention, may be administered using any amount and any route of
administration effective for treating or lessening the severity of
the disorder or disease. The exact amount required will vary from
subject to subject, depending on the species, age, and general
condition of the subject, the severity of the infection, the
particular agent, its mode of administration, and the like.
[0129] In an alternate embodiment, the methods of this invention
comprise the additional step of separately administering to said
patient an additional therapeutic agent. When these additional
therapeutic agents are administered separately they may be
administered to the patient prior to, sequentially with or
following administration of the compositions of this invention.
[0130] The compounds of this invention or pharmaceutical
compositions thereof may also be used for coating an implantable
medical device, such as prostheses, artificial valves, vascular
grafts, stents and catheters. Vascular stents, for example, have
been used to overcome restenosis (re-narrowing of the vessel wall
after injury). However, patients using stents or other implantable
devices risk clot formation or platelet activation. These unwanted
effects may be prevented or mitigated by pre-coating the device
with a pharmaceutically acceptable composition comprising a
compound of this invention.
[0131] Suitable coatings and the general preparation of coated
implantable devices are described in U.S. Pat. Nos. 6,099,562;
5,886,026; and 5,304,121. The coatings are typically biocompatible
polymeric materials such as a hydrogel polymer,
polymethyldisiloxane, polycaprolactone, polyethylene glycol,
polylactic acid, ethylene vinyl acetate, and mixtures thereof. The
coatings may optionally be further covered by a suitable topcoat of
fluorosilicone, polysaccarides, polyethylene glycol, phospholipids
or combinations thereof to impart controlled release
characteristics in the composition. Implantable devices coated with
a compound of this invention are another embodiment of the present
invention. The compounds may also be coated on implantable medical
devices, such as beads, or co-formulated with a polymer or other
molecule, to provide a "drug depot", thus permitting the drug to be
released over a longer time period than administration of an
aqueous solution of the drug.
[0132] Methodology for Synthesis and Characterization of
Compounds
[0133] The compounds of this invention may be prepared in general
by methods known to those skilled in the art for analogous
compounds or by those methods depicted in the Examples below. See,
e.g., the examples described in WO 2005/095400, which is herein
incorporated by reference in its entirety.
[0134] All references provided in the Examples are herein
incorporated by reference. As used herein, all abbreviations,
symbols and conventions are consistent with those used in the
contemporary scientific literature. See, e.g., Janet S. Dodd, ed.,
The ACS Style Guide: A Manual for Authors and Editors, 2nd Ed.,
Washington, D.C.: American Chemical Society, 1997, herein
incorporated in its entirety by reference.
EXAMPLES
Example 1
Preparation of Compounds of the Invention
##STR00430## ##STR00431##
[0135] Step 1
[0136] To a stirred solution of Boc-valine (1; R.sub.1 is Me; 3.8
g, 0.02 mol), EDC (4.63 g, 0.024 mol), HOBt (4.0 g, 0.026 mol),
DIEA (10.5 mL, 0.06 mol) in 100 mL of DCM is added
trifluoroethylamine HCl (2.92 g, 0.022 mol). The reaction mixture
is stirred for 16 h. It is concentrated to dryness and redissolved
in EtOAc, washed successively with 0.5N HCl, saturated aqueous
solution of NaHCO.sub.3 and brine. The organic layer is dried
(Na.sub.2SO.sub.4) and concentrated in vacuo to give 5.4 g (98%) of
2 as a white solid.
Step 2
[0137] Compound 2 (5.32 g, 0.0197 mol) is deprotected with a 1:1
mixture of DCM/TFA at rt for 45 min. Concentration to dryness gives
the intermediate amine that is used directly for the next step. A
mixture of 5-fluoro-2,4-dichloropyrimidine (3; R is F; 3.28 g,
0.0197 mol), the crude amine TFA salt (5.25 g, 0.0197 mol) and DIEA
(10.27 mL, 0.059 mol) are stirred in isopropanol at rt for 16 h.
The reaction mixture is concentrated in vacuo and redissolved in
EtOAc, washed successively with 0.5N HCl, saturated aqueous
solution of NaHCO.sub.3 and brine. The organic layer is dried
(Na.sub.2SO.sub.4) and concentrated in vacuo to give a crude oil
that is subjected to chromatography (50% EtOAc/50% hexanes) to
yield the desired compound 4.
Step 3
[0138] A mixture of 5 (30 mg, 0.075 mmol; prepared according to WO
2005/095400), 4 (23 mg, 0.075 mmol), Pd (Ph.sub.3P).sub.4 (9 mg,
0.0078 mmol) and sodium carbonate 2M (115 uL, 0.23 mmol) in 1 mL of
DME is microwaved at 150.degree. C. for 10 minutes. The reaction
mixture is filtered through a short pad of silica gel with 30%
EtOAc-70% hexanes as eluent to provide, after concentration to
dryness, the crude intermediate that is used directly for the next
step.
[0139] The crude intermediate is dissolved in 1 mL of dry methanol
and 200 uL of sodium methoxide in methanol 25% was added. The
reaction mixture is stirred at 60.degree. C. for 1 h and quenched
with 6N HCl (154 uL). The mixture is dried under a flow of nitrogen
and purified by reverse phase HPLC (10-60 MeCN/water w/0.5% TFA) to
provide the desired material of formula 6a.
[0140] Compounds of formulae 6b and 6c may be prepared in an
analogous manner using the appropriate starting reagents. For
instance, a compound of formula 6b may generally be made by
substituting tert-butyl 2-(2,2,2-trifluoroethylcarbamoyl)
pyrrolidine-1-carboxylate for compound 1, while a compound of
formula 6c may generally be made by substituting tert-butyl
2-(2,2,2-trifluoroethylcarbamoyl)propan-2-ylcarbamate for compound
1.
Example 2
Analytical Results
[0141] Tables 4, 5 and 6 below depicts exemplary .sup.1H-NMR data
(NMR) and liquid chromatographic mass spectral data, reported as
mass plus proton (M+H), as determined by electrospray, and
retention time (RT) for certain compounds of the present invention,
wherein compound numbers in Tables 4, 5 and 6 correspond to the
compounds depicted in Tables 1, 2 and 3, respectively (empty cells
indicate that the test was not performed):
TABLE-US-00004 TABLE 4 Cmpd # M + H RT NMR 1 442.90 2.20 DMSO-d6:
12.4 (br s, 1H); 8.7 (dd, 1H); 8.65 (s, 1H); 8.25 (m, 2H); 8.2 (m,
1H); 4.8 (d, 1H); 4.0-3.8 (m, 4H); 2.3 (m, 1H); 2.05-1.9 (m, 3H) 2
442.90 2.20 DMSO-d6: 12.4 (br s, 1H); 8.7 (dd, 1H); 8.65 (s, 1H);
8.25 (m, 2H); 8.2 (m, 1H); 4.8 (d, 1H); 4.0-3.8 (m, 4H); 2.3 (m,
1H); 2.05-1.9 (m, 3H) 3 430.90 2.50 (CD3OD) 1.7 (s, 6H), 3.8 (m,
2H), 8.15 (s, 1H), 8.2 (d, 1H), 8.25 (m, 1H), 8.5 (t, 1H), 8.85 (d,
1H) 4 463.00 1.90 (CD3OD) 1.9 (s, 6H), 3.8 (m, 2H), 7.75 (t, 1H),
7.9 (d, 1H), 8.05 (t, 1H), 8.35 (d, 1H), 8.55 (d + t, 2H), 8.7 (s,
1H), 8.85 (d, 1H) 5 399.00 1.70 DMSO-d6: 8.92 (m, 1H); 8.60 (m,
2H); 8.32 (s, 1H); 8.18 (m, 1H); 6.65 (m, 1H); 6.72 (m, 1H); 4.80
(m, 1H); 4.00 (m, 2H); 1.42 9d, 3H) 6 417.00 2.40 DMSO-d6: 8.70
(dd, 1H); 8.65 *s, 1H); 8.28 (m, 2H); 8.20 (m, 1H); 7.90 (m, 1H);
4.62 (m, 1H); 3.88 (m, 2H); 1.41 (d, 3H) 7 449.00 2.10 DMSO-d6:
8.86 (m, 1H); 8.76 (m, 1H); 8.55 (m, 1H); 8.40 (m, 1H); 7.96 (m,
1H); 7.85 (m, 1H); 7.70 (m, 1H); 5.00 (m, 1H); 3.98 (m, 2H); 1.58
(d, 3H) 8 459.30 1.70 DMSO-d6: 12.3 (br s, 1H); 8.7 (s, 1H); 8.6
(t, 1H); 8.3 (m, 2H); 8.2 (m, 1H); 4.75 (m, 1H); 4.4 (m, 1H);
4.05-3.7 (m, 5H); 1.9 (m, 1H) 9 457.30 2.20 DMSO-d6: 12.3 (br s,
1H); 8.8 (m, 1H); 8.7 (s, 1H); 8.3 (m, 2H); 8.2 (m, 1H); 4.3 (m,
1H); 4.05-3.8 (m, 4H); 2.25 (m, 1H); 2.1 (m, 1H); 1.7 (m, 1H); 1.15
(m, 3H) 10 459.30 1.80 DMSO-d6: 12.35 (br s, 1H); 8.8 (m, 1H); 8.65
(s, 1H); 8.25 (m, 2H); 8.15 (m, 1H); 4.6 (m, 1H); 4.3 (m, 1H); 4.05
(m, 1H); 3.9-3.8 (m, 3H); 1.95 (m, 2H) 11 455.30 2.10 DMSO-d6:
12.35 (br s, 1H); 8.95 (m, 1H); 8.7 (s, 1H); 8.3 (m, 2H); 8.2 (m,
1H); 4.9 (m, 1H); 4.1-3.9 (m, 4H); 1.8-1.6 (m, 2H); 0.75 (m, 1H);
0.4 (m, 1H) 12 459.30 1.70 DMSO-d6: 12.3 (br s, 1H); 8.7 (s, 1H);
8.6 (t, 1H); 8.25 (m, 2H); 8.15 (m, 1H); 4.75 (m, 1H); 4.4 (m, 1H);
4.05-3.65 (m, 5H); 1.9 (m, 1H) 13 459.30 1.70 DMSO-d6: 12.3 (br s,
1H); 8.8 (m, 1H); 8.7 (s, 1H); 8.3 (m, 2H); 8.2 (m, 1H); 4.8 (m,
1H); 4.45 (m, 1H); 4.05-3.65 (m, 4H); 2.25 (m, 1H); 1.9 (m, 1H) 14
425.00 1.70 DMSO-d6: 12.9 (br s, 1H); 8.9 (m, 1H); 8.6 (m, 2H); 8.4
(s, 1H); 8.35 (m, 1H); 6.7 (m, 1H); 4.9 (m, 1H); 4.1-3.9 (m, 2H);
3.8 (m, 1H); 3.65 (m, 1H); 2.4 (m, 1H); 2.15-1.95 (m, 3H) 15 461.30
2.10 16 425.00 1.70 DMSO-d6: 12.9 (br s, 1H); 8.85 (m, 1H); 8.6 (m,
2H); 8.35 (s, 1H); 8.3 (m, 1H); 6.7 (m, 1H); 4.9 (m, 1H); 4.1-3.9
(m, 2H); 3.75 (m, 1H); 3.6 (m, 1H); 2.4 (m, 1H); 2.15-1.95 (m, 3H)
17 461.30 2.20 18 427.20 1.90 DMSO d6: 13.0 ppm (bs, 1H), 9.0 (t,
1H), 8.7 (s, 1H), 8.6 (s, 1H), 8.4 (s, 1H), 8.2 (d, 1H), 6.8 (bs,
1H), 4.8 (t, 1H), 4.1 (m, 1H), 3.8 (m, 2H), 2.3 (m, 1H), 1.05 (d,
3H), 1.0 (d, 3H) 19 441.20 2.00 DMSO d6: 13.0 ppm (bs, 1H), 9.0 (t,
1H), 8.7 (s, 2H), 8.4 (s, 1H), 8.1 (d, 1H), 6.6 (d, 1H), 4.8 (t,
1H), 3.8-4.2 (m, 4H), 1.7 (bs, 2H), 1.0 (d, 3H), 0.9 (d, 3H) 20
445.20 2.90 DMSO d6: 12.4 ppm (bs, 1H), 8.8 (t, 1H), 8.7 (s, 1H),
8.3 (s, 1H), 8.2 (d, 2H), 7.6 (d, 1H), 4.5 (t, 1H), 3.9-4.1 (m,
2H), 2.2 (m, 1H), 1.0 (d, 3H), 0.9 (d, 3H) 21 459.20 3.00 DMSO d6:
12.4 ppm (bs, 1H), 8.8 (t, 1H), 8.7 (s, 1H), 8.3 (m, 3H), 7.8 (d,
1H), 4.7 (t, 1H), 3.9 (m, 2H), 1.9 (m, 1H), 1.8 (m, 1H), 1.6 (m,
1H), 1.0 (d, 3H), 0.9 (d, 3H) 22 473.20 3.40 DMSO d6: 8.7 ppm (t,
1H), 8.6 (s, 1H), 8.4 (s, 1H), 8.35 (s, 1H), 8.3 (s, 1H), 7.9 (d,
1H), 4.7 (t, 1H), 4.0 (m, 2H), 3.9 (s, 3H), 1.9 (m, 1H), 1.8 (m,
1H), 1.7 (m, 1H), 1.0 (d, 3H), 0.9 (d, 3H) 23 431.10 2.50 DMSO d6:
12.4 (bs, 1H), 8.8 (t, 1H), 8.7 (s, 1H), 8.3 (s, 1H), 8.25 (dd,
2H), 7.7 (bs, 1H), 4.5 (q, 1H), 3.8-4.0 (m, 2H), 1.9 (q, 2H), 1.0
(t, 3H) 24 413.10 1.80 DMSO d6: 12.9 ppm (bs, 1H), 9.0 (t, 2H),
8.65 (s, 1H), 8.6 (s, 1H), 8.4 (s, 1H), 8.1 (d, 1H), 6.7 (bs, 1H),
4.7 (m, 1H), 3.8-4.2 (m, 2H), 1.9 (m, 2H), 1.0 (t, 3H) 25 439.20
2.00 1H NMR (CD3OD, 500 MHz): 1.53-2.05 (m, 6H), 2.45-2.53 (m, 1H),
3.46-3.59 (m, 1H), 3.83-4.32 (m, 3H), 7.06 (s, br., 1H), 8.18 (d,
1H), 8.38 (d, 1H), 8.42 (s, 1H), 8.83 (s, br., 1H) 26 457.10 3.20
1H NMR (CD3OD, 500 MHz): 1.57-2.03 (m, 6H), 2.37-2.44 (m, 1H),
3.50-3.57 (m, 1H), 3.90-4.09 (m, 2H), 4.49-4.57 (m, 1H), 5.38 (s,
br., 1H), 8.26 (s, 1H), 8.28 (d, 1H), 8.31 (d, 1H), 8.60 (d, 1H) 27
429.30 2.30 (CD3OD) 1.3 (m, 2H), 1.8 (m, 2H), 3.9 (m, 2H), 8.25 (m,
3H), 8.6 (t, 1H), 8.8 (d, 1H) 28 439.20 1.90 DMSO d6: 13.0 ppm (bs,
1H), 9.0 (s, 1H), 8.7 (s, 1H), 8.6 (s, 1H), 8.4 (s, 1H), 8.2 (d,
1H), 6.7 (s, 1H), 4.9 (d, 1H), 3.9-4.1 (m, 3H), 1.9 (q, 1H), 1.6
(q, 1H), 0.9 (bs, 1H), 0.5 (m, 2H), 0.2 (m, 2H) 29 457.10 2.80 DMSO
d6: 12.4 ppm (bs, 1H), 8.8 (t, 1H), 8.7 (s, 1H), 8.3 (s, 1H), 8.25
(m, 2H), 7.8 (bs, 1H), 4.7 (q, 1H), 3.8-4.0 (m, 3H), 1.9 (m, 1H),
1.6 (m, 1H), 0.9 (m, 1H), 0.4 (m, 2H), 0.2 (m, 2H) 30 459.10 1.90
DMSO d6: 12.9 ppm (bs, 1H), 9.0 (s, 1H), 8.7 (s, 1H), 8.6 (s, 1H),
8.4 (s, 1H), 8.2 (d, 1H), 6.7 (s, 1H), 4.9 (s, 1H), 3.9-4.1 (m,
2H), 2.5-2.7 (m, 2H), 2.1 (m, 3H), 2.0 (s, 3H) 31 477.10 2.70 DMSO
d6: 12.4 ppm (bs, 1H), 8.8 (t, 1H), 8.7 (s, 1H), 8.3 (s, 2H), 8.25
(s, 1H), 7.9 (s, 1H), 4.8 (q, 1H), 3.8-4.0 (m, 2H), 2.5-2.7 (m,
2H), 2.2 (m, 2H), 2.1 (s, 3H) 32 458.10 1.90 (d4-methanol) 8.71 (s,
1H), 8.24 (d, 1H), 8.20 (s, 1H), 8.15 (s, 1H), 5.11 (br s, 1H),
4.32 (d, 1H), 4.01-3.55 (m, 4 H), 3.17 (dd, 1H), 3.11-2.95 (m, 2H)
33 440.10 1.40 (d4-methanol) 8.72 (d, 1H), 8.28 (d, 1H), 8.22 (s,
1H), 8.21 (d, 1H), 6.65 (d, 1H), 5.25 (br s, 1H), 4.12-3.87 (m, 3
H), 3.57 (d, 1H), 3.44 (dd, 1H), 3.14-2.82 (m, 3H) 34 457.00 3.00
DMSO-d6: 12.4 (s, 1H); 8.65 (s, 1H); 8.35-8.25 (m, 3H); 8.1 (s,
1H); 3.95-3.8 (m, 2H); 3.7 (m, 2H); 2.05 (m, 4H); 1.65 (s, 3H). 35
483.10 2.80 36 469.10 2.50 DMSO d6 12.5 (bs, 1H); 9.0 (m, 1H); 8.7
(m, 3H); 8.3 (m, 1H); 4.8 (bs, 1H); 4.0-3.5 (m, 4); 2.3 (m, 1H);
2.0 (m, 3H) 37 411.10 2.10 1H NMR (CD3OD, 500 MHz): 2.42-2.52 (m,
1H), 2.80-2.93 (m, 1H), 3.89-4.14 (m, 2H), 4.27-4.37 (m, 2H),
5.09-5.16 (m, 1H), 7.34 (d, 1H), 8.18 (d, 1H), 8.30 (s, 1H), 8.50
(s, 1H), 8.66 (s, 1H) 38 459.10 2.90 1H NMR (CD3OD, 500 MHz):
3.46-3.69 (m, 2H), 3.88-4.04 (m, 3H), 4.13-4.52 (m, 3H), 4.83-4.90
(m, 1H), 6.47 (d, 1H), 7.44 (d, 1H), 8.00 (d, 1H), 8.14 (d, 1H),
8.27-8.35 (m, 2H), 8.68 (s, 1H) 39 458.10 1.80 (d4-methanol) 8.74
(d, 1H), 8.42 (d, 1H), 8.25 (s, 1H), 8.23 (d, 1H), 5.62 (br s, 1H),
4.62 (d, 1H), 4.04-3.95 (m, 3H), 3.66 (ddd, 1H), 3.46 (dd, 1H),
3.41-3.34 (m, 2H) 40 440.10 1.40 (d4-methanol) 8.72 (d, 1H), 8.28
(d, 1H), 8.22 (s, 1H), 8.21 (d, 1H), 6.65 (d, 1H), 5.26 (br s, 1H),
4.10-2.84 (m, 8H) 41 525.10 2.70 (d4-methanol) 8.72 & 8.70 (2d,
1H), 8.31 & 8.27 (2d, 1H), 8.21 (d, 1H), 8.18 & 8.14 (2s,
1H), 7.35, 7.24 (2d, 1H), 5.36 (br s, 1H), 4.51-3.52 (m, 10 H) 42
508.10 1.80 (d4-methanol) 8.73 & 8.70 (2d, 1H), 8.36 & 8.33
(2d, 1H), 8.25 (s, 1H), 8.22 (d, 1H), 6.73, 6.61 (2d, 1H), 5.50,
5.22 (2 br s, 1H), 4.51-3.51 (m, 10 H) 43 427.10 1.90 DMSO d6: 13.0
ppm (bs, 1H), 9.0 (s, 1H), 8.6 (d, 2H), 8.4 (s, 1H), 8.2 (d, 1H),
6.7 (s, 1H), 4.8 (s, 1H), 3.8-4.2 (m, 3H), 1.9 (m, 2H), 1.4-1.5 (m,
2H), 0.9 (t, 3H) 44 445.10 2.70 DMSO d6: 12.4 ppm (s, 1H), 8.8 (t,
1H), 8.7 (s, 1H), 8.3 (m, 3H), 7.8 (bs, 1H), 4.6 (q, 1H), 3.8-4.0
(m, 2H), 1.8 (m, 2H), 1.3- 1.5 (m, 2H), 0.9 (t, 3H) 45 425.10 2.20
DMSO-d6: 12.45 (s, 1H); 8.65 (s, 1H); 8.5 (m, 1H); 8.3 (m, 2H); 8.2
(m, 1H); 5.9 (t, 1H); 4.8 (d, 1H); 4.0 (m, 1H); 3.85 (m, 1H);
3.6-3.4 (m, 2H); 2.25 (m, 1H); 2.0 (m, 3H) 46 443.10 2.50 DMSO 1.9
(m, 2H), 2.3 (q, 2H), 2.75 (bq, 2H), 3.8 (m, 2H), 8 (d, 1H), 8.15
(overlap bt, bs, 2H), 8.25 (s, 1H), 8.3 (d, 1H), 8.7 (s, 1H), 12.3
(bs, 1H) 47 407.10 1.60 DMSO-d6: 13.0 (br s, 1H); 8.7-8.6 (m, 3H);
8.4 (m, 1H); 8.3 (m, 1H); 6.75 (d, 0.7H); 6.3 (d, 0.3H); 5.9 (t,
1H); 4.9 (d, 0.7H); 4.65 (0.3H); 4.05-3.6 (m, 2H); 2.35 (m, 1H);
2.05 (m, 3H). 48 413.10 1.70 (CD3OD) 1.75 (s, 6H), 3.85 (m, 2H),
6.75 (d, 1H), 8.05 (d, 1H), 8.3 (d, 1H), 8.5 (d, 1H), 8.65 (bt,
1H), 8.8 (s, 1H) 49 389.10 2.00 DMSO-d6: 12.4 (br s, 1H); 8.65 (s,
1H); 8.3 (m, 2H); 8.25 (m, 1H); 8.05 (m, 1H); 4.7 (d, 1H); 3.95 (m,
1H); 3.8 (m, 1H); 3.5 (m, 1H); 3.1 (m, 1H); 2.25 (m, 1H); 2.0 (m,
3H); 0.95 (m, 3H) 50 457.10 2.70 H NMR (500 MHz, Methanol-d4) 8.76
(d, J = 2.3 Hz, 1H), 8.48 (t, J = 6.2 Hz, 1H), 8.31-8.29 (m, 3H),
3.82 (m, 2H), 3.31 (qn, Methanol-d4), 2.55-2.53 (m, 2H), 2.27-2.24
(m, 2H), 1.88 (m, 4H) 51 471.10 3.07 52 371.20 1.50 DMSO-d6: 13.0
(s, 1H); 8.75-8.6 (m, 2H); 8.4 (m, 1H); 8.3 (m, 1H); 8.2 (m, 1H);
6.75 (d, 0.7H) 6.35 (d, 0.3H); 4.85 (d, 0.7H); 4.55 (d, 0.3H);
3.8-3.6 (m, 2H); 3.2-3.0 (m, 2H); 2.35 (m, 1H); 2.05 (m, 3H); 1.05
(dd, 0.7H); 0.95 (dd, 2.3H) 53 439.20 1.80 DMSO-d6: 12.85 (br s,
1H); 8.7 (s, 1H); 8.5 (s, 1H); 8.4-8.35 (m, 2h); 8.3 (d, 1H); 6.7
(m, 1h); 3.95-3.7 (m, 4H); 2.15 (m, 4H); 1.7 (s, 3H) 54 456.80 2.95
DMSO-d6: 12.25 (br s, 1H); 8.7 (s, 1H); 8.3 (m, 3H); 8.0 (m, 1H);
4.1-3.7 (m, 4H); 2.05 (m, 4H); 1.6 (s, 3H) 55 439.20 1.80 DMSO-d6:
12.85 (br s, 1H); 8.7 (s, 1H); 8.5 (s, 1H); 8.4-8.35 (m, 2h); 8.3
(d, 1H); 6.7 (m, 1h); 3.95-3.7 (m, 4H); 2.15 (m, 4H); 1.7 (s, 3H)
56 469.10 2.00 DMSO-d6: 9.30 (m, 1H); 8.70 (s, 1H); 8.35 (m, 1H);
8.28 (m, 2H); 4.75 (m, 1H); 3.40 (m, 2H); 2.25 (m, 2H); 2.00 (m,
4H) 57 497.10 2.70 DMSO-d6: 8.80 (m, 2H); 8.55 (s, 1h); 8.28 (m,
2H); 4.80 (m, 1H); 4.24 (m, 2H); 3.80 (m, 4H); 2.20 (m, 1H); 1.90
(m, 23H); 1.20 (t, 2H) 58 441.10 2.00 H NMR (500 MHz, DMSO-d6) 12.9
(bs, 1H), 9.00 (s, 1H), 8.66 (s, 1H), 8.63 (s, 1H), 8.41 (d, J =
2.0 Hz, 1H), 8.16 (d, J = 6.2 Hz, 1H), 6.80 (s, 1H), 4.81 (s, 1H),
4.11-4.06 (m, 1H), 3.87 (m, 2H), 2.00 (s, 1H), 1.66 (s, 1H), 1.27-
1.21 (m, 1H), 0.98 (d, J = 6.4 Hz, 3H), 0.92 (t, J = 7.2 Hz, 3H) 59
459.10 3.10 H NMR (500 MHz, DMSO-d6) 12.40 (s, 1H), 8.80 (t, J =
6.3 Hz, 1H), 8.71 (d, J = 2.4 Hz, 1H), 8.34 (d, J = 2.8 Hz, 1H),
8.29 (s, 1H), 8.27 (d, 1H), 7.58 (d, J = 6.2 Hz, 1H), 4.57 (t, J =
8.0 Hz, 1H), 4.04-3.98 (m, 1H), 3.89-3.83 (m, 1H), 2.05- 1.99 (m,
1H), 1.65-1.60 (m, 1H), 1.33-1.23 (m, 1H), 0.96 (d, 3H), 0.88 (t,
3H) 60 441.10 2.00 H NMR (500 MHz, DMSO-d6) 13.0 (bs, 1H), 8.98 (s,
1H), 8.66 (s, 1H), 8.62 (s, 1H), 8.41 (d, J = 1.9 Hz, 1H), 8.17 (d,
J = 6.3 Hz, 1H), 6.84 (s, 1H), 4.90 (s, 1H), 4.08-4.07 (m, 1H),
3.88 (m, 2H), 2.11-2.08 (m, 1H), 1.50 (t, J = 6.9 Hz, 1H), 1.27 (m,
1H), 1.00 (d, J = 6.9 Hz, 3H), 0.92 (q, J = 7.5 Hz, 3H) 61 459.10
3.10 H NMR (500 MHz, DMSO-d6) 12.38 (s, 1H), 8.76 (t, J = 6.3 Hz,
1H), 8.70 (d, J = 2.4 Hz, 1H), 8.28 (m, J = 4.2 Hz, 3H), 8.28 (s,
1H), 7.36 (d, J = 5.7 Hz, 1H), 4.72 (t, 1H), 4.02-3.85 (m, 2H),
2.05 (q, J = 6.8 Hz, 1H), 1.54-1.49 (m, 1H), 1.27-1.21 (m, 1H),
0.99 (d, J = 6.8 Hz, 3H), 0.92 (t, J = 7.4 Hz, 3H) 62 441.10 2.00 H
NMR (500 MHz, DMSO-d6) 13.01 (s, 1H), 9.05 (s, 1H), 8.78 (s, 1H),
8.64 (s, 1H), 8.42 (d, J = 2.0 Hz, 1H), 8.16 (d, J = 6.4 Hz, 1H),
6.91 (s, 1H), 4.89 (d, J = 8.0 Hz, 1H), 4.15-4.07 (m, 1H),
3.82-3.85 (m, 1H), 1.08 (s, 9H) 63 459.10 3.30 H NMR (500 MHz,
DMSO-d6) 12.41 (s, 1H), 8.85 (t, J = 6.3 Hz, 1H), 8.74 (d, J = 2.4
Hz, 1H), 8.31 (d, 1H), 8.29 (s, 2H), 6.86 (d, J = 7.8 Hz, 1H), 4.77
(d, J = 8.8 Hz, 1H), 4.09-4.02 (m, 1H), 3.88-3.82 (m, 1H), 1.08 (s,
9H) 64 429.10 2.39 1H NMR (CD3OD, 500 MHz): 2.45-2.52 (m, 1H),
2.91-3.00 (m, 1H), 3.89-4.14 (m, 2H), 4.50-4.61 (m, 2H), 5.25-5.30
(m, 1H), 8.23- 8.30 (m, 3H), 8.63 (s, 1H) 65 373.40 1.90 DMSO-d6:
12.9 (br s, 1H); 8.7 (s, 1H); 8.6 (s, 1H); 8.4 (s, 1H); 8.3 (s,
1H); 8.15 (m, 1H); 6.8 (s, 1H); 4.6 (s, 1H); 3.1 (m, 1H); 2.7 (m,
1H); 2.25 (m, 1H); 1.1-0.95 (m, 9H) 66 425.10 2.20 H NMR (500 MHz,
Methanol-d4) 8.73 (d, J = 2.0 Hz, 1H), 8.46 (s, 1H), 8.40 (s, 1H),
8.35 (d, J = 2.1 Hz, 1H), 8.10 (d, J = 7.2 Hz, 1H), 6.75 (d, J =
7.2 Hz, 1H), 3.85 (m, 2H), 3.01-2.97 (m, 2H), 2.44-2.39 (m, 2H),
2.16 (m, 2H) 67 409.20 1.80 DMSO-d6: 13.0 (br s, 1H); 8.75 (m, 1H);
8.65 (s, 1H); 8.6 (s, 1H); 8.4 (s, 1h); 8.15 (d, 1H); 6.8 (m, 1h);
6.05 (t, 1H); 4.75 (m, 1H); 3.75-3.5 (m, 2H); 2.25 (m, 1H);
1.1-0.95 (m, 6H) 68 456.60 3.83 1H NMR (CD3OD, 500 MHz): 1.68-2.00
(m, 6H), 2.26-2.33 (m, 1H), 3.49-3.58 (m, 1H), 3.84-4.02 (m, 2H),
4.45-4.53 (m, 1H), 5.36-5.42 (m, 1H), 6.71 (d, 1H), 8.11-8.39 (m,
4H), 8.86-8.92 (m, 1H) 69 497.80 1.79 1H NMR (CD3OD, 500 MHz):
3.38-4.35 (m, 10H), 4.67 (d, 1H), 5.19-5.54 (m, 1H), 6.80-7.07 (m,
1H), 8.23-8.80 (m, 4H) 70 525.80 2.08 1H NMR (CD3OD, 500 MHz): 1.29
(d, 6H), 3.43-4.30 (m, 7H), 4.68 (d, 1H), 4.86-4.94 (m, 1H), 5.44
(s, br., 1H), 7.01 (s, br., 1H), 8.23-8.58 (m, 4H) 71 523.80 2.05
1H NMR (CD3OD, 500 MHz): 3.40-4.30 (m, 7H), 4.53-4.74 (m, 3H),
5.19-5.54 (m, 3H), 5.92-6.01 (m, 1H), 6.98 (s, br., 1H), 8.24-8.57
(m, 4H) 72 459.50 2.99 10.5 (s, 1H), 8.74 (d, 1H), 8.39 (s, 1H),
8.35 (d, 1H), 8.28 (d, 1H), 7.20 (m, 1H), 6.73 (s, 1H), 4.5-4.8 (s,
6H), 3.98 (m, 1H), 3.68 (m, 1H), 2.32 (m, 1H), 1.70 (s, 3H), 1.08
(dd, 6H) (CD3CN) 73 441.20 1.80 74 429.10 1.60 H NMR (500 MHz,
DMSO-d6) 12.95 (bs, 1H), 8.78 (s, 1H), 8.65 (s, 1H), 8.59 (s, 1H),
8.39 (d, J = 1.8 Hz, 1H), 8.17 (d, J = 4.8 Hz, 1H), 6.90 (s, 1H),
5.30 (s, 1H), 4.74 (s, 1H), 4.21 (s, 1H), 4.04-3.80 (m, 2H), 1.21
(d, J = 5.7 Hz, 3H) 75 423.00 1.80 H NMR (500 MHz, DMSO-d6) 12.95
(bs, 1H), 9.07(s, 1H), 8.63 (s, 1H), 8.60 (s, 1H), 8.40 (d, J = 2.1
Hz, 1H), 8.20 (s, 1H), 6.75 (s, 1H), 4.99 (s, 1H), 4.05-3.83 (m,
2H), 2.98 (t, J = 2.4 Hz, 1H), 2.80 (d, J = 7.3 Hz, 2H) 76 429.10
1.60 H NMR (500 MHz, DMSO-d6) 12.96 (s, 1H), 8.79 (s, 1H), 8.65 (s,
1H), 8.61 (s, 1H), 8.40 (d, J = 2.1 Hz, 1H), 8.20-8.17 (m, 1H),
6.91 (s, 1H), 5.25 (bs, 1H), 4.75 (s, 1H), 4.21 (s, 1H), 4.04-3.88
(m, 2H), 1.22 (d, J = 6.2 Hz, 3H) 77 482.40 1.69 1H NMR (CD3OD, 500
MHz): 2.08 (s, 3H), 3.18-4.97 (m, 9H), 6.87-7.08 (m, 1H), 8.24-
8.59 (m, 4H) 78 518.40 1.83 1H NMR (CD3OD, 500 MHz): 2.93 (s, 3H),
3.18-4.97 (m, 9H), 7.00-7.10 (m, 1H), 8.26- 8.56 (m, 4H) 79 526.50
2.00 1H NMR (CD3OD, 500 MHz): 0.98 (t, 3H), 1.67-1.74 (m, 2H),
3.18-4.90 (m, 11H), 6.86-7.00 (m, 1H), 8.24-8.59 (m, 4H) 80 540.50
2.12 1H NMR (CD3OD, 500 MHz): 0.97 (d, 6H), 1.91-2.01 (m, 1H),
3.18-4.90 (m, 11H), 6.86-7.00 (m, 1H), 8.24-8.59 (m, 4H) 81 482.50
1.61 1H NMR (CD3OD, 500 MHz): 2.08 (s, 3H), 3.18-4.97 (m, 9H),
6.87-7.08 (m, 1H), 8.24- 8.59 (m, 4H) 82 518.40 1.82 1H NMR (CD3OD,
500 MHz): 2.93 (s, 3H), 3.18-4.97 (m, 9H), 7.00-7.10 (m, 1H), 8.26-
8.56 (m, 4H) 83 441.20 1.50 DMSO-d6: 12.85 (br s, 1H); 9.05 (s,
0.3H); 8.9 (s, 0.7H); 8.7 (m, 0.3H); 8.65-8.5 (m, 1.7H); 8.4-8.25
(m, 2H); 6.75 (m, 0.7H); 6.2 (m, 0.3H); 4.9 (m, 0.7H); 4.7 (m,
0.3H); 4.5 (m, 1H); 4.05-3.5 (m, 5H); 2.05 (m, 1H) 84 473.10 2.20
DMSO-d6: 12.35 (br s, 1H); 8.7 (s, 1H); 8.35- 8.1 (m, 4H); 6.4 (m,
1H); 4.7 (dd, 1H); 4.0 (m, 2H); 3.8 (m, 2H); 3.15 (m, 1H); 2.25 (m,
1H); 2.0 (m, 3H) 85 459.10 2.00 DMSO-d6: 12.3 (br s, 1H); 8.8 (s,
1H); 8.7 (m, 1H); 8.3 (m, 2H); 8.15 (m, 1H); 4.85 (m, 1H); 4.45 (m,
1H); 4.05-3.7 (m, 5H); 1.9 (m, 1H) 86 413.20 2.30 H NMR (500 MHz,
DMSO) 12.63 (s, 1H), 8.87-8.86 (bs, 1H), 8.61 (m, 2H), 8.35-8.31
(m, 2H), 7.25 (d, J = 4.8 Hz, 1H), 5.39 (q, J = 7.1 Hz, 1H),
3.95-3.81 (m, 2H), 3.18 (s, 3H), 1.43 (d, J = 6.9 Hz, 3H) 87 431.20
2.70 H NMR (500 MHz, DMSO) 12.38 (s, 1H), 8.70-8.65 (m, 2H), 2H)
8.32 (d, J = 6.9 Hz, 1H), 8.29 (dd, J = 2.4, 2.8 Hz, 2H), 5.16 (q,
J = 7.0 Hz, 1H), 3.95-3.86 (m, 2H), 3.17 (d, J = 4.2 Hz, 3H), 1.46
(d, J = 7.0 Hz, 3H) 88 400.10 2.30 DMSO-d6: 12.6 (m, 1H); 8.60 (m,
1H); 8.50 (m, 1H); 8.30 (m, 1H); 8.25 (m, 1H); 4.50 (m, 1H); 3.80
(m, 2H); 1.42 (m, 3H) 89 441.20 2.10 H NMR (500 MHz, DMSO) 12.41
(s, 1H), 8.78 (t, J = 6.3 Hz, 1H), 8.71 (d, J = 2.4 Hz, 1H), 8.36
(d, 1H), 8.33 (d, 1H), 8.30 (d, J = 2.4 Hz, 1H), 4.86 (d, J = 10.4
Hz, 1H), 3.98- 3.88 (m, 2H), 3.20 (d, J = 4.9 Hz, 3H), 2.44- 2.40
(m, 1H), 1.04 (d, J = 6.5 Hz, 3H), 0.90 (d, J = 6.7 Hz, 3H) 90
459.10 3.40 H NMR (500 MHz, DMSO) 12.98 (s, 1H), 8.87 (bs, 1H),
8.70 (s, 2H), 8.42 (d, 1H), 8.38 (d, 1H), 5.4 (bs, 1H), 3.97-3.89
(m, 2H), 3.14 (bs, 3H), 2.51-2.42 (m, 1H), 1.03 (bs, 3H), 0.86 (d,
J = 6.7 Hz, 3H) 91 459.40 2.95 10.95 (s, 1H), 8.68 (s, 1H), 8.51
(s, 1H), 8.36 (s, 1H), 8.28 (d, 1H), 7.25 (m, 2H), 4.1-4.5 (s, 8H),
3.95 (m, 1H), 3.69 (m, 1H), 2.39 (m, 1H), 1.72 (s, 3H), 1.09 (dd,
6H) (CD3CN) 92 445.40 2.70 10.69 (s, 1H), 8.70 (d, 1H), 8.48 (s,
1H), 8.41 (d, 1H), 8.28 (d, 1H), 7.34 (s, 1H), 7.23 (m, 1H),
3.75-4.2 (m, 26H), 2.20 (m, 2H), 1.72 (s, 3H), 0.93 (t, 3H) (CD3CN)
93 487.30 2.10 DMSO-d6: 12.3 (br s, 1H); 8.85 (s, 1H); 8.65 (s,
1H); 8.3 (m, 2H); 8.15 (s, 1H); 4.75 (dd, 1H); 4.25 (m, 1H);
4.05-3.8 (m, 4H); 3.6-3.45 (m, 3H); 2.0 (m, 1H); 1.1 (dd, 3H) 94
499.40 2.20 95 469.40 1.90 DMSO-d6: 12.3 (br s, 1H); 9.1-8.3 (m,
5H); 6.75 (m, 0.7H); 6.2 (m, 0.3H); 4.85 (m, 0.7H); 4.6 (m, 0.3H);
4.3 (m, 1H); 4.1-3.5 (m, 7H); 2.1 (m, 1H); 1.1 (dd, 3H) 96 481.40
2.00 97 426.10 2.51 DMSO-d6: 12.6 (m, 1H); 8.82 (m, 0.5H); 8.75 (s,
0.5H); 8.62 (m, 1H); 8.58 (s, 0.5H); 8.48 (m, 1H); 8.38 (m, 0.5H);
8.35 (m, 0.5H); 8.22 (m, 0.5H); 4.65-4.55 (m, 1H); 3.80-3.60 (m,
4H); 2.25 (m, 1H); 1.90 (m, 3H) 98 414.10 2.52 DMSO-d6: 12.6 (m,
1H); 8.95 (s, 0.5H); 8.70 (m, 0.5H); 8.50 (m, 0.5H); 8.40 (0.5H);
8.20 (m, 2.0H); 8.10-7.90 (m, 1H) 99 427.10 1.80 H NMR (500 MHz,
DMSO-d6) 13.07 (s, 1H), 9.17 (s, 1H), 8.69-8.66 (m, 3H), 8.61 (m,
1H), 8.39 (d, J = 2.2 Hz, 1H), 8.20 (d, J = 7.1 Hz, 1H), 6.78 (d, J
= 6.9 Hz, 1H), 3.83-3.78 (m, 2H), 2.14-2.07 (m, 1H), 2.01-1.94 (m,
1H), 1.61 (s, 3H), 0.88 (t, J = 7.5 Hz, 3H) 100 445.10 2.70 H NMR
(500 MHz, DMSO-d6) 12.36 (s, 1H), 8.68 (d, J = 2.4 Hz, 1H), 8.41
(t, J = 6.4 Hz, 1H), 8.30-8.27 (m, 2H), 8.11 (s, 1H), 7.53 (s, 1H),
3.85- 3.72 (m, 2H), 2.19-2.15 (m, 1H), 1.99-1.95 (m, 1H), 1.55 (s,
3H), 0.81 (t, J = 7.5 Hz, 3H) 101 473.21 2.55 DMSO-d6: 12.3 (br s,
1H); 8.8 (s, 1H); 8.7 (s, 1H); 8.3 (m, 2H); 8.15 (m, 1H); 8.75 (m,
1H); 4.15 (m, 1H); 4.1-3.75 (m, 4H); 3.45 (m, 4H); 2.0 (m, 1H) 102
487.23 2.70 DMSO-d6: 12.3 (br s, 1H); 8.8 (s, 1H); 8.7 (s, 1H); 8.3
(m, 2H); 2H); 8.15 (m, 1H); 4.75 (m, 1H); 4.2 (m, 1H); 4.05-4.75
(m, 4H); 3.5 (m, 3H); 2.0 (m, 1H); 1.1 (dd, 3H) 103 455.10 1.70 104
500.10 1.90 105 499.10 2.90 DMSO-d6: 12.35 (br s, 1H); 8.85 (s,
1H); 8.65 (s, 1H); 8.3 (m, 2H); 8.15 (m, 1H); 5.9 (m, 1H); 5.3 (d,
1H); 5.15 (d, 1H); 4.8 (m, 1H); 4.3 (m, 1H); 4.05 (m, 2H); 4.0-3.8
(m, 5H); 2.0 (m, 1H) 106 455.10 1.70 107 427.40 1.80 10.07 (s, 1H),
8.83 (d, 1H), 8.26 (d, 1H), 8.22 (d, 1H), 8.13 (d, 1H), 7.20 (m,
1H), 6.38 (d, 1H), 6.00 (s, 1H), 3.88 (m, 1H), 3.77 (m, 1H), 1.95
(m, 2H), 1.57 (s, 3H), 0.91 (t, 3H) (CD3CN) 108 359.40 1.65 109
395.40 1.77 110 441.40 1.91 10.01 (s, 1H), 8.71 (d, 1H), 8.23 (d,
1H), 8.17 (d, 1H), 8.12 (d, 1H), 7.16 (m, 1H), 6.40 (d, 1H), 5.86
(s, 1H), 3.97 (m, 1H), 3.61 (m, 1H), 1.53 (s, 3H), 1.02 (dd, 6H)
(CD3CN) 111 414.10 2.50 DMSO-d6: 12.65 (m, 1H); 8.95 (s, 0.5H); ,
8.72 (m, 0.5H); 8.70 (m, 0.5H); 8.50 (m, 1H); 8.48 (m, 0.5H); 8.40
(m, 0.5H); 8.30 (m, 1H); 8.28 (m, 0.5H); 8.03 (m, 0.5H); 4.45 (m,
1H); 3.80 (m, 2H); 1.75 (m, 2H); 1.00 (m, 3H) 112 440.10 2.70
DMSO-d6: 12.68 (m, 1H); 8.98 (s, 0.5H); 8.68 (s, 0.5H); 8.58 (s,
0.5H); 8.48 (s, 0.5H); 8.43 (s, 0.5H); 8.35-8.15 (m, 3.5H); 3.75
(m, 2H); 2.15 (m, 2H); 2.02 (m, 2H); 1.65 (m, 4H) 113 426.10 2.60
DMSO-d6: 12.55 (m, 1H); 8.95 (m, 0.5H); 8.68 (m, 0.5H); 8.62 (m,
0.5H); 8.56 (m, 0.5H); 8.52 (m, 0.5H); 8.45 (m, 0.5H); 8.40 (m,
0.5H); 8.35 (m, 1H); 8.22 (0.5H); 8.16 (m, 1H); 3.80 (m, 2H); 2.70
(m, 1H); 2.40 (m, 1H); 2.25 (m, 2H); 1.88 (m, 2H) 114 512.10 1.80
DMSO-d6: 12.5 (bs, 1H); 8.95 (bs, 1H); 8.50 (m, 2H); 8.32 (m, 2H);
6.80 (m, 1H); 4.50 (m, 1H); 4.00-3.40 (m, 10H); 1.15 (t, 3H) 115
540.10 2.10 116 496.10 1.70 DMSO-d6: 12.6 (m, 1H); 8.95 (m, 1H);
8.50 (m, 2H); 8.32 (m, 2H); 6.80 (m, 1H); 4.50 (m, 1H); 4.00-3.40
(m, 10): 1.15 (t, 3H) 117 508.10 1.70 118 522.20 1.90 119 459.30
1.70 DMSO-d6: 12.35 (br s, 1H); 8.8 (m, 1H); 8.65 (s, 1H); 8.3 (m,
2H); 8.15 (m, 1H); 4.8 (m, 1H); 4.4 (m, 1H); 4.05-3.7 (m, 4H); 2.3
(m, 1H); 1.95 (m, 1H) 120 441.40 1.70 DMSO-d6: 12.9 (br s, 1H);
9.05 (m, 0.3H); 8.9 (m, 0.7H); 8.7-8.5 (m, 2H); 8.4-8.25 (m, 2H);
6.75 (m, 0.7H); 6.2 (m, 0.3H); 4.95 (m, 0.7H); 4.7 (m, 0.3H); 4.5
(m, 1H); 4.05-3.5 (m, 4H); 2.4 (m, 1H); 2.05 (m, 1H) 121 425.00
2.03 10.1 (s, 1H), 8.89 (s, 1H), 8.29 (m, 3H), 7.27 (s, 1H), 6.51
(d, 1H), 3.88 (m, 2H), 3.30 (s, 6H), 1.86 (m, 1H), 1.57 (m, 1H),
1.43 (m, 1H), 1.19 (m, 1H) (CD3CN) 122 461.30 2.40 123 443.30 1.90
124 487.40 2.20 125 479.40 2.30 126 443.30 1.90 127 439.17 1.84 H
NMR (500 MHz, MeOD) 8.79 (d, J = 2.3 Hz, 1H), 8.51 (t, J = 6.4 Hz,
1H), 8.48 (s, 1H), 8.35 (d, J = 2.3 Hz, 1H), 8.06 (d, J = 7.2 Hz,
1H), 6.73 (d, J = 7.2 Hz, 1H), 3.87-3.81 (m, 2H), 2.56-2.52 (m,
2H), 2.25-2.20 (m, 2H), 1.93-1.86 (m, 4H), 0.00 (TMS) 128 441.40
2.20 H NMR (500 MHz, DMSO) 8.66 (s, 1H), 8.62 (s, 1H), 8.58 (s,
1H), 8.38 (d, J = 2.0 Hz, 1H), 8.18 (d, J = 7.0 Hz, 1H), 6.81 (s,
1H), 4.09-3.78 (m, 2H), 2.18-2.16 (m, 2H), 2.10 (m, 2H), 0.77 (t, J
= 7.4 Hz,
6H), 0.00 (TMS) 129 459.40 2.40 130 461.30 2.40 131 377.30 1.67 132
441.09 1.65 H NMR (500 MHz, Me0D) 8.70 (d, J = 2.2 Hz, 1H), 8.48
(s, 1H), 8.36 (d, J = 2.3 Hz, H), 8.12 (d, J = 7.2 Hz, 1H), 7.59
(d, J = 8.2 Hz, 2H *0.7 equiv p-TsOH), 7.37 (d, J = 8.0 Hz, 2H*0.7
equiv p-TsOH), 6.76 (d, J = 7.2 Hz, 1H), 4.41 (d, J = 9.6 Hz, 1H),
4.22 (d, J = 9.5 Hz, 1H), 4.07-4.04 (m, 2H), 3.88-3.83 (m, 2H),
2.88-2.82 (m, 1H), 2.52-2.43 (m, 1H), 2.43 (s, 3H*0.7 equiv
p-TsOH), 0.00 (TMS) 133 443.30 2.86 134 441.16 1.50 135 455.10 1.80
DMSO-d6: 12.8 (br s, 1H); 9.05-8.85 (m, 1H); 8.8-8.4 (m, 2H); 8.35
(m, 2H); 6.75 (m, 0.8H); 6.2 (m, 0.2H); 4.85 (m, 0.8H); 4.6 (m,
0.2H); 4.2 (m, 1H); 4.0 (m, 1H); 3.9-3.6 (m, 3H); 3.3 (s, 3H); 2.2
(m, 1H) 136 455.10 1.80 DMSO-d6: 12.9 (br s, 1H); 8.75-8.25 (m,
5H); 6.75 (m, 0.8H); 8.45 (m, 0.2H); 4.95 (m, 0.8H); 4.75 (m,
0.2H); 4.2 (m, 1H); 4.1-3.7 (m, 4H); 3.2 (s, 3H); 2.3 (m, 1H) 137
473.10 2.00 DMSO-d6: 12.35 (br s, 1H); 8.65 (m, 1H); 8.45 (dd, 1H);
8.25 (m, 2H); 8.15 (m, 1H); 4.8 (d, 1H); 4.1 (m, 1H); 4.0 (m, 1H);
3.9 (m, 1H); 3.85 (m, 2H); 3.2 (s, 3H); 2.2 (m, 1H) 138 397.00 1.74
(500 MHz, CD3OD) 8.57 (t, J = 6.2 Hz, 1H), 8.50 (s, 1H), 8.48 (d, J
= 2.6 Hz, 1H), 8.3 (d, J = 1.2 Hz, 1H), 8.05 (d, J = 7.2 Hz, 1H),
6.7 (d, J = 7.2 Hz, 1H), 3.86-3.8 (m, 2H), 1.74 (s, 6H), 0 (TMS)
139 445.10 3.30 H NMR (500 MHz, DMSO) 12.24 (s, 1H), 8.69 (s, 1H),
8.32 (d, J = 6.9 Hz, 1H), 8.24 (m, 2H), 8.15 (s, 1H), 3.68-3.63 (m,
2H), 3.20 (s, 1H), 1.51 (s, 1H) 140 427.10 1.80 H NMR (500 MHz,
DMSO) 12.7 (bs, 1H), 8.82 (s, 1H), 8.34-8.30 (m, 2H), 8.16 (s, 1H),
8.07 (d, J = 6.2 Hz, 1H), 6.63 (d, J = 6.2 Hz, 1H), 3.77-3.70 (m,
2H), 3.06 (s, 3H), 1.56 (s, 6H) 141 431.10 2.50 DMSO-d6: 12.2 (m,
1H); 8.60 (m, 1H); 8.22 (s, 1H); 8.18 (s, 1H); 8.10 (s, 1H); 7.70
(m, 1H); 5.16 (m, 1H); 4.18 (m, 2H); 3.3 (s, 2.5H); 2.9 (s, 0.5H);
1.35 (m, 3H) 142 413.10 1.80 DMSO-d6: 12.5 (m, 1H); 8.70 (m, 1H);
8.30 (m, 2H); 8.18 (m, 2H); 6.42 (m, 1H); 5.25 (m, 1H); 4.20 (m,
2H); 3.30 (s, 2.5H); 2.90 (s, 0.5H); 1.32 (m, 3H) 143 413.10 1.84
144 377.10 1.70 145 395.10 1.74 146 428.10 2.00 147 411.10 2.00 148
497.10 2.40 149 554.00 2.20 150 498.00 1.80 DMSO-d6: 12.7 (m, 1H);
8.92 (m, 1H); 8.60 (m, 1H); 8.42 (m, 1H); 8.32 (m, 1H); 8.28 (m,
1H); 6.80 (m, 1H); 5.20 (m, 1H); 4.30-3.60 (m, 8H); 3.55 (m, 3H)
151 512.00 1.90 DMSO-d6: 12.5 (m, 1H); 8.90 (m, 1H); 8.55 (m, 1H);
8.42 (m, 1H); 8.32 (m, 1H); 8.30 (m, 1H); 6.70 (m, 1H); 5.20 (m,
1H); 4.35-3.55 (m, 10H); 1.15 (t, 3H) 152 526.10 2.00 153 526.00
2.00 154 540.10 2.10 155 540.10 2.10 156 532.80 3.10 DMSO-d6: 12.35
(br s, 1H); 8.9 (m, 1H); 8.7 (s, 1H); 8.4-8.1 (m, 3H); 4.85 (dd,
1H); 4.35-4.1 (m, 2H); 4.0-3.7 (m, 2H); 3.3 (m, 4H); 2.85 (m, 1H);
2.4 (m, 1H) 157 546.90 3.20 DMSO-d6: 12.35 (br s, 1H); 8.9 (m, 1H);
8.7 (s, 1H); 8.35-8.15 (m, 3H); 4.9 (dd, 1H); 4.1-3.75 (m, 4H);
3.1-2.9 (m, 5H); 2.15 (m, 1H); 1.95 (m, 2H) 158 493.90 1.70 159
522.00 1.90 160 524.00 1.90 161 538.00 2.10 162 511.00 1.70
DMSO-d6: 12.8 (m, 1H); 8.90 (m, 1H); 8.55 z9m, 2H); 8.35 (, 2H);
6.80 (m, 1H); 5.25 (, 1H); 4.20-3.60 (m, 8H); 2.62 (s, 6H) 163
525.00 1.80 164 560.00 2.20 165 508.00 1.80 166 443.00 1.60
DMSO-d6: 12.8 (br s, 1H); 8.95-8.65 (m, 1H); 8.65-8.45 (m, 2H);
8.4-8.25 (m, 2H); 6.75 (m, 0.7H); 6.25 (m, 0.3H); 5.5 (d, 1H); 5.05
(m, 0.7H); 4.85 (m, 0.3H); 4.2-3.7 (m, 4H); 2.8- 2.55 (m, 1H);
2.5-2.35 (m, 1H) 167 460.90 1.80 DMSO-d6: 12.75 (br s, 1H); 9.0 (m,
1H); 8.65-8.3 (m, 4H); 6.7 (m, 1H); 5.15 (m, 1H); 4.2 (m, 2H); 4.0
(m, 1H); 3.85 (m, 1H); 3.1 (m, 1H); 2.6 (m, 1H) 168 443.00 1.60
DMSO-d6: 12.8 (br s, 1H); 9.2-8.9 (m, 1H); 8.7-8.45 (m, 2H); 2H);
8.4-8.3 (m, 2H); 6.75 (m, 0.7H); 6.25 (m, 0.3H); 5.55 (d, 1H); 5.0
(m, 0.7H); 4.8 (m, 0.3H); 4.2-3.7 (m, 4H); 2.9-2.7 (m, 1H); 2.3-2.1
(m, 1H) 169 403.10 2.20 DMSO-d6: 12.45 (s, 1H); 8.7 (s, 1H); 8.3
(m, 2H); 8.25 (m, 1H); 8.0 (dd, 1H); 4.7 (m, 1H); 3.95 (m, 1H); 3.8
(m, 1H); 3.05 (m, 1H); 2.95 (m, 1H); 2.25 (m, 1H); 2.0 (m, 3H); 1.4
(m, 2H); 0.75 (m, 3H). 170 385.10 1.70 DMSO-d6: 12.9 (br s, 1H);
8.7-8.6 (m, 2H); 8.4 (m, 1H); 8.3 (m, 1H); 8.15 (m, 1H); 6.7 (d,
0.7H); 6.3 (d, 0.3H); 4.85 (d, 0.7H); 4.5 (0.3H); 4.05-3.6 (m, 2H);
3.2-3.05 (m, 1H); 2.9 (m, 1H); 2.35 (m, 1H); 2.05 (m, 3H); 1.5-1.3
(m, 2H); 0.8 (m, 1H); 0.7 (m, 2H). 171 387.40 2.00 DMSO-d6: 12.95
(br s, 1H); 8.7 (s, 1H); 8.6 (s, 1H); 8.4 (s, 1H); 8.3 (s, 1H);
8.15 (m, 1H); 6.8 (s, 1H); 4.65 (s, 1H); 3.2 (m, 1H); 3.0 (m, 1H);
2.25 (m, 1H); 1.45 (m, 2H); 1.1-0.95 (m, 6H); 0.85 (m, 3H). 172
457.10 2.40 DMSO-d6: 12.35 (br s, 1H); 8.7 (s, 1H); 8.3-8.25 (m,
3H); 8.2 (m, 1H); 4.65 (d, 1H); 4.0 (m, 1H); 3.8 (m, 1H); 3.5-3.3
(m, 2H); 2.4-2.2 (m, 3H); 2.0 (m, 3H). 173 439.20 1.70 DMSO-d6:
12.9 (br s, 1H); 8.7-8.65 (m, 2H); 8.45-8.25 (m, 3H); 6.75 (d,
0.8H); 6.3 (d, 0.2H); 4.85 (d, 0.8H); 4.55 (d, 0.2H); 4.05-3.55 (m,
4H); 2.4-2.25 (m, 3H); 2.1-2.0 (m, 3H). 174 441.40 2.00 175 373.40
1.74 176 427.30 1.87 177 401.10 2.00 DMSO-d6: 12.45 (s, 1H); 8.7
(s, 1H); 8.3 (m, 2H); 8.25 (s, 1H); 8.15 (s, 1H); 4.6 (d, 1H); 3.9
(m, 1H); 3.8 (m, 1H); 2.6 (m, 1H); 2.25 (m, 1H); 1.95 (m, 3H); 0.6
(m, 2H); 0.4 (m, 1H); 0.35 (m, 1H). 178 383.10 1.60 DMSO-d6: 13.0
(br s, 1H); 8.65 (m, 1H); 8.6 (s, 1H); 8.4 (m, 1H); 8.35-8.2 (m,
2H); 6.75 (d, 0.7H); 6.3 (d, 0.3H); 4.8 (d, 0.7H); 4.5 (0.3H);
4.05-3.6 (m, 2H); 2.7-2.55 (m, 1H); 2.35 (m, 1H); 2.05 (m, 3H);
0.7-0.2 (m, 4H). 179 385.40 1.90 DMSO-d6: 12.95 (br s, 1H); 8.7 (s,
1H); 8.6 (s, 1H); 8.4 (s, 1H); 8.35 (s, 1H); 8.15 (m, 1H); 6.8 (s,
1H); 4.6 (s, 1H); 2.7 (m, 1H); 2.25 (m, 1H); 1.05-0.95 (m, 6H);
0.65 (m, 2H); 0.45 (m, 2H). 180 371.40 1.65
TABLE-US-00005 TABLE 5 Cmpd # M + H RT NMR 181 473.1 1.9 182 415.1
1.8 (500 MHz, DMSO) 12.22 (s, 1H), 8.42 (dd, J = 2.8, 9.9 Hz, 1H),
8.37 (t, J = 6.4 Hz, 1H), 8.26- 8.25 (m, 2H), 8.10 (d, J = 2.5 Hz,
1H), 3.78-3.71 (m, 2H), 1.57 (s, 6H), 0.00 (TMS) 183 361.1 1.6 (500
MHz, DMSO) 12.27 (s, 1H), 8.47 (dd, J = 2.8, 9.8 Hz, 1H), 8.25 (d,
J = 3.0 Hz, 2H), 8.19 (d, J = 2.2 Hz, 1H), 7.75 (t, J = 5.6 Hz,
1H), 7.56 (bs, 1H), 3.02-2.99 (m, 2H), 1.56 (s, 6H), 0.77 (t, J =
7.1 Hz, 3H), 0.00 (TMS) 184 379.1 1.6 (500 MHz, DMSO) 12.3 (s, 1H),
8.45 (dd, J = 2.8, 9.8 Hz, 1H), 8.25 (m, 2H), 8.19 (bs, 1H), 8.05
(t, 1H), 7.7 (bs, 1H), 4.2 (dt, 2H, under water), 3.2 (dq, 2H), 1.6
(s, 6H), 0.00 (TMS) 185 397.1 1.7 (500 MHz, DMSO) 12.28 (s, 1H),
8.44 (dd, J = 2.8, 9.9 Hz, 1H), 8.27 (d, J = 4.4 Hz, 2H), 8.19 (t,
J = 5.9 Hz, 1H), 8.15 (d, J = 2.5 Hz, 1H), 7.69 (bs, 1H), 5.7 (tt,
J = 48 Hz, J = 4.3 Hz, 1H), 3.39-3.31 (m, 2H), 1.57 (s, 6H), 0.00
(TMS) 186 375.1 1.7 187 361.1 2.04 188 379.1 2.21 189 343.1 2.04
190 357.1 2.3 191 457 2.9 (DMSO-d6) 12.35 (s, 1H); 8.7 (d, 1H);
8.4-8.25 (m, 3H); 8.1 (s, 1H); 4.1 (m, 1H); 3.95 (m, 1H); 3.85 (m,
1H); 3.7 (m, 1H); 2.05 (m, 4H); 1.65 (s, 3H). 192 439 1.7 (DMSO-d6)
12.9 (s, 1H); 8.75-8.65 (m, 1.1H); 8.55 (m, 0.9H); 8.45-8.15 (m,
3H); 6.7 (m, 0.9H); 6.1 (m, 0.1H); 4.15 (m, 0.1H); 3.95 (m, 0.9H);
3.8 (m, 3H); 2.2-2.05 (m, 4H); 1.75-1.6 (m, 3H). 193 455.1 1.8 (500
MHz, DMSO) 12.95 (s, 1H), 8.71 (s, 1H), 8.59 (bd, 2H), 8.36 (d, J =
2.2 Hz, 1H), 8.23 (d, J = 6.9 Hz, 1H), 6.82 (s, 1H), 3.82-3.77 (m,
4H), 3.66 (t, J = 10.5 Hz, 4H), 2.27-2.20 (m, 2H), 2.20-2.08 (m,
2H), 0.00 (TMS) 194 439.1 1.7 (500 MHz, DMSO) 12.89 (s, 1H), 8.61
(m, 2H), 8.46 (d, J = 9.6 Hz, 1H), 8.36 (s, 1H), 8.22 (d, J = 6.9
Hz, 1H), 6.82 (bd, 1H), 3.81-3.79 (m, 4H), 3.67-3.63 (m, 2H), 2.23
(t, J = 10.2 Hz, 2H), 2.12 (m, 2H), 0.00 (TMS) 195 409.1 1.8 196
427.08 1.7 197 528.9 2 (DMSO-d6) 12.5 (br s, 1H); 8.9 (m, 1H); 8.65
(m, 1H); 8.4-8.3 (m, 3H); 6.75 (m, 0.5H); 6.5 (m, 0.5H); 4.9 (m,
1H); 4.1-3.7 (m, 4H); 3.1-2.9 (m, 5H); 2.2 (m, 1H); 1.95 (m, 2H).
198 409.1 1.9 (500 MHz, MeOD) 8.91 (d, J = 2.2 Hz, 1H), 8.72 (s,
1H), 8.55 (d, J = 8.3 Hz, 1H), 8.38 (d, J = 2.2 Hz, 1H), 8.03 (t, J
= 7.6 Hz, 2H), 7.88 (d, J = 8.3 Hz, 1H), 7.74 (t, J = 7.8 Hz, 1H),
3.21-3.15 (m, 2H), 1.87 (s, 6H), 0.89 (t, J = 7.2 Hz, 3H). 199
447.1 1.79 (500 MHz, MeOD) 8.73 (s, 1H), 8.63 (d, J = 9.5 Hz, 1H),
8.57 (m, 2H), 8.33 (s, 1H), 8.03 (m, 1H), 7.89 (d, J = 8.4 Hz, 1H),
7.74 (t, J = 7.7 Hz, 1H), 3.82 (m, 2 H), 2.66 (s, 1.3H), 1.88 (s,
6H). (Peak at 2.66 is unidentified.) 200 397.1 1.65 (500 MHz,
DMSO-d6) 12.90 (s, 1H), 9.05 (s, 1H), 8.66 (s, 1H), 8.40 (s, 1H),
8.37 (s, 1H), 8.16 (d, J = 6.4 Hz, 1H), 6.73 (s, 1H), 4.75 (s, 1H),
4.08-4.01 (m, 2H), 3.87 (d, J = 6.5 Hz, 1H), 1.93-1.83 (m, 2H),
1.00 (t, J = 7.4 Hz, 3H), 0.00 (TMS) 201 445 1.7 (DMSO-d6) 12.75
(br s, 1H); 9.0 (dd, 1H); 8.55 (s, 1H); 8.45-8.25 (m, 3H); 6.7 (m,
1H); 5.2 (m, 1H); 4.2 (m, 2H); 4.05-3.7 (m, 2H); 3.1 (m, 1H); 2.6
(m, 1H). 202 441 2.7 (DMSO-d6) 12.25 (br s, 1H); 8.4 (d, 1H); 8.35
(dd, 1H); 8.3 (d, 1H); 8.25 (s, 1H); 8.1 (s, 1H); 4.1 (m, 1H); 3.95
(m, 1H); 3.8 (m, 1H); 3.7 (m, 1H); 2.1-2.0 (m, 4H); 1.65 (s, 3H).
203 423 1.7 (DMSO-d6) 12.8 (br s, 1H); 8.5-8.2 (m, 5H); 6.7 (m,
1H); 4.0-3.7 (m, 4H); 2.2-2.0 (m, 4H); 1.7 (s, 3H). 204 427 1.5
(DMSO-d6) 12.85 (br s, 1H); 9.2-9.0 (m, 1H); 8.7-8.6 (m, 1H); 8.4
(m, 3H); 6.85 (m, 0.8H); 6.25 (m, 0.2H); 5.55 (d, 1H); 5.05 (dd,
0.8H); 4.8 (m, 0.2H); 4.2-3.6 (m, 4H); 2.8 (m, 1H); 2.3-2.15 (m,
1H). 205 423.1 2 206 441.1 2 207 459.1 2.1 (500 MHz, DMSO) 13.17
(s, 1H), 8.87 (s, 1H), 8.80-8.60 (m, 2H), 8.40-8.30 (m, 2H), 8.05-
7.94 (m, 1H), 7.89 (d, J = 8.3 Hz, 1H), 7.70 (m, 1H), 5.70 (tt, J =
15.1, 3.9 Hz, 1H), 3.40- 3.30 (m, 2H), 2.38-2.31 (m, 1H), 2.07 (m,
1H), 1.70 (s, 3H), 0.89 (t, J = 7.5 Hz, 3H). 208 477.1 2.2 (500
MHz, DMSO) 8.85 (s, 1H), 8.67-8.55 (m, 3H), 8.39 (s, 1H), 7.99 (m,
1H), 7.89 (d, J = 8.1 Hz, 1H), 7.69 (m, 1H), 3.86-3.71 (m, 2H),
2.40-2.34 (m, 1H), 2.10-2.06 (m, 1H), 1.70 (s, 3H), 0.89 (t, J =
7.5 Hz, 3H). 209 359.1 1.6 (500 MHz, MeOD) 8.48 (dd, J = 2.8, 9.3
Hz, 1H), 8.43 (s, 1H), 8.35-8.33 (m, 1H), 8.28- 8.27 (m, 1H), 3.21
(q, J = 7.2 Hz, 2H), 1.77- 1.75 (m, 2H), 1.29 (m, 2H), 0.97 (t, J =
7.2 Hz, 3H). 210 395.1 1.7 (500 MHz, DMSO) 12.35 (s, 1H), 8.57 (s,
1H), 8.39 (d, J = 6.1 Hz, 2H), 8.31 (d, J = 3.9 Hz, 1H), 8.27-8.25
(m, 2H), 5.95-5.71 (m, 1H), 3.45-3.37 (m, 2H), 1.53 (br, 2H), 1.16
(br, 2H). 211 413 1.8 (500 MHz, MeOD) 8.46-8.43 (m, 2H), 8.37 (t, J
= 4.8 Hz, 1H), 8.27-8.26 (m, 1H), 3.90- 3.83 (m, 2H), 1.82 (m, 2H),
1.38 (m, 2H). Multiplet (0.47H) at 8.71, identified as an
exchangeable proton that did not fully exchange, which decreased to
0.38H after 1 h. 212 373.1 1.72 (500 MHz, DMSO-d6) 13.04 (s, 1H),
9.16 (d, J = 3.2 Hz, 1H), 8.82 (s, 1H), 8.66 (d, J = 3.0 Hz, 1H),
8.39 (d, J = 2.0 Hz, 1H), 8.15 (d, J = 7.0 Hz, 1H), 7.64 (d, J =
7.2 Hz, 1H), 6.68 (d, J = 7.1 Hz, 1H), 3.88-3.84 (m, 1H), 1.60 (s,
6H), 0.84 (d, J = 6.2 Hz, 6H), 0.00 (TMS) 213 405.1 1.6 (500 MHz,
MeOD) 8.83 (d, J = 2.3 Hz, 1H), 8.58 (s, 1H), 8.35 (d, J = 2.3 Hz,
1H), 8.18 (m, 1H), 4.21 (t, J = 4.8 Hz, 1H), 4.11 (t, J = 4.8 Hz,
1H), 3.37-3.32 (m, 2H), 2.58 (s, 3H), 2.27 (s, 3H), 1.79 (s, 6H).
214 423 1.71 (500 MHz, MeOD) 8.79 (d, J = 2.3 Hz, 1H), 8.58 (s,
1H), 8.36 (d, J = 2.3 Hz, 1H), 8.29 (m, 1H), 5.67-5.43 (m, 1H),
3.48-3.38 (m, 2H), 2.58 (s, 3H), 2.27 (s, 3H), 1.79 (s, 6H). 215
441 1.8 (500 MHz, MeOD) 8.77 (d, J = 2.3 Hz, 1H), 8.56 (s, 1H),
8.44-8.34 (m, 1H), 8.34 (d, J = 2.2 Hz, 1H), 3.86-3.79 (m, 2H),
2.58 (s, 3H), 2.28 (s, 3H), 1.79 (s, 6H). 216 471 2.9 (500 MHz,
DMSO) 12.32 (s, 1H), 8.69 (m, 2H), 8.28-8.13 (m, 3H), 4.9-4.75 (m,
1H), 4.7-4.5 (m, 1H), 3.95-3.75 (m, 3H), 2.15-1.95 (m, 1H), 1.87
(m, 2H), 1.6 (s, 1H), 1.44-1.41 (m, 1H), 1.1-0.85 (m, 3H) 217 439
1.8 (500 MHz, MeOD) 8.77 (s, 1H), 8.22-8.19 (m, 3H), 6.40 (s, 1H),
4.69 (s, 1H), 4.32 (bs, 1H), 4.01-3.91 (m, 2H), 2.43-2.38 (m, 1H),
2.27-2.16 (m, 2H), 1.86-1.82 (m, 1H), 1.45 (d, J = 6.0 Hz, 3H) 218
457 2.7 (500 MHz, MeOD) 8.78-8.77 (m, 1H), 8.20 (d, J = 2.1 Hz,
1H), 8.15-8.10 (m, 2H), 4.90 (d, J = 9.4 Hz, 1H), 3.94-3.82 (m,
2H), 2.58- 2.40 (m, 1H), 2.24-2.21 (m, 1H), 2.0-2.1 (m, 1H), 1.82
(m, 1H), 1.50 (d, 1H), 1.4-1.23 (m, 3H) 219 452.9 2 (500 MHz, MeOD)
8.76 (s, 1H), 8.21-8.17 (m, 3H), 6.40 (d, J = 5.9 Hz, 1H), 4.90 (d,
J = 9.1 Hz, 1H), 4.04-3.88 (m, 2H), 3.63 (s, 1H), 2.53-2.39 (m,
1H), 2.22-2.11 (m, 3H), 2.01- 1.92 (m, 1H), 1.60-1.45 (m, 1H), 1.08
(t, J = 7.2 Hz, 2H), 1.01 (t, J = 7.1 Hz, 1H), 220 469.1 1.84 (500
MHz, DMSO) 13.52-13.35 (br, 1H), 13.12-12.96 (br, 1H), 9.07-8.61
(br, 1H), 8.93 (s, 1H), 8.37 (s, 1H), 8.07-7.54 (m, 2H), 7.40-7.27
(br, 1H), 3.02-2.97 (m, 2H), 1.71 (s, 6H), 0.72 (t, J = 7.1 Hz,
3H). 221 487.1 1.85 (500 MHz, MeOD) 8.93 (d, J = 2.3 Hz, 1H), 8.61
(s, 1H), 8.37 (d, J = 2.2 Hz, 1H), 8.21 (m, 1H), 7.98 (s, 1H), 7.31
(s, 1H), 4.20 (t, J = 4.8 Hz, 1H), 4.11 (t, J = 4.9 Hz, 1H), 4.07
(s, 3H), 4.06 (s, 3H), 3.36-3.35 (m, 2H), 1.87 (s, 6H). 222 505.1
1.9 (500 MHz, MeOD) 8.89 (d, J = 2.3 Hz, 1H), 8.61 (s, 1H), 8.37
(d, J = 2.3 Hz, 1H), 8.33 (m, 1H), 7.99 (s, 1H), 7.32 (s, 1H),
5.67-5.43 (m, 1H), 4.07 (s, 3H), 4.06 (s, 3H), 3.35-3.33 (m, 2H),
1.87 (s, 6H). 223 483 1.9 (500 MHz, MeOD) 8.91 (d, J = 2.3 Hz, 1H),
8.62 (s, 1H), 8.37 (d, J = 2.3 Hz, 1H), 7.98 (s, 1H), 7.31 (s, 1H),
4.07 (s, 3H), 4.07 (s, 3H), 3.12-3.08 (m, 2H), 1.86 (s, 6H),
1.33-1.25 (m, 2H), 0.62 (t, J = 7.5 Hz, 3H). 224 329.05 1.4 (500
MHz, MeOD) 8.49 (d, J = 3.2 Hz, 1H), 8.45-8.40 (m, 1H), 8.33 (d, J
= 1.5 Hz, 1H), 8.03 (d, J = 7.1 Hz, 1H), 6.69 (d, J = 6.9 Hz, 1H),
4.77-4.75 (m, 1H), 3.3 (m overlap with meoh signal, 2H), 1.61 (d,
7.1 Hz, 3H), 1.10 (t, J = 7.2 Hz, 3H), 0.00 (TMS) 225 346.93 1.4
226 365 1.4 (500 MHz, MeOD) 8.49 (s, 1H), 8.41 (d, J = 7.9 Hz, 1H),
8.33-8.32 (m, 1H), 8.04 (d, J = 6.9 Hz, 1H), 6.70 (d, J = 6.6 Hz,
1H), 5.84 (t, J = 55.8 Hz, 1H), 3.74-3.44 (2m, 2H), 1.63 (d, J =
7.2 Hz, 3H), 0.00 (TMS) 227 383 1.6 228 391.1 2.3 (500 MHz, DMSO)
12.96 (s, 1H), 8.65 (s, 1H), 8.42-8.38 (m, 2H), 8.25 (s, 1H), 8.20
(d, J = 7.0 Hz, 1H), 6.68 (d, J = 6.8 Hz, 1H), 5.76 (t, J = 56.1
Hz, 1H), 3.43-3.37 (m, 2H), 2.81- 2.78 (m, 2H), 2.30 (dd, J = 8.6,
18.9 Hz, 2H), 2.01 (qn, J = 8.1 Hz, 2H), 0.00 (TMS) 229 409.1 2.4
(500 MHz, DMSO) 12.91 (s, 1H), 8.62 (s, 1H), 8.46 (s, 1H), 8.41 (d,
J = 8.8 Hz, 1H), 8.36 (s, 1H), 8.20 (d, J = 6.7 Hz, 1H), 6.66 (d, J
= 6.6 Hz, 1H), 3.82-3.79 (m, 2H), 2.84 (m, 2H), 2.32-2.28 (m, 2H),
2.02-1.95 (m, 2H), 0.00 (TMS) 230 369.2 1.6 (500 MHz, DMSO) 12.92
(s, 1H), 8.63 (s, 1H), 8.47 (d, J = 8.5 Hz, 1H), 8.37 (s, 1H), 8.18
(d, J = 6.8 Hz, 1H), 7.84 (s, 1H), 6.65 (d, J = 6.5 Hz, 1H), 2.97
(m, 2H), 2.79 (m, 2H), 2.26 (m, 2H), 2.00 (m, 2H), 1.23 (dd, J =
6.9, 14.1 Hz, 2H), 0.54 (t, J = 7.1 Hz, 3H), 0.00 (TMS) 231 373.1
1.76 (500 MHz, DMSO-d6) 13.02 (s, 1H), 8.99 (s, 1H), 8.76 (s, 1H),
8.63 (s, 1H), 8.39 (d, J = 2.3 Hz, 1H), 8.16 (d, J = 6.7 Hz, 1H),
7.92 (s, 1H), 6.75 (d, J = 4.9 Hz, 1H), 3.07-3.05 (m, 2H),
2.10-1.93 (m, 2H), 1.58 (s, 3H), 0.86 (t, J = 7.5 Hz, 3H), 0.81 (s,
3H), 0.00 (TMS) 232 391.1 1.77 (500 MHz, DMSO-d6) 13.66-13.49 (m,
1H), 12.96-12.93 (m, 1H), 8.76 (s, 1H), 8.57 (d, J = 10.2 Hz, 1H),
8.37 (s, 1H), 8.16-8.13 (m, 2H), 6.68 (d, J = 9.6 Hz, 1H), 4.21 (d,
J = 51.9 Hz, 2H), 3.28 (q, J = 5.4 Hz, 2H), 2.10- 1.94 (m, 2H),
1.57 (s, 3H), 0.87 (t, J = 7.5 Hz, 3H), 0.00 (TMS) 233 409.1 1.87
(500 MHz, DMSO-d6) 13.02 (s, 1H), 9.05 (s, 1H), 8.70 (s, 1H), 8.62
(s, 1H), 8.39 (d, J = 2.2 Hz, 1H), 8.35 (s, 1H), 8.18 (d, J = 7.0
Hz, 1H), 6.75 (d, J = 5.6 Hz, 1H), 5.86-5.64 (m, 1H), 3.43-3.37 (m,
2H), 2.12-1.93 (m, 2H), 1.59 (s, 3H), 0.88 (t, J = 7.5 Hz, 3H),
0.00 (TMS) 234 387.1 1.87 (500 MHz, DMSO-d6) 13.56 (s, 1H), 12.89
(s, 1H), 8.89 (s, 1H), 8.57 (s, 1H), 8.36 (s, 1H), 8.16 (d, J = 6.8
Hz, 1H), 6.63 (s, 1H), 3.24 (s, 3H), 2.94 (s, 2H), 2.20-1.87 (m,
2H), 1.57 (s, 3H), 0.87 (t, J = 7.4 Hz, 3H), 0.75 (s, 3H), 0.00
(TMS) 235 523.1 1.9 236 355.2 1.8 237 373.1 1.8 238 398 2.6
(DMSO-d6) 12.56 (m, 1H); 8.80 (m, 0.5H); 8.55 (s, 0.5H); 8.50 (s,
0.5H); 8.45 (m, 1.0H); 8.40-8.30 (m, 1.5H); 8.28 (m, 1.5H); 8.10
(m, 0.5H); 3.80 (m, 2H); 1.42 (m, 6H) 239 410.9 1.7 (500 MHz, DMSO)
(warmed at 100 C.) 12.26 (s, 1H), 8.84 (d, J = 2.2 Hz, 1H), 8.43
(bs, 1H), 8.38 (s, 1H), 8.29 (d, J = 2.4 Hz, 1H), 8.23 (d, J = 6.3
Hz, 1H), 8.13 (bt, 1H), 6.46 (d, J = 6.3 Hz, 1H), 3.93-3.83 (m,
2H), 1.62-1.60 (m, 2H), 1.23-1.17 (m, 2H), 0.0 (TMS) 240 395 1.6
(500 MHz, CD3OD, RT) 8.8 (m, 0.6 H), 8.65 (bt, 1H), 8.5 (s, 1H),
8.45 (bd, 1H), 8.25 (m, 1.3H), 8.1 (d, 0.8 H), 6.7 (d, 1H), 3.9 (m,
2H),
1.8 (bm, 2H), 1.35 (bm, 2H), 0 (TMS) 241 371.1 1.76 242 393.1 1.77
243 411.1 1.86 244 341.1 1.5 (500 MHz, MeOD, rt, contains
conformers) 8.77 (dd, J = 2.8, 9.2 Hz, 0.29H), 8.54-8.49 (m,
1.66H), 8.31 (d, J = 1.5 Hz, 1H), 8.26-8.24 (m, 0.3H), 8.10 (dd, J
= 4.3, 7.2 Hz, 0.82H), 6.70 (d, J = 7.3 Hz, 0.29H), 6.66 (dd, J =
4.3, 7.2 Hz, 0.71H), 3.27-3.18 (m, 2H), 1.77-1.72 (m, 2H),
1.28-1.24 (m, 2H), 1.09 (t, J = 7.1 Hz, 0.98H), 0.96 (t, J = 7.1
Hz, 2.2H). 245 359.1 1.6 (500 MHz, MeOD, rt, contains conformers)
8.82-8.72 (m, 0.26H), 8.50 (m, 1.67H), 8.43- 8.31 (m, 1.84H), 8.25
(br, 0.26H), 8.10 (d, J = 6.4 Hz, 0.72H), 6.70-6.65 (m, 1H),
4.48-4.25 (m, 2H), 3.49-3.37 (m, 2H), 1.80 (m, 2H), 1.27 (br, 2H).
246 377.1 1.65 (500 MHz, MeOD, rt, contains conformers) 8.77 (dd, J
= 2.8, 9.1 Hz, 0.28H), 8.57-8.45 (m, 2.29H), 8.32 (d, J = 1.5 Hz,
1H), 8.27-8.26 (m, 0.29H), 8.11 (dd, J = 4.0, 7.1 Hz, 0.74H), 6.72
(d, J = 7.3 Hz, 0.29H), 6.68 (d, J = 7.1 Hz, 0.73H), 5.89-5.60 (m,
1H), 3.59-3.47 (m, 2H), 1.80-1.76 (m, 2H), 1.34-1.30 (m, 2H). 247
355.1 1.6 (500 MHz, MeOD, rt, contains conformers) 8.77 (dd, J =
2.8, 9.3 Hz, 0.28H), 8.56-8.50 (m, 1.68H), 8.31 (d, J = 1.5 Hz,
1H), 8.26 (dd, J = 4.4, 7.2 Hz, 0.28H), 8.10 (dd, J = 4.4, 7.2 Hz,
0.75H), 6.72-6.70 (m, 0.29H), 6.67 (m, 0.72H), 3.18-3.12 (m, 2H),
1.77-1.72 (m, 2H), 1.50 (m, 0.6H), 1.38 (m, 1.57H), 1.29-1.24 (m,
2H), 0.87 (t, J = 7.4 Hz, 0.92H), 0.67 (t, J = 7.3 Hz, 2.2H). 248
460.9 2.7 (DMSO-d6) 12.4 (s, 1H); 8.9 (m, 1H); 8.65 (s, 1H); 8.35
(d, 1H); 8.3 (s, 1H); 8.2 (m, 1H); 5.5 (d, 1H); 4.9 (dd, 1H);
4.3-3.8 (m, 4H); 2.7 (m, 1H); 2.2-2.0 (m, 1H). 249 478.9 2.9
(DMSO-d6) 12.4 (s, 1H); 8.9 (m, 1H); 8.65 (s, 1H); 8.4 (d, 1H); 8.3
(m, 1H); 8.2 (m, 1H); 5.05 (m, 1H); 4.3 (m, 2H); 3.9 (m, 2H); 3.0
(m, 1H); 2.5 (m, 1H). 250 373 1.59 (500 MHz, MeOD) 8.81 (d, J = 2.1
Hz, 1H), 8.45 (s, 1H), 8.36 (d, J = 2.1 Hz, 1H), 7.99 (s, 1H), 3.98
(s, 1H), 3.19 (q, J = 7.2 Hz, 2H), 2.31 (s, 3H), 1.79 (s, 6H), 0.90
(t, J = 7.2 Hz, 3H). 251 391 1.61 (500 MHz, DMSO) 13.07-12.73 (br,
1H), 8.83 (d, J = 2.0 Hz, 1H), 8.55 (s, 1H), 8.36 (d, J = 1.8 Hz,
1H), 8.12 (s, 1H), 8.09 (br, 1H), 4.18 (t, J = 5.1 Hz, 1H), 4.08
(t, J = 5.1 Hz, 1H), 3.27 (q, J = 5.3 Hz, 1H), 3.22 (q, J = 5.3 Hz,
1H), 2.24 (s, 3H), 1.65 (s, 6H). 252 409.1 1.69 (500 MHz, MeOD)
8.79 (d, J = 2.1 Hz, 1H), 8.44 (s, 1H), 8.37 (d, J = 2.0 Hz, 1H),
8.32 (br, 1H), 8.01 (s, 1H), 5.58 (m, 1H), 3.48-3.42 (m, 2H), 2.31
(s, 3H), 1.79 (s, 6H). 253 427.1 1.77 (500 MHz, MeOD) 8.78 (s, 1H),
8.46 (br, 1H), 8.42 (s, 1H), 8.35 (s, 1H), 8.01 (s, 1H), 3.85- 3.82
(m, 2H), 2.32 (s, 3H), 1.79 (s, 6H). Unidentified peak at d 1.94.
254 387 1.66 (500 MHz, MeOD) 8.81 (d, J = 2.0 Hz, 1H), 8.45 (s,
1H), 8.36 (d, J = 2.0 Hz, 1H), 8.00 (s, 1H), 3.98 (s, 1H),
3.12-3.09 (m, 2H), 2.31 (s, 3H), 1.79 (s, 6H), 1.33 (m, 2H), 0.67
(t, J = 7.4 Hz, 3H). 255 344 2 (500 MHz, MeOD) 8.79 (br, 0.27H),
8.59 (d, J = 8.9 Hz, 0.69H), 8.53 (s, 1H), 8.47 (s, 1H), 8.24 (s,
1H), 3.17 (m, 2H), 1.66 (s, 6H), 1.08 (br, 0.93H), 0.91 (m, 2.14H).
256 385 1.9 257 403 1.8 258 421 2 259 399.1 2 260 428 2.7 (500 MHz,
MeOD) 9.07 (s, 0.33H), 8.78 (s, 0.56H), 8.57-8.31 (m, 3.58H), 3.88
(m, 2H), 2.18 (m, 1H), 2.05-2.03 (m, 1H), 1.66 (m, 3H), 0.96 (t, J
= 7.4 Hz, 3H). 261 412 2.5 (500 MHz, MeOD) 8.80 (m, 0.35H),
8.56-8.47 (m, 3.2H), 8.40 (m, 0.36H), 8.26 (m, 1H), 3.85 (m, 2H),
2.18 (m, 1H), 2.04 (m, 1H), 1.66 (m, 3H), 0.96 (t, J = 7.5 Hz, 3H).
262 360 2.1 263 445 2.4 (DMSO-d6) 12.3 (br s, 1H); 8.9 (m, 1H); 8.4
(d, 1H); 8.35 (d, 1H); 8.25 (s, 1H); 8.2 (s, 1H); 5.5 (d, 1H); 4.9
(dd, 1H); 4.3-3.75 (m, 4H); 2.7 (m, 1H); 2.2-2.0 (m, 1H). 264 463
2.8 (DMSO-d6) 12.3 (br s, 1H); 8.9 (dd, 1H); 8.4-8.3 (m, 2H);
8.25-8.2 (m, 2H); 5.05 (d, 1H); 4.35 (m, 2H); 3.9 (m, 2H); 3.0 (m,
1H); 2.5 (m, 1H). 265 432.2 2.6 (CD3CN) 10.40 (s, 1H), 8.80 (s,
1H), 8.29 (m, 3H), 6.97 (m, 1H), 5.22 (m, 1H), 4.79 (m, 1H), 4.43
(dt, 2H), 3.49 (dt, 2H), 2.54 (m, 1H), 2.43 (m, 1H), 2.39 (m, 1H),
2.22 (m, 1H) 266 450.2 2.7 (CD3CN) 10.48 (s, 1H), 8.79 (s, 1H),
8.30 (m, 3H), 7.01 (t, 1H), 5.90 (tt, 1H), 5.24 (m, 1H), 5.83 (m,
1H), 3.60 (m, 2H), 2.53 (m, 1H), 2.42 (m, 1H), 2.36 (m, 1H), 2.21
(m, 1H) 267 468.2 2.86 (CD3CN) 10.38 (s, 1H), 8.79 (s, 1H), 8.29
(m, 3H), 7.21 (t, 1H), 5.21 (m, 1H), 4.83 (m, 1H), 3.99 (m, 1H),
3.86 (m, 1H), 2.51 (m, 1H), 2.45 (m, 1H), 2.35 (m, 1H), 2.20 (m,
1H) 268 450.1 1.88 269 450.1 1.93 270 374.1 2.3 (500 MHz, MeOD)
9.05 (s, 0.32H), 8.84 (s, 0.65H), 8.53 (s, 1H), 8.43 (s, 1H), 8.29
(s, 1H), 3.27-3.17 (m, 2H), 2.18-2.10 (m, 1H), 2.07-2.00 (m, 1H),
1.64 (m, 3H), 1.08 (m, 1H), 0.95 (t, J = 7.4 Hz, 5H). 271 358 2.1
(500 MHz, MeOD) 8.78 (br, 0.33H), 8.58 (d, J = 8.6 Hz, 0.81H), 8.53
(s, 1H), 8.46 (s, 1H), 8.24 (s, 1H), 3.26-3.16 (m, 2H), 2.17-2.13
(m, 1H), 2.01 (m, 1H), 1.71-1.57 (m, 3H), 0.95 (t, J = 7.5 Hz, 6H).
272 450 2.4 (500 MHz, MeOD) 8.87 (s, 1H), 8.56 (bt, 1H), 8.53 (s,
1H), 8.43 (d, J = 6.9 Hz, 1H), 8.35 (d, J = 2.2 Hz, 1H), 6.91 (d, J
= 6.7 Hz, 1H), 5.09 (apparent d, 1H), 4.86 (apparent d, 1H),
4.02-3.96 (m, 1H), 3.87- 3.81 (m, 1H), 2.03 (m, 1H), 1.88-1.80 (m,
2H), 1.48-1.43 (m, 1H), 0.00 (TMS) 273 464.1 2.5 (500 MHz, MeOD)
8.86 (d, J = 2.1 Hz, 1H), 8.44 (t, 1H), 8.40 (s, 1H), 8.37 (d, J =
6.6 Hz, 1H), 8.31 (d, J = 2.2 Hz, 1H), 6.52 (bs, 1H), 4.85 (s, 2H),
3.93 (m, 2H), 2.86 (m, 2H), 2.72 (m, 2H), 2.25 (m, 1H), 2.06 (m,
1H), 0.00 (TMS) 274 428 2.4 (DMSO-d6) (rotational mixture about
1.3:1): 12.6 (m, 1H); 9.0 (dd, 0.6H); 8.8 (dd, 0.4H); 8.65-8.3 (m,
4H); 5.6-5.35 (m, 1H); 4.8 (t, 0.6H); 4.7 (t, 0.4H); 4.35 (m,
0.4H); 4.2 (m, 0.6H) 4.1-3.7 (m, 3H); 2.75-2.6 (m, 1H); 2.25-2.05
(m, 1H). 275 428 2.3 (DMSO-d6) (rotational mixture about 1.3:1):
12.6 (m, 1H); 8.7-8.25 m, 5H); 5.5-5.3 (m, 1H); 4.9 (d, 0.6H); 4.75
(d, 0.4H); 4.1-3.7 (m, 4H); 2.75-2.6 (m, 1H); 2.4-2.3 (m, 1H). 276
444 2.5 (DMSO-d6) (rotational mixture about 1.3:1): 12.7 (m, 1H);
9.0-8.3 (m, 5H); 5.6-5.4 (m, 1H); 4.8 (t, 0.6H); 4.7 (t, 0.4H);
4.4-3.75 (m, 4H); 2.8-2.6 (m, 1H); 2.25-2.05 (m, 1H). 277 473 2.3
(DMSO-d6) 12.35 (m, 1H); 8.75-8.6 (m, 2H); 8.35-8.15 (m, 3H); 4.75
(m, 1H); 4.0-3.7 (m, 4H); 2.3 (m, 1H); 2.0 (m, 1H); 1.35 (s, 3H).
278 487 2.5 (DMSO-d6) 12.35 (m, 1H); 8.75-8.6 (m, 2H); 8.35-8.15
(m, 3H); 4.75 (m, 1H); 4.0-3.7 (m, 4H); 2.3 (m, 1H); 2.0 (m, 1H);
1.6 (m, 2H); 1.0 (m, 3H). 279 468.1 1.59 280 455 1.5 (DMSO-d6)
13.05-12.9 (m, 1H); 8.8-8.25 (m, 5H); 6.75 (m, 0.7H); 6.35 (m,
0.3H); 4.95 (m, 0.7H); 4.75 (m, 0.3H); 4.05-3.6 (m, 4H); 2.4-2.1
(m, 2H); 1.4 (m, 3H). 281 469 1.6 (DMSO-d6) 13.0-12.9 (m, 1H);
8.8-8.25 (m, 5H); 6.7 (m, 0.7H); 6.3 (m, 0.3H); 5.05- 4.8 (m, 1H);
4.1-3.6 (m, 4H); 2.4-2.05 (m, 2H); 1.75-1.6 (m, 2H); 1.05-0.9 (m,
3H). 282 392.9 2.7 (500 MHz, MeOD) 8.80 (d, J = 2.3 Hz, 1H), 8.35
(s, 1H), 8.33 (s, 1H), 8.28 (d, J = 2.3 Hz, 1H), 3.19 (q, J = 7.2
Hz, 2H), 1.74 (s, 6H), 0.93 (t, J = 7.2 Hz, 3H). 283 410.9 2.7 (500
MHz, MeOD) 8.81 (d, J = 2.3 Hz, 1H), 8.35 (s, 1H), 8.33 (s, 1H),
8.28 (d, J = 2.2 Hz, 1H), 8.19-8.17 (m, 0.33H), 4.23 (dt, J = 47.4,
5.1 Hz, 2H), 3.42 (dt, J = 25.5, 5.1 Hz, 2H), 1.75 (s, 6H). 284
439.9 1.9 (500 MHz, MeOD) 8.72 (s, 1H), 8.57-8.53 (m, 2H), 8.45 (s,
1H), 8.26 (s, 1H), 3.85-3.78 (m, 2H), 1.75 (s, 6H). 285 428 2.8
(500 MHz, MeOD) 9.07 (d, J = 1.9 Hz, 0.53H), 8.81-8.78 (m, 0.84H),
8.55 (d, J = 10.5 Hz, 1H), 8.45 (d, J = 15.6 Hz, 1H), 8.30 (s, 1H),
4.56- 4.52 (m, 1H), 4.06-4.00 (m, 1H), 3.89-3.84 (m, 1H), 2.34-2.24
(m, 1H), 1.12-1.06 (m, 6H). 286 428.9 2.9 (500 MHz, MeOD) 8.79 (d,
J = 2.3 Hz, 1H), 8.36 (s, 1H), 8.33-8.28 (m, 2.8H), 5.64 (tt, J =
56.5, 4.2 Hz, 1H), 3.51-3.43 (m, 2H), 1.74 (s, 6H). 287 446.9 3
(500 MHz, MeOD) 8.78 (d, J = 2.3 Hz, 1H), 8.45 (t, J = 6.1 Hz, 1H),
8.34 (s, 1H), 8.25 (d, J = 3.3 Hz, 2H), 3.86-3.44 (m, 2H), 1.73 (s,
6H). 288 437.96 2.9 (500 MHz, MeOD) 9.24 (m, 0.5H), 8.87-8.73 (m,
0.27H), 8.62-8.29 (m, 2.7H), 7.76-7.37 (m, 0.46H), 3.86-3.76 (m,
2H), 1.80-1.50 (m, 6H). 289 403.5 2.9 (DMSO-d6) 12.3 (br s, 1H);
8.7 (s, 1H); 8.3-8.2 (m, 2H); 8.1 (s, 1H); 7.65 (m, 1H); 4.1-3.85
(m, 2H); 3.15-2.9 (m, 2H); 2.1-1.9 (m, 4H); 1.6 (s, 3H); 0.8 (m,
3H). 290 421.5 2.9 (DMSO-d6) 12.3 (br s, 1H); 8.7 (s, 1H); 8.25 (m,
2H); 8.1 (s, 1H); 7.95 (m, 1H); 4.35-4.05 (m, 3H); 3.95 (m, 1H);
3.35-3.2 (m, 2H); 2.1-1.9 (m, 4H); 1.6 (s, 3H). 291 439.5 3
(DMSO-d6) 12.3 (br s, 1H); 8.7 (s, 1H); 8.3 (m, 2H); 8.15-8.05 (m,
2H); 5.8 (dd, 1H); 4.1 (m, 1H); 3.9 (m, 1H); 3.4 (m, 2H); 2.1-1.9
(m, 4H); 1.6 (s, 3H). 292 417.1 2.7 (DMSO-d6) 12.3 (s, 1H); 8.7 (s,
1H); 8.25 (m, 2H); 8.1 (s, 1H); 7.7 (dd, 1H); 4.1 (m, 1H); 3.9 (m,
1H); 3.1-2.8 (m, 2H); 2.1-1.9 (m, 4H); 1.6 (s, 3H); 1.35-1.15 (m,
2H); 0.6 (m, 3H). 293 455.1 2.09 294 483.1 2.42 295 453 2.02 296
410.3 1.75 297 407.1 2.3 (DMSO-d6): 12.45 (br s, 1H); 8.7 (s, 1H);
8.4-8.2 (m, 4H); 5.5 (d, 1H); 4.75 (t, 1H); 4.25-3.9 (m, 2H);
3.2-3.0 (m, 2H); 2.6-2.0 (m, 2H); 1.0 (m, 3H). 298 421.2 2.5
(DMSO-d6) 12.4 (br s, 1H); 8.7 (s, 1H); 8.4-8.2 (m, 4H); 5.5 (d,
1H); 4.75 (t, 1H); 4.25-3.9 (m, 2H); 3.8 (m, 1H); 3.0 (m, 1H);
2.3-2.0 (m, 2H); 1.45-1.2 (m, 2H); 0.75 (m, 3H). 299 425.1 2.3
(DMSO-d6) 12.4 (br s, 1H); 8.7 (s, 1H); 8.6 (m, 1H) 8.35-8.2 (m,
3H); 5.5 (d, 1H); 4.8 (t, 1H); 4.45 (m, 1H); 4.3-3.9 (m, 3H); 3.3
(m, 1H); 2.7 (m, 1H); 2.3-2.0 (m, 2H). 300 443.1 2.5 (DMSO-d6) 12.4
(br s, 1H); 8.8-8.6 (m, 2H); 8.4-8.2 (m, 3H); 5.9 (dd, 1H); 5.5 (d,
1H); 4.85 (t, 1H); 4.3-3.9 (m, 2H); 2.75-2.0 (m, 4H). 301 441.1 2.6
302 465.2 1.9 303 411.2 1.8 304 447.2 1.8 305 425.2 1.9 306 437.2
1.8 307 455.2 2 308 437.2 1.9 309 457.1 1.8 (DMSO-d6) 12.3 (br s,
1H); 8.75 (s, 1H); 8.35-8.2 (m, 3H); 8.1 (s, 1H); 6.45 (m, 1H);
5.55 (m, 1H); 4.2-3.7 (m, 4H); 2.4-2.2 (m, 2H); 1.7 (s, 3H).
TABLE-US-00006 TABLE 6 Cmpd # M + H RT NMR 310 409.00 1.80 DMSO-d6:
12.25 (br s, 1H); 8.8 (m, 1H); 8.7 (m, 1H); 8.35-8.3 (m, 2H); 8.2
(m, 1H); 7.2 (m, 1H); 4.85 (d, 1H); 4.0 (m, 1H); 3.95-3.8 (m, 3H);
2.35 (m, 1H); 2.1-1.85 (m, 3H). 311 409.00 1.80 DMSO-d6: 12.25 (br
s, 1H); 8.8 (m, 1H); 8.7 (m, 1H); 8.35-8.3 (m, 2H); 8.2 (m, 1H);
7.2 (m, 1H); 4.85 (d, 1H); 4.0 (m, 1H); 3.95-3.8 (m, 3H); 2.35 (m,
1H); 2.1-1.85 (m, 3H). 312 444.90 2.20 500 MHz DMSO-d6 @60 C.: 12.8
(br m, 1H), 8.85 (m, 1H), 8.8 (m, 1H), 8.65 (s, 1H), 8.3 (d, 1H),
8.25 (1H), 7.75 (br m, 1H), 7.3 (d, 1H), 4.85 (m, 1H), 3.9 (m, 2H),
3.0 (d m, 2H), 2.2 (s, 3H) 313 495.00 2.30 314 438.00 2.00 500 MHz
MeOD-d4: 8.68 (m, 1H), 8.5 (s, 1H), 8.35 (s, 1H), 8.1 (d.1H), 6.71
(d, 1H), 4.04 (m, 1H), 3.99m, 1H), 2.7 (t, 2H), 2.4 (m, 1H), 2.24
(m, 1H) 315 456.00 2.80 500 MHz MeOD-d4: 8.66 (s, 1H), 8.4 (s, 1H),
8.35 (d, 1H), 8.3 (d.1H), 5.45 (m, 1H, parially ex), 5.04 (m, 1H),
4.01m, 1H), 3.93 (m, 1H), 2.73 (t, 2H), 2.5 (m, 1H), 2.32 (m, 1H)
316 488.00 2.10 500 MHz MeOD-d4: 8.77 (s, 1H), 8.71 (s, 1H), 8.5
(d, 1H), 8.35 (s. 1H), 8.02 (t, 1H), 7.88 (d, 1H), 7.71 (t, 1H),
5.25 (m, 1H), 4.02 (m, 1H), 3.90 (m, 1H) 2.73 (t, 2H), 2.6 (m, 1H),
2.5 (m, 1H) 317 482.00 2.70 DMSO d5 12.8 (bs, 1H); 8.7 (bs, 1H);
8.5 (m, 2H); 8.4 (s, 1H); 7.7 (s, 1H); 6.9 (s, 1H); 4.8 (m, 1H);
3.8 (m, 2H); 3.6 (m, 3H); 29 (m, 2H); 2.0 (m, 2H); 1.2 (m, 2H) 318
496.10 2.90 DMSO d5 12.6 (bs, 1H); 8.8 (bs, 1H); 8.7 (m, 2H); 8.4
(s, 1H); 7.7 (s, 1H); 6.9 (s, 1H); 4.8 (m, 1H); 3.8 (m, 2H); 3.6
(m, 2H); 3.5 (m, 5H); 2.0 (m, 2H); 1.2 (t, 3H) 319 510.10 3.10 DMSO
d5 12.6 (bs, 1H); 8.9 (bs, 1H); 8.6 (m, 2H); 8.4 (s, 1H); 7.8 (s,
1H); 4.7 (m, 1H); 3.9 (m, 2H); 3.7 (m, 2H); 3.3 (m, 2H); 2.0 (m,
2H); 1.5 (m, 2H); 0.9 (t, 3H) 320 508.10 3.00 DMSO d5 12.6 (bs,
1H); 8.8 (bs, 1H); 8.6 (m, 2H); 8.4 (s, 1H); 7.7 (s, 1H); 4.7 (m,
1H); 4.0 (m, 2H); 3.8 (m, 2H); 2.9 (s, 1H); 2.0 (m, 2H); 1.9 (m,
3H); 0.8 (t, 2H); 0.6 (m, 1H) 321 424.20 1.50 (d4-methanol) 8.86
(d, 1H), 8.40 (d, 1H), 8.29 (d, 1H), 8.25 (s, 1H), 7.30 (dd, 1H),
5.65 (br s, 1H), 4.62 (d, 1H), 4.03-3.35 (m, 7H) 322 403.10 2.10
DMSO-d6: 12.5 (s, 1H); 8.7 (s, 1H); 8.3 (m, 3H); 7.9 (d, 1H); 4.65
(d, 1H); 3.95 (m, 1H); 3.85 (m, 2H); 2.25 (m, 1H); 2.0 (m, 3H);
1.05 (m, 3H). 323 395.10 1.70 (500 MHz, DMSO-d6) d 12.31 (s, 1H),
8.79 (s, 1H), 8.65 (d, J = 7.8 Hz, 1H), 8.61 (t, J = 6.3 Hz, 1H),
8.38 (d, J = 4.1 Hz, 1H), 8.29 (dd, J = 4.7, 1.5 Hz, 1H), 8.24 (s,
1H), 7.15 (dd, J = 7.9, 4.7 Hz, 1H), , 3.81 (m, 2H), 1.57 (t, 2H),
1.19 (t, 2H) 324 385.20 1.70 DMSO-d6: 13.0 (br s, 1H); 8.7-8.6 (m,
2H); 8.4 (m, 1H); 8.3 (m, 1H); 8.15 (d, 0.3H); 8.0 (d, 0.7H); 6.75
(d, 0.7H); 6.3 (d, 0.3H); 4.85 (d, 0.7H); 4.5 (0.3H); 4.0-3.85 (m,
1H); 3.8- 3.6 (m, 2H); 2.35 (m, 1H); 2.05 (m, 3H); 1.1 (dd, 2H);
0.95 (dd, 4H). 325 399.10 2.10 DMSO-d6: 12.4 (br s, 1H); 8.65 (s,
1H); 8.55 (m, 1H); 8.3 (m, 2H); 8.25 (s, 1H); 4.7 (d, 1H); 3.95 (m,
1H); 3.85 (m, 2H); 3.8 (m, 1H); 3.0 (s, 1H); 2.25 (m, 1H); 2.0 (m,
3H). 326 452.39 3.60 CD3OD/CDCl3: 1.68 (6H, s), 2.14 (2H, m), 3.38
(2H, m), 7.98 (1H, t), 8.22 (1H, s), 8.28 (1H, s), 8.54 (1H, s),
8.83 (1H, s) 327 438.41 3.56 CD3OD/CDCl3: 1.70 (6H, s), 3.81 (2H,
m), 7.59 (1H, m), 8.22 (1H, s), 8.26 (1H, s), 8.45 (1H, t), 8.58
(1H, s), 8.81 (1H, s) 328 404.34 3.23 DMSO-d6/CD3OD/CDCl3: 1.58
(6H, s), 3.12 (1H, s), 3.75 (2H, m), 7.21 (1H, m), 8.19 (1H, s),
8.28 (1H, m), 8.45 (1H, t), 8.69 (1H, s), 8.71 (1H, d) 329 470.35
3.24 MeOD: 1.75 (6H, s), 2.16 (2H, m), 3.35 (2H, m), 8.34 (2H, s),
8.48 (1H, s), 8.75 (1H, s), 8.85 (1H, s) 330 381.20 1.50 DMSO-d6:
12.8 (s, 1H); 8.7-8.5 (m, 3H); 8.4-8.25 (m, 2H); 6.7 (m, 0.7H) 6.3
(m, 0.3H); 4.8 (m, 0.7H); 4.6 (m, 0.3H); 4.0-3.6 (m, 4H); 2.95 (m,
1H); 2.35 (m, 1H); 2.05 (m, 3H). 331 383.20 1.70 DMSO-d6: 12.9 (br
s, 1H); 8.8 (s, 1H); 8.7 (s, 1H); 8.6 (s, 1H); 8.4 (s, 1H); 8.15
(m, 1H); 6.8 (s, 1H); 4.7 (s, 1H); 4.05-3.85 (m, 2H); 3.1 (s, 1H);
2.25 (m, 1H); 1.1-0.95 (m, 6H). 332 387.40 2.00 DMSO-d6: 12.95 (br
s, 1H); 8.7 (s, 1H); 8.6 (s, 1H); 8.4 (s, 1H); 8.15 (m, 2H); 6.8
(s, 1H); 4.6 (s, 1H); 3.9 (m, 1H); 2.25 (m, 1H); 1.1-0.95 (m, 12H).
333 400.20 2.00 DMSO-d6: 12.35 (br s, 1H); 8.77 (dd, 1H); 8.65 (s,
1H); 8.3 (m, 2H); 8.2 (s, 1H); 4.7 (d, 1H); 4.1 (m, 2H); 3.95 (m,
1H); 3.8 (m, 1H); 2.25 (m, 1H); 2.0 (m, 3H). 334 382.20 1.50
DMSO-d6: 12.9 (br s, 1H); 8.95 (dd, 1H); 8.75 (m, 0.4H); 8.6 (m,
1.6H); 8.4-8.3 (m, 2H); 6.75 (d, 0.8H); 6.35 (d, 0.2H); 4.9 (d,
0.8H); 4.65 (d, 0.2H); 4.2-4.0 (m, 2H); 3.8 (m, 1H); 3.6 (m, 1H);
2.35 (m, 1H); 2.1-2.0 (m, 3H). 335 387.40 2.00 336 403.40 1.90 337
385.40 1.80 338 511.20 2.50 DMSO-d6: 8.60 (m, 2H); 8.30 (s, 1H);
8.23 (bs, 1H); 5.50 (m, 2H); 4.38 (m, 2H); 4.10 (m, 2H); 3.38 (m,
4H); 2.50 (m, 1H); 1.90-2.00 (m, 3H); 1.32 (t, 3H) 339 421.30 2.00
340 455.20 2.10 341 439.20 1.90 DMSO-d6: 13.0 (bs, 1H); 8.55 (m,
1H); 8.45 (m, 1H); 8.35 (m, 1H); 6.72 (m, 1H); 5.60 (m, 1H);
4.20-3.70 (m, 5H); 3.30 (s, 3H); 2.00 (m, 3H) 342 457.10 2.40
DMSO-d6: 8.30 (m, 1H); 8.30 (m, 3H); 7.70 (m, 1H); 5.40 (m, 1H);
4.20-3.70 (m, 5H); 3.30 (s, 3H); 2.00 (m, 3H) 343 379.20 2.04 (500
MHz, DMSO) 12.83 (s, 1H), 9.30 (s, 1H), 8.61 (t, J = 7.6 Hz, 2H),
8.37 (d, J = 4.5 Hz, 1H), 8.17 (d, J = 7.1 Hz, 1H), 7.27 (dd, J =
4.7, 7.7 Hz, 1H), 6.69 (d, J = 6.9 Hz, 1H), 3.79-3.76 (m, 2H), 1.63
(s, 6H) 344 366.10 1.87 DMSO-d6: 12.5 (m, 1H); 8.95 (m, 0.5 H);
8.78 (m, 0.5H); 8.65 (m, 0.5H); 8.52 (m, 0.5H); 8.48 (s, 1H);
8.32-8.25 (m, 2H); 8.30 (m, 1.5H); 8.12 (m, 1H); 7.20 (m, 1H); 4.54
(m, 1H); 3.80 (m, 2H); 1.32 (m, 3H) 345 411.20 1.90 (500 MHz,
DMSO-d6) 12.20 (s, 1H), 8.67 (dd, J = 1.4, 7.9 Hz, 1H), 8.43 (t, J
= 6.2 Hz, 1H), 8.32-8.28 (m, 2H), 8.10 (s, 1H), 7.5 (bs, 1H), 7.20
(dd, J = 4.7, 7.9 Hz, 2H), 3.81-3.73 (m, 2H), 2.20-2.16 (m, 1H),
1.99-1.95 (m, 1H), 1.56 (s, 3H), 0.82 (t, J = 7.5 Hz, 3H) 346
393.20 1.60 (DMSO-d6, 300 MHz) 11.95 (bs, 1H), 8.7 (d, 1H), 8.25
(m, 2H), 8.12 (d, 1H), 8.02 (d, 1H), 7.28 (s, 1H), 7.13 (dd, 1H),
6.38 (bd, 1H), 3.75 (m, 2H), 2.06 (m, 1H), 1.83 (m, 1H), 1.46 (s,
3H), 0.8 (t, 3H); 347 425.27 2.25 (500 MHz, MeOD) 8.87 (d, J = 8.1
Hz, 1H), 8.60 (t, 1H), 8.36 (d, 1H), 8.27-8.26 (m, 2H), 7.39 (dd, J
= 5.0, 8.0 Hz, 1H), 3.86 (m, 2H), 2.29 (t, J = 7.5 Hz, 4H), 0.87
(t, J = 7.5 Hz, 6H) 348 407.20 1.67 (500 MHz, DMSO-d6) d 12.81 (s,
1H), 8.92 (s, 1H), 8.68-8.57 (m, 3H), 8.38 (d, J = 3.3 Hz, 1H),
8.17 (d, 1H), 7.30-7.27 (m, 1H), 6.82 (d, 1H), 3.82-3.74 (m, 2H),
2.26-2.12 (m, 2H), 2.12-2.05 (m, 2H), 0.82-0.78 (m, 6H) 349 373.40
1.74 350 407.40 1.72 CD3CN: 9.89 (s, 1H), 8.79 (d, 1H), 8.27 (m,
1H), 8.19 (d, 1H), 8.10 (d, 1H), 7.18 (m, 2H), 6.49 (d, 1H), 5.80
(s, 1H), 3.97 (m, 1H), 3.59 (m, 1H), 1.53 (s, 3H), 1.02 (dd, 6H)
351 425.40 1.40 DMSO-d6: 12.2 (br s, 1H); 8.85 (m, 1H); 8.7 (d,
1H); 8.3 (m, 2H); 8.15 (m, 1H); 7.2 (m, 1H); 4.9 (dd, 1H); 4.45 (m,
1H); 4.05-3.7 (m, 4H); 2.3 (m, 1H); 1.95 (m, 1H). 352 407.40 1.40
DMSO-d6: 12.8 (br s, 1H); 9.1 (m, 1H); 8.7- 8.6 (m, 2H); 8.45-8.3
(m, 2H); 7.4 (m, 0.3H); 7.3 (m, 0.7H); 6.85 (d, 0.7H); 6.35 (d,
0.3H); 5.1 (dd, 0.7H); 4.8 (dd, 0.3H); 4.5 (m, 1H); 4.2-3.6 (m,
4H); 2.4 (m, 1H); 2.1 (m, 1H). 353 401.40 1.95 354 387.40 1.87 355
369.30 1.69 356 409.40 2.25 357 423.30 1.90 358 405.40 1.80 359
399.10 1.80 DMSO-d6: 12.7 (br s, 1H); 8.8 (s, 1H); 8.7- 8.2 (s,
3H); 6.5 (m, 0.8H); 6.2 (m, 0.2H); 4.2 (m, 0.3H); 4.0 (m, 0.7H);
3.8-3.6 (m, 2H); 3.4 (m, 1H); 3.2-3.05 (m, 1H); 2.7 (m, 2H); 2.2
(m, 3H); 2.05 (m, 1H); 1.7 (s, 2.7H); 1.6 (s, 0.3H); 1.0 (m, 0.3H);
0.7 (m, 2.7H). 360 379.20 1.60 DMSO-d6: 11.92 (m, 1H); 8.72 (bs,
1H); 8.22 (m, 1H); 8.05 (m, 2H); 7.42 (m, 1H); 7.18 (m, 1H); 6.32
(bs, 1H); 5.22 (m, 1H); 4.20 (m, 2H); 3.32 (s, 3H); 1.35 (m, 3H)
361 397.10 1.90 DMSO-d6: 11.9 (m, 1H); 8.55 (m, 1H); 8.25 (m, 1H);
8.18 (m, 1H); 7.98 (m, 1H); 7.65 (m, 1H); 7.15 (m, 1H); 5.15 (m,
1H); 4.18 (m, 2H); 3.30 (s, 2.5H); 2.90 (s, 0.5H); 1.35 (m, 3H) 362
357.10 1.51 363 343.10 1.40 364 361.10 1.41 365 391.10 1.85 366
393.10 1.60 (500 MHz, DMSO) 12.83 (s, 1H), 9.2 (bs, 1H), 9.07 (s,
1H), 8.68 (d, J = 7.8 Hz, 1H), 8.61 (s, 1H), 8.42 (d, J = 4.6 Hz,
1H), 8.15 (d, J = 7.1 Hz, 1H), 7.35 (dd, J = 4.8, 7.8 Hz, 1H), 6.86
(d, J = 7.2 Hz, 1H), 4.86 (t, J = 6.3 Hz, 1H), 4.12-4.04 (m, 1H),
3.90-3.85 (m, 1H), 2.31 (t, J = 6.6 Hz, 1H), 1.02 (d, 6H) 367
410.91 2.10 (500 MHz, DMSO) 12.36 (s, 1H), 8.86 (t, J = 6.3 Hz,
1H), 8.72 (dd, J = 1.4, 7.9 Hz, 1H), 8.35-8.31 (m, 3H), 7.86 (s,
1H), 7.26 (dd, J = 4.7, 7.9 Hz, 1H), 4.60 (t, J = 7.6 Hz, 1H),
4.04- 3.96 (m, 1H), 3.90-3.83 (m, 1H), 2.28 (td, J = 13.8, 6.9 Hz,
1H), 1.02 (t, 6H), 368 474.00 1.60 369 490.00 1.80 370 504.10 1.90
371 477.00 1.50 372 491.00 1.60 373 409.00 1.40 DMSO-d6: 12.9 (m,
1H); 8.95-8.85 (m, 1H); 8.8-8.65 (m, 2H); 8.55-8.3 (m, 2H); 7.4 (m,
0.3H); 7.3 (m, 0.7H); 6.85 (d, 0.7H); 6.5 (d, 0.3H); 5.55 (d, 1H);
5.2 (d, 0.7H); 5.0 (d, 0.3H); 4.3-3.8 (m, 4H); 2.8-2.6 (m, 1H);
2.5- 2.4 (m, 1H). 374 427.00 1.60 DMSO-d6: 12.8 (br s, 1H); 9.1 (m,
1H); 8.7- 8.35 (m, 4H); 7.3 (m, 1H); 6.8 (m, 0.7H); 6.5 (m, 0.3H);
5.3 (m, 0.7H); 5.1 (m, 0.3H); 4.3 (m, 2H); 3.9 (m, 2H); 3.15 (m,
1H); 2.65 (m, 1H). 375 409.00 1.40 DMSO-d6: 12.9 (m, 1H); 9.25-9.1
(m, 1H); 8.75-8.6 (m, 2H); 8.45-8.35 (m, 2H); 7.4 (m, 0.3H); 7.3
(m, 0.7H); 6.9 (d, 0.7H); 6.3 (d, 0.3H); 5.6 (d, 1H); 5.1 (dd,
0.7H); 4.9 (dd, 0.3H); 4.5 (m, 0.3H); 4.2 (m, 0.7H); 4.3-3.6 (m,
3H); 2.8 (m, 1H); 2.3-2.1 (m, 1H). 376 343.10 1.37 377 361.10 1.48
378 325.10 1.37 379 339.10 1.49 380 397.10 1.60 381 379.10 1.99 382
429.35 1.70 (500 MHz, MeOD) 8.83 (d, J = 8 Hz, 2H), 8.68 (s, 1H),
8.59-8.57 (m, 2H), 8.42-8.41 (m, 1H), 8.07-8.03 (m, 1H), 7.90 (dd,
J = 4.4, 8.2 Hz, 1H), 7.77-7.73 (m, 1H), 7.41 (m, 1H), 3.83-3.76
(m, 2H), 1.88 (s, 6H). 383 423.00 2.10 DMSO-d6: 12.3 (s, 1H); 8.7
(d, 1H); 8.45-8.25 (m, H); 8.15 (s, 1H); 7.25 (m, 1H); 4.15 (m,
1H); 4.0 (m, 1H); 3.85 (m, 1H); 3.7 (m, 1H); 2.05 (m, 4H); 1.75 (s,
3H). 384 405.10 1.50 DMSO-d6: 12.8 (s, 1H); 8.8-8.2 (m, 5H); 7.4
(m, 0.2H); 7.25 (m, 0.8H); 6.8 (d, 0.8H); 6.15 (d, 0.2H); 4.2 (m,
0.2H); 3.95 (m, 0.8H); 3.8 (m, 3H); 2.2-2.0 (m, 4H); 1.8-1.6 (m,
3H). 385 488.00 1.70 386 380.00 1.90 DMSO-d6: 12.4 (bs, 1H); 8.92
(m, 0.5H); 8.62 (m, 0.5H); 8.50 (s, 0.5H); 8.42 (s, 0.5H);
8.40-8.20 (m, 4H); 7.20 (m, 0.5H); 7.15 (m, 0.5H); 3.72 (m, 2H);
1.45 (m, 6H) 387 421.10 1.50 (500 MHz, DMSO) 12.81 (s, 1H),
8.65-8.56 (m, 3H), 8.36 (d, J = 4.4 Hz, 1H), 8.22 (d, J = 6.9 Hz,
1H), 7.26 (dd, J = 4.7, 7.9 Hz, 1H), 6.85 (d, J = 6.4 Hz, 1H), 3.80
(bm, 4H), 3.66- 3.62 (m, 2H), 2.26-2.22 (m, 2H), 2.15 (m, 2H), 0.00
(TMS) 388 453.30 1.68 (500 MHz, MeOD) 8.88 (dd, J = 1.5, 8.1 Hz,
1H), 8.60 (s, 1H), 8.40 (d, J = 3.1 Hz, 1H), 8.32-8.26 (m, 1H),
7.99 (s, 1H), 7.40 (dd, J = 4.7, 8.0 Hz, 1H), 7.31 (s, 1H), 4.19
(t, J = 4.8 Hz, 1H), 4.11-4.09 (m, 1H), 4.07 (s, 3H), 4.07 (s, 3H),
3.35-3.32 (m, 2H), 1.87 (s, 6H), 1.38- 1.29 (m, 2H, impurity). 389
489.00 1.78 (500 MHz, MeOD) 8.82 (dd, J = 1.4, 8.1 Hz, 1H), 8.58
(s, 1H), 8.52 (m, 1H), 8.40 (d, J = 3.2 Hz, 1H), 8.00 (s, 1H), 7.39
(dd, J = 4.7, 8.0 Hz, 1H), 7.32 (s, 1H), 4.08 (s, 3H), 4.07 (s,
3H), 3.80-3.77 (m, 2H), 1.87 (s, 6H). 390 471.10 1.70 (500 MHz,
MeOD) 8.85 (dd, J = 1.4, 8.1 Hz, 1H), 8.60 (s, 1H), 8.42-8.40 (m,
1H), 8.37- 8.30 (m, 1H), 8.00 (s, 1H), 7.40 (dd, J = 4.7, 8.0 Hz,
1H), 7.32 (s, 1H), 5.64-5.41 (m, 1H), 4.08 (s, 3H), 4.07 (s, 3H),
3.44 (m, 2H), 1.87 (s, 6H). 391 449.20 1.70 (500 MHz, MeOD)
8.88-8.87 (m, 1H), 8.59 (s, 1H), 8.40 (d, J = 3.3 Hz, 1H),
8.03-8.02 (m, 1H), 7.99 (s, 1H), 7.40 (dd, J = 4.7, 8.1 Hz, 1H),
7.31 (s, 1H), 4.07 (s, 3H), 4.07 (s, 3H), 3.07 (m, 2H), 1.86 (s,
6H), 1.29 (m, 2H), 0.61 (t, J = 7.5 Hz, 3H). 392 339.10 1.45 393
353.10 1.56 394 357.10 1.47 395 375.10 1.56 396 427.00 1.90
DMSO-d6: 12.25 (s, 1H); 8.95 (m, 1H); 8.7 (d, 1H); 8.35 (d, 1H);
8.3 (m, 1H); 8.2 (m, 1H); 7.25 (dd, 1H); 5.5 (d, 1H); 4.95 (dd,
1H); 4.3- 3.75 (m, 4H); 2.7 (m, 1H); 2.2-2.0 (m, 1H). 397 445.00
2.30 DMSO-d6: 12.15 (s, 1H); 8.9 (m, 1H); 8.65 (d, 1H); 8.35 (d,
1H); 8.3 (m, 1H); 8.15 (m, 1H); 7.2 (m, 1H); 5.1 (m, 1H); 4.3 (m,
2H); 3.9 (m, 2H); 3.0 (m, 1H); 2.5 (m, 1H). 398 394.00 2.10 (500
MHz, MeOD) 9.14 (m, 0.25H), 8.95 (d, J = 6.7 Hz, 0.66H), 8.59-8.41
(m, 3.64H), 7.45 (m, 1H), 3.84 (m, 2H), 2.21-2.18 (m, 1H),
2.05-2.02 (m, 1H), 1.67 (m, 3H), 0.97 (t, J = 7.3 Hz, 3H). 399
325.90 1.60 400 340.00 1.80 (500 MHz, MeOD) 9.07 (br, 0.24H), 8.54
(s, 1H), 8.46 (s, 1H), 8.36 (d, J = 4.3 Hz, 1H), 7.39-7.36 (m, 1H),
3.25-3.15 (m, 2H), 2.19- 2.00 (m, 2H), 1.65 (m, 3H), 0.97-0.90 (m,
6H). 401 410.10 2.10 DMSO-d6 (rotational mixture about 1.3:1):
12.45 (m, 1H); 9.05-8.3 (m, 5H); 7.3-7.2 (m, 1H); 5.6-5.4 (m, 1H);
4.8 (t, 0.6H); 4.7 (t, 0.4H); 4.45 3.75 (m, 4H); 2.8-2.6 (m, 1H);
2.25-2.1 (m, 1H). 402 410.10 2.00 DMSO-d6 (rotational mixture about
1.3:1): 12.45 (m, 1H); 8.8-8.3 m, 5H); 7.3-7.15 (m, 1H); 5.5-5.35
(m, 1H); 4.9 (d, 0.6H); 4.75 (d, 0.4H); 4.15-3.8 (m, 4H); 2.75-2.6
(m, 1H); 2.4-2.3 (m, 1H). 403 392.10 2.00 404 409.10 1.50 405
409.00 1.50
Example 3
JAK3 Inhibition Assay
[0142] Compounds were screened for their ability to inhibit JAK3
using the assay shown below. Reactions were carried out in a kinase
buffer containing 100 mM HEPES (pH 7.4), 1 mM DTT, 10 mM
MgCl.sub.2, 25 mM NaCl, and 0.01% BSA. Substrate concentrations in
the assay were 5 .mu.M ATP (200 uCi/.mu.mole ATP) and 1 .mu.M
poly(Glu).sub.4Tyr. Reactions were carried out at 25.degree. C. and
1 nM JAK3.
[0143] To each well of a 96 well polycarbonate plate was added 1.5
.mu.l of a candidate JAK3 inhibitor along with 50 .mu.l of kinase
buffer containing 2 .mu.M poly(Glu).sub.4Tyr and 10 .mu.M ATP. This
was then mixed and 50 .mu.l of kinase buffer containing 2 nM JAK3
enzyme was added to start the reaction. After 20 minutes at room
temperature (25.degree. C.), the reaction was stopped with 50 .mu.l
of 20% trichloroacetic acid (TCA) that also contained 0.4 mM ATP.
The entire contents of each well were then transferred to a 96 well
glass fiber filter plate using a TomTek Cell Harvester. After
washing, 60 .mu.l of scintillation fluid was added and .sup.33P
incorporation detected on a Perkin Elmer TopCount.
Example 4
JAK2 Inhibition Assay
[0144] The assays were as described above in Example 3 except that
JAK-2 enzyme was used, the final poly(Glu).sub.4Tyr concentration
was 15 .mu.M, and final ATP concentration was 12 .mu.M.
[0145] All compounds depicted in Tables 1, 2 and 3 were found to
inhibit JAK3 with a Ki of less than 0.1 .mu.M except for compounds
22, 35, 56, 68, 177, 223, 310, 317, 318, 319, 320, 321, 322, 326,
336, 337, 338, 339, 340, 351, 356, 367, 369, 370, 388, and 390. All
Table 1, 2 and 3 compounds inhibited JAK3 with a Ki of less than
2.0 .mu.M except for compounds 68 and 319. All Table 1, 2 and 3
compounds were found to inhibit JAK2 with a Ki of less than 0.5
.mu.M except for compounds 9, 22, 35, 56, 57, 68, 310, 317, 38,
319, 320, 321, 336, 338, 339, 340, 348, 351, 356, 367 and 372. All
Table 1, 2 and 3 compounds inhibited JAK2 with a Ki of less than
5.0 .mu.M except for compounds 68, 318 and 319.
Example 5
JAK3 Cellular Inhibition Assay
[0146] HT-2 clone A5E cells (ATCC Cat. # CRL-1841) were grown and
maintained at 37.degree. C. in a humidified incubator in cell
culture medium (RPMI 1640 supplemented with 2 mM L-glutamine
adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10
mM HEPES, 1.0 mM sodium pyruvate, 0.05 mM 2-mercaptoethanol, 10%
fetal bovine serum, and 10% by volume rat T-STIM factor [Fisher
Scientific Cat # CB40115] with Con A). On the day of the
experiment, HT-2 cells were washed, resuspended at a density of
5.times.10.sup.6 cells per ml in fresh cell culture medium without
T-STIM and incubated for 4 hours without T-STIM. After four hours,
50 .mu.l (0.25.times.10.sup.6 cells) of the resuspended cells were
added to each well of a 96 well plate. Serial dilutions of
compounds were made in DMSO and then added to RPMI. 100 .mu.l of
the diluted compounds were added to each well and the plates were
incubated for 1 hour at 37.degree. C. 50 .mu.l of recombinant
murine interleukin-2 (rmIL-2) at 40 ng/ml (R & D systems Inc.
Cat #402-ML) was added and the plates were incubated for 15 minutes
at 37.degree. C.
[0147] The plates were then centrifuged for 5 minutes at 1000 rpm,
the supernatant was aspirated and 50 .mu.l of 3.7% formaldehyde in
phosphate buffered saline (PBS) was added per well. The plates were
incubated for 5 minutes at room temperature on a plate shaker. The
plates were again centrifuged at 1000 rpm for 5 minutes. The
supernatant was aspirated, 50 .mu.l of 90% methanol was added to
each well, and the plate was incubated on ice for 30 minutes. The
supernatant was aspirated and the plate washed with PBS. 25 .mu.l
per well of 1:10 diluted Phospho STAT-5 (Y694) PE conjugated
antibody (PS-5 PE antibody; Becton-Dickinson Cat. #61256) was added
to the plates and the plates were incubated for 45 minutes at room
temperature on a plate shaker. 100 .mu.l PBS was added and the
plates were centrifuged. The supernatant was aspirated and the
cells resuspended in 100 .mu.l PBS. The plate was then read on a 96
well FACS reader (Guava PCA-96).
[0148] Compounds of the invention were found to inhibit JAK3 in
this assay.
Example 6
JAK2 Cellular Inhibition Assay
[0149] TF-1 cells (ATCC Cat. # CRL-2003) were grown and maintained
at 37.degree. C. in a humidified incubator in cell culture medium
(RPMI 1640 supplemented with 2 mM L-glutamine adjusted to contain
1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, 1.0 mM
sodium pyruvate, 10% fetal bovine serum and recombinant human
granulocyte-macrophage colony stimulating factor [rhGMCSF, R&D
Systems Inc. Cat. #215-GM]). On the day of the experiment, TF-1
cells were washed, resuspended at a density of 5.times.10.sup.6
cells per ml in fresh cell culture medium without rhGMCSF and
incubated for 4 hours without rhGMCSF. After four hours, 50 .mu.l
(0.25.times.10.sup.6 cells) of the resuspended cells were added to
each well of a 96 well plate. Serial dilutions of compounds were
made in DMSO and then added to RPMI. 100 .mu.l of the diluted
compounds were added to each well and the plates were incubated for
1 hour at 37.degree. C. 50 .mu.l of rhGMCSF at 10 ng/ml was added
and the plates were incubated for 15 minutes at 37.degree. C. The
plates were then processed for FACS analysis as detailed above in
Example 5. Compounds of the invention were found to inhibit JAK2 in
this cellular assay.
[0150] While we have described a number of embodiments of this
invention, it is apparent that our basic examples may be altered to
provide other embodiments which utilize the compounds and methods
of this invention. Therefore, it will be appreciated that the scope
of this invention is to be defined by the appended claims rather
than by the specific embodiments that have been represented by way
of example above.
* * * * *